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ABSTRACT 
 
Post-translational modification of the γ-secretase protease complexes and their 
substrates has an important role in controlling receptor-initiated signalling events, 
which are critically important in the pathogenesis of cancer, inflammatory and 
Alzheimer’s disease. Our lab has previously characterised an interaction between TRAF6 
and presenilin-1, which lead to the identification of interleukin-1 (IL-1) receptor type 1 
(IL-1R1) (Elzinga et al., 2009b) and Toll-like receptor-4 (TLR4) as novel γ-secretase 
substrates. Subsequently our group showed that TRAF6 promoted ubiquitination and γ-
secretase cleavage of IL-1R1 (Twomey et al., 2009).   
The aim of this project is to study the association between TRAF6 and the presenilins, 
the critical γ-secretase complex components, and to determine the functional 
importance of TRAF6-mediated ubiquitination of γ-secretase substrates. Firstly, we 
show that the full-length presenilins are novel substrates of TRAF6-mediated Lysine-63-
linked polyubiquitination. Secondly, we show that co-expression of TRAF6 and the 
presenilins increases the stability and alters the turnover of the presenilins. Thirdly, we 
reveal that TRAF6-mediated ubiquitination of presenilin does not affect γ-secretase 
enzyme activity, but may regulate the full-length presenilin functions such as ER Ca2+ 
signalling. 
Previously, we have reported IL-1R1 as a novel substrate of TRAF6-mediated 
ubiquitination. In this study, we identified five lysine residues in the IL-1R1 intracellular 
domain targeted by TRAF6-mediated polyubiquitination. Furthermore, mutagenesis of 
IX 
these five lysine residues led to decreased IL-1R1 cell surface expression, precluded the 
ectodomain shedding and attenuated the responsiveness to IL-1β stimulation, 
demonstrating the critical role of TRAF6 in IL-1R1 trafficking. 
  
X 
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Chapter 1: 
INTRODUCTION 
 
This section has been published in part as a review by Current Signal Transduction 
Therapy. [Yan, R. and McCarthy, J.V. (2009). Presenilin and gamma-secretase activity: 
a viable therapeutic target for Alzheimer's disease? Current Signal Transduction 
Therapy, Volume 5, Number 2, May 2010, pp. 128-140(13).] 
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1.1 Alzheimer’s disease and APP cleavage 
Alzheimer’s disease (AD) is pathologically characterised by the formation and 
deposition of amyloid-β (Aβ) peptides in neuritic plaques in specific brain regions and 
cerebral vasculature. Aβ peptides are generated following the sequential proteolytic 
cleavage of amyloid precursor protein (APP) by the proteases, β-secretase and γ-
secretase (Haass and Selkoe, 1993; Citron et al., 1995; Nunan and Small, 2000) 
(Figure 1.1). APP is first cleaved by β-secretase releasing the larger soluble APP 
ectodomain (sAPPβ) and generating the amino terminus of Aβ peptides in the form 
of a membrane spanning 99-amino acid APP C-terminal fragment (CTF), APP C99. The 
membrane-anchored C99 is subsequently cleaved by γ-secretase at two locations: 
the ε-site to liberate cytosolic APP intracellular domain (AICD) and the γ-site to 
generate heterogeneous N-termini of Aβ-peptides (Weidemann et al., 2002). For this 
reason, both β- and γ-secretase are considered prime targets for the 
pharmacological reduction of APP cleavage and formation of Aβ peptides in the 
prevention and treatment of AD (Ghosh et al., 2005; Ghosh et al., 2008; Wolfe, 
2008b, a). However, an important fact which should be kept in consideration is that 
in excess of one hundred type I membrane proteins including Notch, a critical 
receptor which is to determine in cell fate, are also cleaved by β- and γ-secretase 
(McCarthy et al., 2009a). So any potential treatment for reducing Aβ production 
should selectively inhibit APP cleavage, but not cleavage of Notch or other substrates.  
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The major β-secretase is a membrane anchored aspartyl protease of the pepsin family, 
termed BACE1 (β-site APP-cleaving enzyme 1), which is primarily expressed in the 
brain (Vassar et al., 1999; Luo et al., 2001). Biochemical and genetic studies have 
revealed that antagonising β-secretase activity is associated with mild phenotypes 
(Harrison et al., 2003; Ohno et al., 2004; Willem et al., 2006) and has therefore 
emerged as an attractive therapeutic target for the development of AD therapies 
(Ghosh et al., 2002; Ghosh et al., 2008). However, recent studies showed that BACE1 is 
required for the accurate targeting of olfactory sensory neuron axons and the proper 
formation of glomeruli in the olfactory bulbs and BACE1 deficiency causes 
spontaneous and pharmacologically-induced seizure activity (Hitt et al., 2010; 
Rajapaksha et al., 2011). Additionally, neuregulin-1, which is a critical factor in the 
development of the nervous system, has been shown as a substrate of BACE1 
dependent proteolysis, underscoring the importance of substrate selectivity when 
inhibiting β-secretase activity for potential AD therapies (Vartanian et al., 1999; Fleck 
et al., 2011). Subsequently, the extracellular catalytic domain of β-secretase was 
crystallised (Hong et al., 2000; Hong et al., 2002), facilitating structure-based inhibitor 
design and accelerating the transition of β-secretase inhibitors into clinical trials, 
reviewed in (Ghosh et al., 2008; Ghosh et al., 2012). In contrast to β-secretase, the 
protease responsible for γ-secretase activity is a complex of four different integral 
membrane proteins: presenilin, Nicastrin, anterior pharynx defective 1 (Aph-1) and 
presenilin enhancer 2 (Pen-2) (Tolia and De Strooper, 2008).  
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Figure 1.1 Schematic of APP cleavage. In this model the progressive proteolytic 
cleavage of amyloid precursor protein (APP) is illustrated. Firstly (a), cleavage in the 
APP ectodomain by β-secretase produces soluble ectodomain (sAPPβ) and the 
membrane-anchored C99 carboxyl-terminal domain. Next (b), the γ-secretase complex 
is recruited to APP-derived C99 and cleaves at the ε-cleavage-site to liberate the APP 
intracellular domain (AICD). Finally (c), γ-secretase cleaves the remaining membrane-
associated fragment at the γ-cleavage site to liberate Aβ peptide fragments.   
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Furthermore, while β-secretase has few reported in vivo substrates (Sinha et al., 1999; 
Yan et al., 1999; Willem et al., 2006), subsequent to the identification of γ-secretase 
and its association with the proteolytic cleavage of APP, several independent studies 
have linked γ-secretase protease activity with the cleavage of over one hundred other 
substrates (Boulton et al., 2008; Lleo, 2008; McCarthy et al., 2009b) raising concerns 
about the selectivity, adverse toxicity and the overall validity of γ-secretase as a viable 
therapeutic target in the prevention and treatment of AD . 
1.2 Gamma-secretase protease complexes 
The initial discovery of two related genes (PSEN1 and PSEN2) encoding the 
presenilin-1 (PS1) and presenilin-2 (PS2) proteins, and their association with 
autosomal dominant forms of familial AD (FAD) (Hutton and Hardy, 1997) has led to 
significant breakthroughs in our understanding of disease pathogenesis and 
development of potential AD therapeutics. To date more than 160 mutations in 
PSEN1 and 10 mutations in PSEN2 have been linked to early onset FAD 
(http://www.molgen.ua.ac.be/ADMutations). Most Aβ peptides range from 39 to 43 
residues in length. Aβ42 and Aβ40 are composed of 42 and 40 amino acid residues 
respectively, of which toxic Aβ42 aggregates are considered critical in causing AD 
(Wang et al., 1996). Though the mutations occur throughout the presenilins they all 
cause a shift in the ratio of Aβ42:Aβ40 peptides resulting in a general increased 
accumulation of the more amyloidogenic Aβ42 peptide (De Strooper, 2007). Genetic 
knockout of PSEN1 in mice provided the first evidence that PS1 was absolutely 
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required for γ-secretase activity where it was demonstrated that PSEN1-deficency 
dramatically reduced production of Aβ peptides with a concomitant accumulation of 
the γ-secretase substrate, γ-secretase generated APP C99 fragments (De Strooper et 
al., 1998). Later reports demonstrated that knockout of both PSEN1 and PSEN2 
resulted in complete ablation of γ-secretase activity and inhibition of Aβ peptide 
generation (Herreman et al., 2000). Some groups proposed that familial AD is caused 
by a partial loss of presenilin function because most of the AD-associated mutations 
in presenilins also cause a reduction in overall proteolytic activity (Song et al., 1999; 
Moehlmann et al., 2002; Schroeter et al., 2003; Bentahir et al., 2006). However, 
there are arguments showing that complete loss-of-function mutations in PS1, Pen-2 
and Nicastrin in humans cause familial skin disorder but not AD (Wang et al., 2010) 
and AD mutations have only been found in APP but not any other γ-secretase 
substrate, suggesting that altered proteolytic cleavage of APP and shifted Aβ42:Aβ40 
ratio are the critical factors for AD development.  
In independent biochemical studies aimed at purifying presenilin-associated γ-
secretase activity, PS1 and PS2 consistently co-purified with γ-secretase activity as 
part of larger high molecular weight multi-protein complexes (Li et al., 2000a; Li et al., 
2000b; Esler et al., 2002; Kimberly et al., 2003), suggesting that PS1 and PS2 required 
additional cellular co-factors for biological and protease-associated functions. 
Subsequent high-grade biochemical purification studies and genetic screens lead to 
the identification and characterisation of three such co-factors, Nicastrin, APH-1 and 
PEN-2 (Tolia and De Strooper, 2008). The unconditional requirement for each of 
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these four integral membrane proteins for γ-secretase activity was verified following 
genetic ablation or RNAi knockdown of one or the other of the components, and 
genetic reconstitution of γ-secretase activity in Saccharomyces cerevisiae, which lack 
endogenous γ-secretase protease components (Edbauer et al., 2003; Tolia and De 
Strooper, 2008). All four proteins associate with each other and their co-expression 
results in increased γ-secretase activity in Drosophila, mammalian cells and 
reconstituted activity in yeast (De Strooper, 2003; Edbauer et al., 2003; Kimberly et 
al., 2003). This new multi-protein identity of the γ-secretase protease was 
subsequently corroborated by several studies reporting the purification of the active 
γ-secretase protease complex (Fraering et al., 2004a; Fraering et al., 2004b; 
Wakabayashi et al., 2009; Winkler et al., 2009; Teranishi et al., 2010). Presenilins are 
reported as the catalytic core of γ-secretase complex and two highly conserved 
aspartate residues in the transmembrane domain 6 and 7 (D257 and D385 in PS1, 
D263 and D366 in PS2) are essential for the endoproteolysis of presenilin and the 
proteolytic activity of γ-secretase (Steiner et al., 1999c; Wolfe et al., 1999). 
Additionally, γ-secretase inhibitors were shown to directly bind to the heterodimers 
of presenilin, providing evidence that presenilins contain the active sites of γ-
secretase (Esler et al., 2000).Although presenilins are considered as the catalytic core 
of γ-secretase, recent studies showed the importance of the incorporation of the 
other subunits. Immature γ-secretase complex containing presenilin were suggested 
to have a relatively open conformation within the hydrophilic pore which was 
rendered a narrower pore structure that enables the enzymatic activity of γ-
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secretase after the recruitment of the other subunits (Takeo et al., 2012). The 
activity of γ-secretase complex is also regulated by its adaptor proteins including the 
notable γ-secretase activating protein which interacts with both γ-secretase and APP 
CTF and confers substrate specificity to APP cleavage, providing a potential target for 
Alzheimer’s disease therapy (He et al., 2010). 
It is now generally well accepted that the γ-secretase protease complex consists of 
the four integral membrane proteins, presenilin, nicastrin, APH-1 and PEN-2 in a 
stoichiometry of 1:1:1:1 (Sato et al., 2007; Wakabayashi et al., 2009). However, in all 
examined species there are two PSEN genes (PSEN1 and PSEN2), while in humans 
there are two Aph-1 genes, Aph-1a and Aph-1b, which are alternatively spliced, and 
in rodents gene duplication of Aph-1b produces a third gene, Aph-1c (Hebert et al., 
2004). Together with biochemical studies demonstrating that PS1 and PS2, or APH-
1a and APH-1b/c, never coexist in the same γ-secretase protease complex, the 
potential existence of at least six distinct γ-secretase complexes in humans is 
proposed (Shirotani et al., 2004; Ma et al., 2005; Shirotani et al., 2007). Firstly, the 
presenilins and APH-1 proteins display different tissue distribution patterns. 
Secondly, PS1-deficient and PS2-deficient mice have dramatically different 
phenotypes suggesting a diversity of presenilin-associated cellular functions and 
incomplete functional redundancy. Indeed, biochemically purified PS1-associated γ-
secretase complexes have higher specific activity (>150 fold) than PS2-associated γ-
secretase complexes (Lai et al., 2003; Yonemura et al., 2011), and both are 
differentially antagonised by pharmacological inhibitors of γ-secretase activity. 
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Thirdly, from phenotypic characterisation of Aph-1 deficient mice, differential 
contribution of the Aph-1 genes (Aph-1a or Aph-1b/c) to γ-secretase activity have 
been reported (Serneels et al., 2005; Dejaegere et al., 2008) where the APH-1a-
containing γ-secretase complexes appear to be critical for Notch signalling while 
APH-1b/c-containing γ-secretase complexes are dispensable for Notch signalling 
during embryogenesis. In contrast deficiency of APH-1b/c-containing γ-secretase 
complexes antagonises cleavage of the γ-secretase substrate neuregulin-1 (Nrg1), 
but not other substrates (ErbB4, Syndecan and Notch,) (Dejaegere et al., 2008), 
suggesting brain-specific function for APH-1b/c-containing γ-secretase complexes. 
Indeed, it has now been clearly demonstrated that different APH-1-contaning γ-
secretase complexes have heterogeneous biochemical and physiological properties 
(Serneels et al., 2009). Specifically, APH-1b-containing γ-secretase complexes 
contribute to total γ-secretase activity in the human brain, while inactivation of the 
APH-1b in a murine AD model contributes to improvements of AD-relevant 
phenotypic features without any apparent Notch-related side effects (Serneels et al., 
2009). 
1.3 Non-proteolytic function of presenilins 
In the brain, presenilins are predominantly present as NTF and CTF heterodimer 
which are reported to be generated in the endoplasmic reticulum (ER) and 
incorporated into the γ-secretase complex during the its transport from the ER to the 
Golgi apparatus (Spasic et al., 2006a). However, Presenilin functions independent of 
γ-secretase complex are also being studied which contributes to the understanding 
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between presenilin functions and AD pathogenesis. To verify a presenilin function is 
γ-secretase independent, the phenotype in presenilin deficient cells should be 
rescued by the endoproteolytically inactive presenilin mutants and not mimicked by 
γ-secretase inhibitors. 
Earlier and recent studies both showed that full-length presenilins are localised 
predominantly in the ER (Walter et al., 1996b; Area-Gomez et al., 2009). Consistent 
with this observation, full-length presenilins are reported as passive ER Ca2+ leak 
channels and this function is disrupted by many FAD mutations (Tu et al., 2006; 
Nelson et al., 2007; Nelson et al., 2010; Zhang et al., 2010; Nelson et al., 2011). Full-
length presenilins alone are capable to exert ER Ca2+ signalling function and 
deficiency of the ER Ca2+ signalling in the presenilin double knockout (DKO) cells 
could be rescued by presenilin aspartate mutations revealing a  γ-secretase 
independent full-length presenilin function (Brunello et al., 2009). Inducing ER stress 
by tunicamycin elevates PS1 transcription which could confer resistance to ER stress 
by forming complex of PS1 holoprotein and sarco ER calcium-ATPase channel, thus 
regulating intracellular Ca2+ homeostasis (Jin et al., 2010). Similarly, inhibition of c-
jun-NH2-terminal kinase (JNK) activation represses PSEN1 transcription and leads to 
impaired  ER Ca2+ leak function which is also observed with FAD mutations (Das et al., 
2012). Because altered Ca2+ release was detected from a large proportion of AD 
family members prior to the development of their AD symptoms but not in the 
family members who failed to develop AD (Etcheberrigaray et al., 1998), late studies 
then aimed to explore the role of FAD presenilin mutations and revealed the 
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deficiency in ER Ca2+ signalling caused by the many FAD mutations which leads to the 
proposal of the “calcium hypothesis”. The calcium hypothesis attempts to explain 
altered Ca2+ signalling of AD either as results of Aβ oligomerisation which acts as or 
activates plasma membrane channels to increase Ca2+ entry, or as the down-stream 
signalling events of APP ICD which may alter the expression of the key ER 
components such as ryanodine receptor (Berridge, 2010; Zhang et al., 2010). Knock-
out of presenilins or presenilin FAD mutations has also been shown to associate with 
lysosomal defects including autophagic deficits and abnormal lysosomal acidification 
(Lee et al., 2010; Neely et al., 2011). Some groups proposed that lysosomal fusion 
events may require Ca2+ release from lysosome and reduced Ca2+ loading into 
lysosomes which causes lysosomal abnormalities may potentially result from 
impaired ER Ca2+ leak function in presenilin DKO or FAD cells (Bezprozvanny, 2012). 
Supporting this hypothesis, one study showed that content of lysosomal Ca2+ stores 
was significantly reduced in PS DKO MEF cells and in PS1 KO neurons which could be 
rescued by stable retroviral transduction with PS1 or γ-secretase activity defective 
PS1 mutant (Coen et al., 2012). 
Another γ-secretase-independent presenilin function has been reported as its 
interaction with and regulation of β-catenin and β-catenin mediated cell adhesion. β-
catenin is targeted for constitutive degradation mediated by protein kinase A (PKA) 
and glycogen synthase-3β (GSK-3β) which requires a scaffold complex comprised of 
Axin and APC (Huang and He, 2008). Wnt signalling blocks phosphorylation by GSK-
3β, thus preventing β-catenin degradation and allowing its nuclear translocation. 
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Presenilin was initially identified as a negative regulator of β-catenin function (Cox et 
al., 2000; Noll et al., 2000). Follow-up studies either proposed presenilin as a 
suppressor of Wnt-mediated stabilization and nuclear translocation of β-catenin 
(Killick et al., 2001), or as an alternative scaffold for β-catenin phosphorylation after 
Axin is targeted for degradation during Wnt signalling (Kang et al., 1999; Soriano et 
al., 2001; Kang et al., 2002). Notably, PS1 D257A mutant, defective in γ-secretase 
activity, restored β-catenin turnover as same as the wild-type PS1, revealing a γ-
secretase-independent presenilin function (Kang et al., 2002). β-catenin also 
functions to link the cadherins to α-catenin which enables the formation of a linkage 
between adherence junctions and the cytoskeleton, thus stabilize intercellular 
adhesions (Parisiadou et al., 2004). Expression of PS1 has been shown to stabilize the 
E-cadherin/β-catenin/α-catenin complex and absence of PS1 results in decreased 
complex and cellular adhesion (Baki et al., 2001). Consistent with this, abnormalities 
in the cytoskeleton within a kind of presenilin inactivated moss was also observed, 
which could be rescued by human presenilin Asp-mutations (Khandelwal et al., 2007). 
However, other studies suggested that presenilin regulates β-catenin mediated cell 
adhesion and signalling through γ-secretase mediated cleavage of leukocyte-
common antigen-related (LAR) receptor tyrosine phosphatase which argued that 
presenilin mediated β-catenin regulation is γ-secretase dependent (Haapasalo et al., 
2007). Similar to the regulation of β-catenin mediated cell adhesion, loss of 
presenilins also leads to enhanced maturation and cell-surface delivery of mature 
integrin β1, resulting in increased cell adhesion which could not be mimicked by γ-
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secretase inhibitors and presenilin was suggested to inhibit the maturation of 
integrin β1 in the ER (Zou et al., 2008). 
Presenilins have also been implicated in protein trafficking presumably through its 
association with several vesicle transport proteins, for example, syntaxins (Smith et 
al., 2000; Suga et al., 2004)or members of the Rab family of small GTPase proteins 
(Dumanchin et al., 1999; Kametani et al., 2004; Scheper et al., 2004). One well 
studied non-proteolytic function of presenilins in trafficking is their role in the 
turnover of autophagic vacuoles. Deficiency of PS1 or presenilin DKO led to 
telencephalin (TLN or ICAM-5) and α- and β-synuclein abnormal aggregation 
respectively, resulting in failed fusion of autophagic vacuoles with the 
endosome/lysosome thus affecting autophagic vacuoles maturation (Annaert et al., 
2001; Wilson et al., 2004). The abnormal trafficking of TLN in PS1 deficient neurons 
was rescued by expression of wild-type PS1 or PS1 D256A and was not mimicked by 
γ-secretase inhibitors, indicative of a γ-secretase independent function of presenilin 
(Esselens et al., 2004). In another case, deficiency of PS1 or expression of some FAD 
PS1 mutants led to impaired kinesin-I-mediated fast axonal transport which was 
observed with increased GSK-3β activity (Pigino et al., 2003; Lazarov et al., 2007). 
GSK-3β phosphorylates kinesin light chains and causes the dissociation of kinesin-I 
from membrane-bound organelles, resulting in impaired kinesin-I-mediated 
transport (Morfini et al., 2002). PS1 was shown to inactivate GSK-3β by promoting 
the phosphorylation of GSK-3β through the PI3K/Akt signalling in a γ-secretase 
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inhibitor insensitive manner, thus proposed to regulate kinesin-I-mediated transport 
indirectly (Baki et al., 2008). 
1.4 Transcriptional regulation of PSEN1 and PSEN2 
Endogenous transcription of presenilins is tightly regulated which maintains 
relatively stable levels of presenilin protein. Increasing the levels of PS1 protein 
decreases normal PSEN1 transcription and blockage of PS1 translation increases 
PSEN1 transcription (Thinakaran et al., 1997; Nornes et al., 2008; Newman et al., 
2012). Mutations in PS1 promoter have also been implicated with increased risk of 
developing AD (Theuns et al., 2000; Lambert et al., 2001; Theuns et al., 2003). 
Expression of PSEN1 is activated by a variety of transcriptional activators including 
Ets, Ets related molecule (ERM), 12-O-tetradecanoylphorbol 13-acetate (TPA) and 
cAMP-response element-binding protein (CREB) (Mitsuda et al., 2001; Pastorcic and 
Das, 2002, 2004, 2007a). Some of these transcriptional activators also bind to their 
repressor proteins, for example p53 interacts with Ets1/2 and ZNF237 and CHD3/ZFH 
bind to ERM, all leading to suppressed PS1 transcription (Pastorcic and Das, 2007a, b; 
Lee and Das, 2008). In addition, human PSEN2 promoter is modulated by 
transcription factor Egr-1 (Ounallah-Saad et al., 2009). AICD has been shown to 
interact with p53 and enhance its transcriptional and pro-apoptotic functions (Ozaki 
et al., 2006). Inhibition of JNK activation represses PS1 transcription by losing p-JNK 
inhibiting effect on p53 activity (Lee and Das, 2008). Transcription of PS1 is also 
triggered by intracellular stimuli events. Firstly, ER stress induced by tunicamycin 
increases PS1 expression and results in enhanced γ-secretase activity and ER Ca2+ 
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signalling ability (Jin et al., 2010; Ohta et al., 2011). Moreover, ethacrynic acid 
induced oxidative stress increases PS1 expression, causes enhanced PS1 protein 
levels in lipid rafts and results in higher Aβ secretion (Oda et al., 2010). Additionally, 
knock-down of the purine reutilization enzyme hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) leads to reduced PS1 expression and concomitant 
altered PS1 fragment levels (Kang et al., 2011). Collectively, there appears to be a 
close loop control between PSEN transcription and its functions where altered 
presenilin function leads to disrupted cellular homeostasis (altered AICD production, 
ER stress or oxidative stress) which consequently causes adjustment in presenilin 
transcription thus feeding back to presenilin functions. 
1.5 Presenilin post-translational modification 
Full-length presenilins are synthesized as inactive holoproteins which are 
subsequently endoproteolytically cleaved producing active presenilin NFT/CTF 
heterodimers (Thinakaran et al., 1996). Posttranslational modifications of presenilins 
which includes proteolysis, phosphorylation and ubiquitination are not only essential 
for the stability and activation of presenilins, but are also important for the 
formation and activity of γ-secretase complexes. 
1.5.1 Endoproteolysis and caspase cleavage 
The presenilin proteins are multi-transmembrane proteins consisting of nine 
transmembrane domains (TMD), which are endoproteolytically cleaved into a ~30-
kDa NH2-terminal fragment (NTF) and a ~20-kDa COOH-terminal fragment (CTF). Due 
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to the short half-life of presenilin holoproteins (approximately 1h) and comparably 
long half-life of presenilin fragments (~24h), NTF/CTF heterodimers are the major 
presenilin species in vivo. The endoproteolytic event occurs between residues 
Met292/Val293 and Met298/Val299 within the large cytosolic loop in human PS1 
and PS2 and stable NTF/CTF complexes are formed (Thinakaran et al., 1996; 
Jacobsen et al., 1999) (Figure 1.2). The NTF/CTF heterodimers comprise the catalytic 
component of γ-secretase (Kopan and Ilagan, 2004), and two active site aspartate 
residues are located in each fragment, Asp257 in the NTF (TMD6) and Asp385 in the 
CTF (TMD7) in human PS1 (Wolfe et al., 1999), Asp263 and Asp366 in human PS2 
(Steiner et al., 1999b). Mutations of these conserved aspartate residues abolish γ-
secretase activity and presenilin endoproteolysis but not affect the expression of 
presenilin or the formation of the γ-secretase complex (Yu et al., 2000; Nyabi et al., 
2003). The presenilins are endoproteolysed by an unknown protease, presenilinase, 
which is assumed to be γ-secretase or presenilin itself because mutations of the 
catalytic aspartate residues abolish presenilin proteolysis. Although it has not been 
formally proven, the presenilins are proposed to undergo an autoproteolytic event 
that activates itself to form the active NTF/CTF heterodimers (Li et al., 2000b; 
Brunkan et al., 2005; Fukumori et al., 2010). A human PS1 Exon 9 deletion mutant 
(PS1ΔE9), in which the putative endoproteolysis site is removed, is able to induce a 
structural change that stabilizes the uncleaved full-length PS1 and perform biological 
and pathological function suggesting the implicated activity of full-length presenilins 
independent of the γ-secretase activity (Steiner et al., 1999a). 
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Figure 1.2 Presenilin structure, functional domains and potential sites of 
posttranslational modification. (A), Schematic representation of presenilin-1 (PS1) 
structure. PS1 contains ten hydrophobic domains arranged in a predominant nine-
transmembrane domain (TMD) topology with a large hydrophilic loop domain 
between TMD six and seven. The protease activity of γ-secretase complexes is 
mediated by two aspartyl protease active site motifs (YD and GxGD) located in the 
centre of adjacent TMD 6 and TMD 7 with reverse orientation, and the PAL motifs 
located in TMD 9. The cytosolic loop contains the Presenilinase and caspase cleavage 
sites, mapped as indicated. (B) Previously described covalent posttranslational 
modifications of human presenilins, PS1 and PS2. PS1 contains three GSK3β 
phosphorylation sites (underlined) whereas PS2 contains none. PS1 is subject to 
serine/threonine phosphorylation by PKA (●), PKC (○), CDK5 (■), GSK3β (□) and JNK 
(◊) and PS2 is subject to serine/threonine phosphorylation by CK1/2 (*) and mapped 
to specific individual residues. PS1 is also ubiquitinated by Sel-10, but the site(s) have 
not been mapped to individual residues. The endoproteolysis and caspase cleavage 
sites are also indicated (arrows).  
  
18 
 
 
19 
 
Another study demonstrates that Presenilinase-mediated endoproteolysis of 
presenilins is not essential for the maturation of presenilins in Drosophila (Barakat et 
al., 2009). Endoproteolysis of the presenilin NTF/CTF appears to be tightly regulated. 
The levels of full-length PS1 increase corresponding to the levels of expressed mRNA 
encoding human PS1, but no increase is observed in corresponding human PS1 NTF 
and CTF. Furthermore, overexpression of the presenilin proteins does not result in a 
parallel increase of fragments formation indicating that additional proteins are 
required for presenilins to mature into stable NTF/CTF heterodimers (Thinakaran et 
al., 1996). Another study shows that overexpression of ubiquilin, which interacts 
with presenilins, decreases presenilin NTF and CTF levels (Massey et al., 2005). 
Phosphorylation by GSK-3β, protein kinase C (PKC) and PKA in PS1 CTF hydrophilic 
loop domain also regulate the level of PS1 CTF (Kirschenbaum et al., 2001a). 
Presenilin NTF/CTF generated by endoproteolysis is indispensable components of the 
γ-secretase complex, and the fragments are also important for the maturation and 
stability of presenilin complex. 
In addition to the endoproteolysis, presenilins also undergo caspase-dependent 
cleavage. Several groups have reported the caspase-dependent cleavage sites 
revealed by N-terminal protein sequencing that human PS2 is endoproteolyted 
between Asp329 and Ser330 (Loetscher et al., 1997), and human PS1 is cleaved 
between Asp345 and Ser346 (Grunberg et al., 1998) (Figure 1.2B), with both sites 
conforming to the consensus caspase-recognition sites. Phosphorylation of PS1 at 
Ser346 by PKC in vitro and in vivo inhibits this caspase-dependent cleavage (Fluhrer 
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et al., 2004). Similarly, PS2 is phosphorylated by the second messenger-independent 
casein kinase 1 (CK-1) and/or casein kinase 2 (CK-2) at serine 327 and 330, which 
inhibits the caspase-dependent cleavage in vitro and in vivo (Walter et al., 1996a; 
Walter et al., 1999). Phosphorylation of proteins at caspase recognition sites 
modulates the progression of apoptosis, and it has been suggested that the caspase-
cleaved PS1 CTF promotes apoptosis (Kim et al., 1997a; Loetscher et al., 1997). Co-
expression of PS1-NTF and caspase-cleaved PS1 CTF reconstitute γ-secretase activity 
in presenilin-null cells (Hansson et al., 2006), indicating the redundancy of the N-
terminus end of PS1 CTF. Furthermore, caspase-cleaved PS1 CTF containing γ-
secretase complex was shown to exhibit increased production of Aβ42 and increased 
Aβ42/Aβ40 ratio (Hedskog et al., 2011). However another study reported that 
deletion of the hydrophilic loop containing the caspase cleavage sites in PS1 does not 
disrupt Aβ production (Saura et al., 2000), suggesting that alteration with the 
caspase cleavage of PS1 does not alter γ-secretase activity. 
1.5.2 Phosphorylation of the presenilins 
As demonstrated previously, human PS1 CTF is phosphorylated at Ser 346 by PKC in 
vitro and in vivo, whereas PKA phosphorylates human PS1 CTF exclusively at Ser310 
(Fluhrer et al., 2004) (Figure 1.2B). It has been suggested that caspase-cleaved PS1 
CTF promotes apoptosis (Kim et al., 1997a; Loetscher et al., 1997) and PKC-mediated 
phosphorylation reduces the generation of caspase-cleaved PS1 CTF which might 
explain the inhibition effect on the progression of apoptosis. However, 
phosphorylation by PKA does not inhibit the caspase-dependent cleavage of PS1, 
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with the function of this phosphorylation remaining unknown (Fluhrer et al., 2004). 
The presenilins are also reported to regulate PKC levels and activity, which might be 
explained as the activation of the system to protect the presenilin proteins from 
caspase-cleavage (Dehvari et al., 2007). Human PS2 CTF is phosphorylated in vivo by 
CK-1 and/or CK-2 at Ser327 and Ser330 which are adjacent to the reported caspase-
cleavage sites (Asp326 and Asp329). Phosphorylation of PS2 CTF also blocks caspase-
dependent cleavage of PS2 CTF and interferes with its function in apoptosis. It was 
also demonstrated that cellular expression of phosphorylated PS2 CTF dramatically 
inhibits apoptosis (Walter et al., 1999). Considering the relevant properties in the 
caspase-dependent cleavage and apoptosis progression, phosphorylation of the 
presenilins at caspase recognition sites are suggested to provide a mechanism to 
protect the presenilins against caspase-dependent cleavage and stabilize the anti-
apoptotic protein. 
Given that the presenilins contain several putative phosphorylation sites, it is no 
surprise that the presenilin proteins have been shown to be phosphorylated by 
several other kinases. Firstly, PS1 is an unprimed substrate of glycogen synthase 
kinase 3β (GSK3β) and is phosphorylated at Ser353, Ser357, Ser397 and Ser410 by 
GSK3β (Kirschenbaum et al., 2001b; Twomey and McCarthy, 2006) (Figure 1.2B). 
GSK3β-mediated phosphorylation of PS1 regulates its binding to N-cadherin. GSK3β-
mediated phosphorylation also regulates APP cleavage by γ-secretase (Uemura et al., 
2007). Another study has demonstrated that GSK3β-mediated phosphorylation 
induces a structural change of the hydrophilic loop of PS1 and reduces the 
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interaction of PS1 with β-catenin which leads to the reduction of β-catenin 
phosphorylation and ubiquitination and stabilizes β-catenin (Prager et al., 2007). 
Another GSK3β phosphorylation site (Ser397) within the loop domain of PS1 has also 
been identified, phosphorylation of which regulates the PS1 CTF levels 
(Kirschenbaum et al., 2001a). Secondly, PS1 is reported to be phosphorylated by 
cyclin-dependent kinase-5/p35 (cdk5/p35) at Thr354 within PS1 CTF both in vitro and 
in vivo (Lau et al., 2002) (Figure 1.2B). Phosphorylation of cdk5/p35 is suggested to 
stabilize PS1 CTF selectively, therefore act as a regulator of PS1 metabolism. Similarly, 
PS1 was showed to be phosphorylated by the dual-specificity tyrosine(Y)-
phosphorylation-regulated kinase 1A (Dyrk1A) also at Thr (354) which stabilizes PS1 
and increases γ-secretase activity (Ryu et al., 2010).Moreover, another study 
identified a c-Jun N-terminal kinase (JNK) phosphorylation site within human PS1 at 
Ser319 and Thr320. This study shows that JNK-dependent phosphorylation of PS1 
enhances the stability of PS1 CTF, and mediates tumour necrosis factor (TNF)-α-
induced stimulation of γ-secretase (Kuo et al., 2008), suggesting that 
phosphorylation of PS1 by JNK might contribute to γ-secretase protease activity and 
therefore the pathogenesis of AD. Finally, recent study showed that phosphorylation 
of PS1 inhibits insulin receptor transcription and expression thus promotes down-
regulation of insulin signalling which may be associated with AD pathology 
considering the role of insulin resistance as a risk factor for sporadic AD (Maesako et 
al., 2012). 
1.5.3 Ubiquitination of presenilins 
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It is reported that, human SEL-10, a homologue of yeast Cdc4, a member of the 
Skp1-Cdc53/CUL1-F-box protein E2-E3 ligase family, interacts with human PS1, and 
enhances its ubiquitination. Furthermore, transfection of SEL-10 increases Aβ levels 
observed with the unexpected reduction of PS1 NTF and CTF levels, suggesting that 
SEL-10-mediated ubiquitination might regulate PS1 activity in APP processing (Li et 
al., 2002). Another earlier report shows that, elimination of SEL-10 activity leads to 
the functional reducing of SEL-12, a C. elegans presenilin homologue (Wu et al., 
1998), which also suggests that SEL-10 regulates presenilin levels and activities. 
Additionally, inhibition of phosphatidylinositol-3 kinase (PI3K) leads to the multiple 
mono-ubiquitination of PS1 and precludes PS1 degradation through the proteasomal 
pathway thus increases level of PS1 and alters its distribution (Aoyagi et al., 2010). 
Moreover, it has been shown that mutation of two lysine residues in PS2 reduces its 
ubiquitination, results in the destabilization of PS2 and inhibits its binding to 
ubiquilin demonstrating the importance of ubiquitination modification for the 
stability and activity of PS2 (Ford and Monteiro, 2007). 
Presenilins undergo proteasome degradation after being modified by 
polyubiquitination (Kim et al., 1997b; Fraser et al., 1998; Marambaud et al., 1998). 
Ubiquilin is an important presenilin-interacting protein involving in proteasome 
degradation pathway of presenilins. Ubiquilin is proposed to interact with 
polyubiquitinated presenilin through its ubiquitin-associated (UBA) domain, thus 
inhibiting presenilin being targeted by proteasomal degradation and leading to 
accumulation of high molecular weight (polyubiquitinated) presenilin (Mah et al., 
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2000; Massey et al., 2004). Mutations of PS2 which disables its binding to Ubiquilin 
result in destabilization of PS2 and increased degradation by proteasome (Ford and 
Monteiro, 2007). AD associated Ubiquilin transcript variant which lacks the 
proteasome-interaction domain also increases levels of full-length PS1 and high 
molecular weight PS1, accumulation of which leads to aggresome formation that is 
further targeted by autophagosome (Viswanathan et al., 2011). Inhibition of 
proteasome degradation or overexpression of presenilin both lead to chaperone-
mediated formation of presenilin-containing aggresome which is considered as a 
general cellular response to misfolded protein that is removed by autophagocytosis 
(Johnston et al., 1998; Kovacs et al., 2006). Other proteins were also reported to 
involve in presenilin proteasomal degradation. Firstly, deletion of the ubiquitin-like 
domain of Herp inhibits the degradation of overexpressed full-length presenilin 
(Marutani et al., 2011). Secondly, inhibition of PI3K increases PS1 level by inducing 
multiple mono-ubiquitination of PS1 which precludes the degradation of PS1 
through the proteasomal pathway (Aoyagi et al., 2010). Finally, knock-out of 
Nicastrin results in decreased PS1 fragments but accumulation of the full-length PS1 
in the ER which is subjected to the proteasome-mediated degradation (Zhang et al., 
2005). 
All studies discussed above confirm a fact that the presenilins are subjected to 
posttranslational modifications which alter the presenilin functions and interactions 
with other proteins. Collectively, a variety of presenilin-dependent activities are 
modulated by posttranslational modification of presenilins. Firstly, caspase-
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dependent cleavage of presenilins is inhibited by the PKC and CK-1/2 induced 
phosphorylation of the presenilin proteins (Walter et al., 1996a; Walter et al., 1999). 
Secondly, β-catenin stability and its nuclear signalling are facilitated by GSK3β-
mediated phosphorylation through modulating the interaction between PS1 and β-
catenin (Prager et al., 2007). Finally, turnover of PS1 and its fragments is affected by 
SEL-10-induced ubiquitination of PS1. Stability of PS1 CTF is altered by cdk5/p35 and 
JNK-dependent phosphorylation of PS1 (Lau et al., 2002; Kuo et al., 2008). Moreover, 
TNF-α-stimulated, JNK-dependent phosphorylation is suggested to mediate γ-
secretase activity (Kuo et al., 2008), indicating a proposed linkage between presenilin 
posttranslational modifications and γ-secretase activity. 
1.6 Protein ubiquitination 
Ubiquitin is a highly conserved 76-amino-acid protein which is covalently attached to 
its ubiquitinated targets through an isopeptide bond between its C-terminal glycine 
and the lysine of the target protein (Vijay-Kumar et al., 1987). Four types of enzymes 
are involved in ubiquitination: E1-E4. First, a high-energy thioester bond is formed 
between E1 (ubiquitin-activating enzyme) and the C-terminal of ubiquitin in an ATP-
dependent reaction. Then the activated ubiquitin is transferred to the cysteine 
residue of E2 (ubiquitin-conjugating enzyme). The E3 enzymes (ubiquitin-ligase) 
catalyses the formation of isopeptide bond with the lysine residue in the substrate 
proteins (Figure 1.3). After the first ubiquitin is attached (monoubiquitination), E3  
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Figure 1.3 The ubiquitination pathway. Ubiquitin is activated in an ATP-dependent 
manner by an ubiquitin-activating enzyme (E1), and it is transferred to an ubiquitin-
conjugating enzyme (E2). The RING domain ubiquitin-protein ligases (E3) interact 
with both E2 and the substrate and transfer the ubiquitin directly from E2 to the 
substrate. The HECT domain E3s firstly link to ubiquitin via E2 and then recruit the 
substrate and catalyse the substrate ubiquitination. 
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ligases can elongate the ubiquitin chain by creating ubiquitin-ubiquitin linkages 
through their lysine residues present in ubiquitin (polyubiquitination). The E4 
enzymes (chain elongation factors) are a subclass of E3-like enzymes which only 
function in ubiquitin chain extension (Pickart, 2004; Ikeda and Dikic, 2008). In the 
human proteome, there are two ubiquitin E1s, ~40 E2s and ~600 E3s. All E2s contain 
an ubiquitin-conjugating domain of ~140 amino acids which has a cysteine residue at 
the active site. E3 ubiquitin ligases can be classified into two subfamilies: HECT 
(homology to E6AP C-terminus) domain E3s which contain a highly conserved 
cysteine residue, and RING (really interesting new gene) domain E3s. There is no 
classical active enzyme site in RING domain E3s, but they can bind to E2s and 
substrates and mediate the ubiquitination of substrates by E2s (Chen and Sun, 2009). 
Ubiquitin has seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, Lys63), 
all of which can be conjugated with another ubiquitin to form polyubiquitin chains of 
different linkages (Peng et al., 2003). Polyubiquitin chains linked through Lys48 of 
ubiquitin lead to degradation of the substrates by the 26S proteasome, whereas 
Lys63 chains perform not only degradation but also other biological functions 
including endocytosis, protein sorting, receptor trafficking and DNA damage repair 
(Pickart, 2001; Madura, 2002). Ubiquitins on substrates can also be disassembled by 
deubiquitination enzymes (DUBs) (Nijman et al., 2005), therefore ubiquitination and 
deubiquitination of target protein can act as a reversible modification. 
At least 20 different ubiquitin-binding domains (UBDs) have been reported, and most 
of them bind to a hydrophobic region surrounding Ile44 of ubiquitin. CUE (coupling 
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of ubiquitin to ER degradation) domain is one of the UBDs which use α-helix to 
contact the Ile44 surface of ubiquitin (Kang et al., 2003; Prag et al., 2003). It is 
reported that CUE domain promotes monoubiquitination of proteins within which it 
is carried and may serve as a scaffold for interaction with E2 enzymes (Ponting, 
2000a; Shih et al., 2003b). 
1.7 TRAF family proteins 
The TNF receptor-associated factor (TRAF) family of proteins have been shown to 
play an important role in several signalling pathway to activate the nuclear factor-
kappa B (NF-κB) transcription factor and mitogen-activated protein kinases (MAPK) 
(Bradley and Pober, 2001; Chung et al., 2002b). Seven members of the TRAF family 
(TRAF1-TRAF7) have been identified so far (Figure 1.4). They share a common 
structural domain, the C-terminal homology region, which is able to bind to the 
cytoplasmic domain of receptors and other TRAF proteins. All TRAF proteins, except 
TRAF1, also contain an N-terminal RING domain which is found in a number of E3 
ubiquitin ligases, followed by several zinc fingers. The RING domain and zinc finger 
domains are essential for the activation of downstream signalling cascades (Chung et 
al., 2002b).  
TRAF6 contains a C-terminal domain, an N-terminal domain, and a series of four zinc 
fingers which connects the N- and C-terminal regions. One study showed that the 
first zinc finger and an intact RING domain of TRAF6 are required for its functions in   
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Figure 1.4 Domain structure of the TNF receptor-associated factor (TRAF) protein 
family. TRAF1, unlike other TRAF members, does not contain the N-terminal really 
interesting new gene (RING) and zinc-finger (Zn) domains. The C-terminal TRAF 
domain comprises of the coiled-coil domain and a highly conserved TRAF-C domain. 
TRAF7 is structurally different by identification of seven WD40 domains at its C-
terminus instead of the TRAF domain. 
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interleukin-1 (IL-1), lipopolysaccharide (LPS) and receptor activator of nuclear factor-
κB ligand (RANKL) signalling (Lamothe et al., 2008). In conjugation with a dimeric E2 
enzyme complex (Ubc13-UeV1A), the RING domain of TRAF6 achieves E3 ubiquitin 
ligase activity to catalyse the formation of a poly-ubiquitin chain linked through Lys-
63 of ubiquitin (Deng et al., 2000). Unlike Lys48-linked polyubiquitination, which 
targets proteins for proteasomal degradation, Lys63-linked polyubiquitination does 
not degrade targeted proteins, but activates signalling pathways. 
TRAF6 can facilitate its own site-specific autoubiquitination by generating a Lys63-
linked polyubiquitination chain (Deng et al., 2000) and also activate itself by Lys63-
linked polyubiquitination. Autoubiquitination of TRAF6 leads to recruitment and 
activation of TAK1 (transforming growth factor β (TGFβ)-activated kinase 1) –TAB1 
(TAK1-binding protein 1) –TAB2/3 complex, as TAB2/3 specifically recognizes Lys63-
linked polyubiquitination chain on TRAF6 and recruits TAK1 to TRAF6 complexes 
(Figure 1.5). Activated TAK1 complex then phosphorylates and activates inhibitor of 
κ-B kinase (IKK) and mitogen-activated protein kinase kinases (MKKs) and these in 
turn phosphorylates and activate NF-κB and MAPKs such like JNK and p38 (Wang et 
al., 2001; Kanayama et al., 2004). NF-κB essential modifier (NEMO) acts like a target 
of Lys63-linked polyubiquitination within the IKK complex and TRAF6-mediated 
polyubiquitination of NEMO was reported to be required for the optimal NF-κB 
activation by Toll-like receptor 4 (TLR4) (Abbott et al., 2007). In the IL-1 or LPS 
induced IL-1R1 or TLR4 signalling pathway, myeloid differentiation protein 88  
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Figure 1.5 TRAF6 mediated IL-1R1/TLR4 signalling pathway. IL-1R/TLR4 stimulation 
leads to the formation of the complex with IL-1RAcP or TLR4 itself, allowing the 
recruitment of downstream adaptor including Mal or Tollip, MyD88 and IRAK1/4. 
Endocytosis of this complex is followed by recruitment of TRAF6 (require for TRIF 
and TRAM for TLR4). In combination with an E2 enzyme Ubc13, TRAF6 ubiquitinates 
and activates itself via Lys63-linked polyubiquitination chain. This autoubiquitination 
of TRAF6 leads to recruitment and activation of the downstream TAK1-TAB1-TAB2/3 
complex. Both IKKβ and MKK family members are targets of TAK1 phosphorylation, 
and subsequently phosphorylate and activate IκB and JNK and p38 MAPKs. Activated 
inhibitor of NF-κB (IκB) is targeted by Lys48-linked polyubiquitination and is 
degraded by 26S proteasome, thus releasing NF-κB. 
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(MyD88) and IL-1 receptor associated kinase (IRAK) form complex with IL-1R1 or 
TLR4 after stimulation of IL-1 or LPS, and then TRAF6 is recruited as an adaptor 
protein in the endosome to the IL-1R1 or TLR4 complex, formation of which leads to 
the activation of NF-κB (Greenfeder et al., 1995b; Huang et al., 1997a; Wesche et al., 
1997; Hull et al., 2002; Li et al., 2006b). Collectively, TRAF6 is involved in the 
activations of IKK, p38 and JNK induced by IL-1 and LPS. TRAF6 also plays an essential 
role in RANKL-dependent osteoclastogenesis by associating with RANK (Bai et al., 
2005). Moreover, TRAF6 negatively regulates TNFα-induced NF-κB activation through 
its ubiquitin ligase activity (Funakoshi-Tago et al., 2009). TRAF6 also negatively 
regulates the Jak1-Erk pathway in IL-2 signalling by competing with Jak1 for IL-2R 
binding site (Motegi et al., 2011). More recently, TRAF6 has been shown to promote 
myogenic differentiation and muscle regeneration via the TAK1/p38 MAPK and Akt 
pathways suggesting its importance beyond inflammatory response (Xiao et al., 
2012). 
1.8 Role of TRAF6 and calcium signalling in osteoclastogenesis. 
Association between TRAF6 and RANK is essential for RANKL-mediated NF-κB, c-Src 
kinase, Akt and PI3K activation (Galibert et al., 1998; Darnay et al., 1999; Wong et al., 
1999). RANK is a critical signalling receptor modulating osteoclast differentiation, 
activation and survival (Lacey et al., 1998; Yasuda et al., 1998; Burgess et al., 1999; 
Lacey et al., 2000). Interaction of TRAF6 with RANK was shown to be required for the 
proper formation of cytoskeletal structures and functional bone resorption of 
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osteoclasts (Armstrong et al., 2002). Additionally, TRAF6 E3 ligase activity is required 
in regulating RANK signalling and osteoclast differentiation (Lamothe et al., 2007b). 
Deficiency of TRAF6 results in severe osteopetrosis in vivo, which was observed with 
defective interleukin-1 (IL-1), CD40 and lipopolysaccharide (LPS) signalling 
transductions (Lomaga et al., 1999b; Naito et al., 1999). In addition to RANKL-
mediated osteoclast activation, TRAF6 is also reported to be essential for TNF-
related apoptosis-induced ligand (TRAIL) induced osteoclast differentiation, 
suggesting a broader role of TRAF6 in regulating functions of osteoclast (Yen et al., 
2012). 
Calcium signalling also plays a critical role in the differentiation and functions of 
osteoclasts. RANKL signalling induces oscillatory changes in intracellular Ca2+ 
concentration (Takayanagi et al., 2002). Ca2+ oscillation results in dephosphorylation 
and activation of nuclear factor of activated T cell c1 (NFATc1), which translocates to 
the nucleus and induces osteoclast-specific gene transcription to trigger the 
differentiation of osteoclasts.   Abolishment of RANKL-induced Ca2+ oscillation leads 
to impaired up-regulation of NFATc1 and osteoclastogenesis (Yang and Li, 2007), 
suggesting the importance of RANKL-induced Ca2+ oscillation in osteoclastogenesis. 
RANKL signalling triggers production of Inositol trisphosphate (IP3) through the 
activation of PLCγ, which leads to the release of Ca2+ from ER (Shinohara et al., 
2008). Store-operated Ca2+ entry after Ca2+ release from ER is an important 
component of the Ca2+ oscillations, blocking of which results in abolished RANKL-
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induced Ca2+ oscillations and bone resorption activity of osteoclasts (Mentaverri et 
al., 2003). 
Skeletal defects have been observed in PS1 deficient mice (Shen et al., 1997; 
Mastrangelo et al., 2005) and these defects were attributed to disrupted γ-secretase 
cleavage of Notch. In vitro studies have shown that osteoclastogenesis can be 
regulated negatively by Notch1 signalling or positively by Notch2 signalling (Bai et al., 
2008; Fukushima et al., 2008). However, Wnt signalling, which is negatively regulated 
by presenilin, is also required for osteoclast differentiation (Glass and Karsenty, 
2006; Dobrowolski et al., 2012). Moreover, the APP Swedish mutation was suggested 
to regulate osteoclast differentiation in an age-dependent manner (Cui et al., 2011). 
Although presenilin itself was reported to function as passive ER Ca2+ leak channel, 
the role of this Ca2+ signalling event in osteoclastogenesis has not been discovered so 
far. 
1.9 IL-1R1/TLR4 signalling and receptor post-translational modifications 
Nine members of the IL-1 receptor (IL-1R) superfamily and thirteen members of the 
Toll-like receptor (TLR) superfamily have been discovered over the last decade. 
Besides the homologous cytoplasmic Toll/IL-1R resistance (TIR) domain, IL-1R 
superfamily members all contain extracellular Ig domains whereas TLR superfamily 
members contain Leucine-rich repeat domain in the N-terminus. Upon IL-1α/β 
binding, IL-1R1 associates with IL-1 receptor accessory protein (IL-1RAcP) 
(Greenfeder et al., 1995a; Huang et al., 1997b), leading to the recruitment of the TIR 
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domain containing adaptor MyD88, the serine/threonine kinase IL-1 receptor-
associated kinase 1 (IRAK1), IRAK4 and the toll interacting protein (Tollip) (Wesche et 
al., 1997; Burns et al., 2000). IRAK1 contains three TRAF6 interaction consensus 
motifs in the C-terminal domain which enable the recruitment of TRAF6 (Ye et al., 
2002). Activation of IRAK4 through its intramolecular autophosphorylation leads to 
the phosphorylation of IRAK1 and the full kinase activity (Kollewe et al., 2004; Cheng 
et al., 2007). IRAK1 and IRAK4 then dissociate from MyD88 and interact with TRAF6 
while they still remain in the complex with IL-1R1 and IL-1RAcP (Deng et al., 2000; 
Brikos et al., 2007). TRAF6 is then activated by K63-linked autoubiquitination, 
dependent on the activity of E2 ubiquitin-conjugating complex Ubc13 and Uev1a 
(Deng et al., 2000). The IRAK/TRAF6 can then recruit TAK1 in a complex with TAB1 
and TAB2 (or TAB3) and activation of TAK1 leads to the translocation of the complex 
to the cytosol (Qian et al., 2001; Jiang et al., 2002). Activated TAK1 then couples to 
the IKK complex containing NEMO and IKK where IKK is phosphorylated and 
activated by TAK1 which leads to the degradation of IκB and the consequent NF-κB 
activation (Wang et al., 2001). TAK1 also couples to the MKKs which leads to the 
activation of p38 and JNK. IRAK1 dissociated upon TAK1 activation remains in the 
membrane and undergoes K63-linked polyubiquitination mediated by Pellino (Butler 
et al., 2007; Schauvliege et al., 2007; Ordureau et al., 2008). It has been proposed 
that K63-linked polyubiquitination of IRAK1 recruits NEMO and may therefore 
provide an alternative pathway for NF-κB activation (Conze et al., 2008). 
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Signalling of TLR4 shares the general theme with IL-1R1 signalling but is more 
complex and involves a variety of adaptor proteins. Upon lipopolysaccharide (LPS) 
stimulation, TLR4 forms homodimers and recruits MyD88 through another TIR 
domain-containing adaptor, MyD88 adaptor like (Mal). Then the IRAK1/4 and TRAF6 
are recruited which leads to the activation of the NF-κB pathway and MAPK 
pathways same as described above for IL-1R1 signalling. Additionally, the 
TLR4/Mal/MyD88 complex is also endocytosed to the early endosome where the TIR 
domain-containing adaptor-inducing interferon-β (TRIF) and TRIF-related adapter 
molecule (TRAM) are recruited (Kagan et al., 2008). TRIF associates with TRAF6 to 
induce NF-κB activation and with receptor-interacting protein 1 (RIP1) to apoptosis 
(O'Neill and Bowie, 2007). This complex also activates TANK-binding kinase-1 and 
IKKε, leading to the dimerization and phosphorylation of the transcription factor 
interferon regulatory factor 3 (IRF3), which is required for activation of type I 
interferon promoters (Kawai and Akira, 2006).  
Although many studies have been carried out to understand the functions IL-
1R1/TLR4 signalling complexes and the exact role of each adaptor protein, very little 
is known about the post-translational modification of IL-1R1 and TLR4 themselves. 
Extracellular domain of IL-1R1 is glycosylated which is considered essential for its 
optimal binding to IL-1 (Mancilla et al., 1992). Similarly, glycosylation of TLR4 
extracellular domain is essential for the LPS-induced activation of TLR4 signalling 
pathway as well as TLR4 plasma membrane expression (da Silva Correia and Ulevitch, 
2002). Murine IL-1R1 is phosphorylated upon PMA treatment, but no consequent 
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effect was observed for this modification (Bird et al., 1991). IL-1R1 is also shown to 
be poly-ubiquitinated upon IL-1β stimulation and interact with two ubiquitin-binding 
proteins Tollip and Tom1, which modulates sorting of IL-1R1 in the late endosome to 
lysosome degradation (Brissoni et al., 2006). Besides of IL-1β, high glucose also 
triggers down regulation of IL-1R1 through lysosome degradation (Aveleira et al., 
2010). The same study also observed translocation of IL-1R1 to the nucleus upon 
stimulation of IL-1β or high glucose. Previously, our group reported IL-1R1 as a 
substrate for γ-secretase-dependent regulated intramembrane proteolysis inhibition 
of which impairs its activation upon IL-1β stimulation (Elzinga et al., 2009a). An 
intracellular fragment was observed after γ-secretase cleavage of the C-terminus 
fragment, which is speculated to translocate to the nucleus. Furthermore, TRAF6 was 
shown to promote poly-ubiquitination of IL-1R1, increasing the cellular levels of full-
length IL-1R1 protein as well as the C-terminus domain and the intracellular domain 
(Twomey et al., 2009). 
1.10 TNFR1 signalling 
Not like IR-1R1 or TLR4, TNFR1 signalling is mediated by TRAF2 and TRAF5 (Au and 
Yeh, 2007). Knock-out of TRAF6 results in no defects in NF-κB activation in response 
to TNFα treatment (Lomaga et al., 1999a). However, TRAF6 is required for the 
signalling of two other TNFR superfamily members, CD40 and RANK (Lomaga et al., 
1999a; Davies et al., 2005). Additionally, TRAF2 and TRAF6 are both required for 
TNFα-induced activation of mixed lineage kinase 3 (MLK3), which is a MAP3K 
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member (Korchnak et al., 2009). Stimulation of TNFα leads to the activation of 
TNFR1 and the recruitment of the signalling molecule TNFR associated death domain 
(TRADD) and the receptor interacting protein 1 (RIP1) (Hsu et al., 1996b; Hsu et al., 
1996a). Activated complex is then relocated to lipid rafts, where TNFR1 and RIP1 
become polyubiquitinated (Legler et al., 2003; Lee et al., 2004). RIP1 then recruits 
and activates TAK1 which leads to downstream activation of NF-κB. Another member 
of MAP3K, MEKK3, is also recruited to TNFR1 complex via RIP1 upon TNFα treatment 
(Yang et al., 2001; Blonska et al., 2004). MEKK3 then phosphorylates and activates 
IKKβ, providing a TAK1-independent pathway for NF-κB activation. TRAF5 has also 
been implicated in TNF-induced NF-κB activation, as depletion of TRAF2 only 
abolishes TNF-induced JNK activation whereas depletion of both TRAF2 and TRAF5 
are required for abrogating NF-κB activation (Tada et al., 2001). In addition, 
activation of TNFR1 complex leads to internalisation and recruitment of Fas-
associated death domain (FADD) and caspase-8 to induce apoptosis (Micheau and 
Tschopp, 2003). In contrast to the positive role of TRAF6 in IL1-R1/TLR4 signalling, 
TRAF2 and TRAF6 have been report to negatively regulate TNFR1 activity. Firstly, 
deficiency of TRAF2 results in hyperactivity of certain TNFR1 signals (Nguyen et al., 
1999). Moreover, TNFα-induced IKK activation, IκBα degradation and transcriptional 
activation of NF-κB are all enhanced in TRAF6-deficient MEFs, suggesting that TRAF6 
negatively regulates TNFα-induced NF-κB activation (Funakoshi-Tago et al., 2009). 
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1.11 Diversity of gamma-secretase substrates 
Subsequent to the characterisation of γ-secretase-mediated proteolysis of APP and 
its association with the pathogenesis of AD, several independent groups have 
reported γ-secretase mediated proteolysis of more than 100 type-I membrane 
proteins, including Notch receptor (Figure 1.5) (Boulton et al., 2008; Lleo, 2008; 
McCarthy et al., 2009b; Haapasalo and Kovacs, 2011; Lleo and Saura, 2011). 
Although the absence of any immediately obvious or unifying biological function 
makes it difficult to predict whether or not a protein is a γ-secretase substrates, from 
the characterisation of known γ-secretase substrates there are emerging patterns 
that indicate the existence of some degree of regulation and unifying characteristics 
common to most substrate. Indeed all γ-secretase substrates are united in that all 
are (i) type-I integral membrane proteins (ii) have undergone ectodomain shedding 
as a result of proteolysis in their extracellular domains (iii) have a prerequisite for 
ectodomain shedding prior to γ-secretase cleavage of the remaining membrane-
tethered C-terminal fragment. The lack of any significant substrate-specificity and 
ever increasing numbers of reported substrates has led to studies aimed at 
understanding the regulation of γ-secretase complexes and their proteolytic 
activities. The requirement for ectodomain shedding has led to the proposal that 
some degree of regulation must surround subsequent γ-secretase cleavage, which is 
supported by the observed ligand-induced ectodomain shedding and γ-secretase 
cleavage of many substrates. Likewise, posttranslational modification of certain γ-
secretase substrates has been shown to regulate substrate cleavage, where   
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Figure 1.5 Regulated Intramembrane proteolysis and Notch signalling. Cell surface 
heterodimeric Notch receptor is activated by binding to ligand presented by a 
neighbouring transmitting (signal) cell, and activates a signalling cascade through 
sequential proteolytic cleavage events. Ligand binding is proposed to induce a 
conformational change in the ligand-bound receptor, enabling Notch extracellular 
domain cleavage at site 2 (S2) by a disintigrin and metalloproteinase (ADAM) 
protease, release of Notch extracellular domain and generation of the membrane-
anchored Notch extracellular truncation (NEXT) fragment. Subsequently, NEXT is 
progressively cleaved within the transmembrane domain by γ-secretase at site 3 (S3) 
and site 4 (S4) cleavage sites to generate the cytosolic Notch intracellular domain 
(NICD). Notch cleavage by γ -secretase can occur at the plasma membrane or 
endosomal compartments producing NICD fragments with different stability. NICD 
then enters the nucleus where it interacts with the DNA-binding protein CSL 
(CBF1/RBPjκ/Su (H)/Lag-1), releases co-repressors (CoR), and enables recruitment of 
transcriptional co-activators Mastermind and p300. These interactions convert CSL 
from a transcriptional repressor to an activator. Notch ligands (Delta and Jagged) are 
also γ-secretase substrates, though the physiological consequence remains to be 
determined. 
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ubiquitination of human Notch-CTD (Gupta-Rossi et al., 2004a) and Interleukin-1 
receptor type 1 (IL-1R1) (Twomey et al., 2009) and palmytolation of the p75NTR 
(Underwood et al., 2008) are a prerequisite for γ-secretase cleavage. However, 
recent data suggest that posttranslational modification may not be a general 
requirement for cleavage of all γ-secretase substrates (McCarthy et al., 2009b). One 
further and important factor that requires further investigation arises from studies 
proposing that γ-secretase activity and cleavage of certain substrates may be 
determined by their spatiotemporal location (Hass et al., 2008), prompting more 
rigorous in vivo studies. 
Despite the fact that all reported substrates have little or no sequence homology 
around their cleavage sites mutagenesis studies on APP, Notch and other substrates 
have identified certain hydrophobic residues in the transmembrane and intracellular 
juxtamembrane domains that determine γ-secretase cleavage efficiency and 
importantly, substrate-specificity (Schroeter et al., 1998; Weidemann et al., 2002). 
These reports have led to the proposed hypothesis that γ-secretase requires subtle 
sequence or structural characteristics, which enable substrate recognition and 
cleavage. Likewise, certain PS1 variants associated with FAD have been shown to 
differentially affect APP proteolysis at the ε- and γ-cleavage sites (Tolia et al., 2006; 
Tolia et al., 2008). Indeed, site-directed mutagenesis studies have reported that 
substitution of a phenylanine at position x of the GxGD aspartyl protease active site 
motif of presenilin results in preferential cleavage of APP over Notch (Yamasaki et al., 
2006), while a single substitution (I437C) in TMD9 renders γ-secretase inactive 
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towards cleavage of Notch, but not APP (Tolia et al., 2008). Based on the diversity of 
reported γ-secretase substrates, there are a number of proposed functional 
consequences of regulated intramembrane proteolysis. Firstly, it is proposed that 
following receptor-ectodomain shedding, γ-secretase may be involved in the 
proteolytic removal of membrane-anchored protein fragments from the membrane, 
acting as the proteasome of the membrane (Kopan and Ilagan, 2004). Secondly, it 
has been demonstrated for certain specific substrates, that the γ-secretase 
generated intracellular domain (ICD) has a central role in mediating ligand-initiated 
nuclear signalling events whereby the ICD can translocate to the nucleus and 
regulate gene transcription (Pardossi-Piquard et al., 2005; Hebert et al., 2006; Sardi 
et al., 2006; Wolfe, 2008a; Carpenter and Red Brewer, 2009; Maetzel et al., 2009). 
Thirdly, γ-secretase cleavage of substrates may function to initiate a novel receptor-
independent function whereby the soluble ICD can translocate to another 
intracellular compartment to initiate a novel biological function (Boulton et al., 2008; 
Hass et al., 2008). Finally, γ-secretase cleavage may also function to terminate a 
transmembrane receptor-mediated signalling event (Jung et al., 2003). In summary, 
although increasing numbers of γ-secretase substrates are being identified and 
attributed in vitro biological functions (Hass et al., 2008; McCarthy et al., 2009b), no 
unifying regulatory mechanism controlling γ-secretase activity or common in vivo 
biological consequence of γ-secretase cleavage has emerged. To date there are only 
three γ-secretase substrates wherein an in vivo physiological signalling function has 
been convincingly attributed to γ-secretase cleavage, further highlighting the need 
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for more rigorous in vivo studies to delineate the physiological importance of γ-
secretase-mediated cleavage of each reported substrate (Louvi and Artavanis-
Tsakonas, 2006; Sardi et al., 2006; Wang et al., 2008). 
Having given the description of covalent and proteolytic posttranslational 
modifications of presenilins, the existence of six subtypes of γ-secretase complex, a 
diversity of γ-secretase interacting partners and substrates and the complexity of the 
signalling pathways of IL-1R1, TLR4 and TNFR1, it is self-evident that a 
comprehensive understanding of the regulation and mechanism of γ-secretase 
complexes and presenilins as well as of the γ-secretase substrates (IL-
1R1/TLR4/TNFR1) will be requisite for the development of cell biology and 
therapeutic strategies for AD and immune disorders. 
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1.12 Research objective 
The aim of this research project was to characterise and determine the importance 
of the interaction between presenilins and TRAF6 and the regulation of IL-1R1 by 
TRAF6. TRAF2 and TRAF6 are E3 ubiquitin ligases that specifically interact with the 
presenilin proteins, suggesting that this interaction serves as a novel means of 
regulating presenilin functions and γ-secretase activity. Additionally, TRAF2, TRAF5 
and TRAF6 have been reported to form signalling complexes with TNFR1 and IL-
1R1/TLR4 respectively and to be essential for the signalling transduction. However, 
the roles of the TRAF regulation on the receptors themselves have not been widely 
studied. This project employed in vitro cell-based experimental approaches, 
recombinant DNA technologies, co-immunoprecipitation and immunobiology to 
determine the importance of the interactions between presenilins and TRAFs and 
their effects on presenilin and γ-secretase activity. Moreover, regulation of IL-1R1 by 
TRAF6 has been further explored, revealing the novel role of TRAF6 other than 
adaptor protein. This study yields new insights into TRAF6-mediated presenilin and 
IL-1R1 functions and contributes to our understanding of the regulation and 
complexity of presenilin biology and IL-1R1 signalling. 
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2.1 Materials  
2.1.1 General chemicals and reagents 
All salts, reagents and Anti-Flag Agarose Beads were purchased from Sigma-Aldrich 
(Dublin, Ireland) unless otherwise stated. Protein G-sepharose beads and DNA ladder 
were procured from Invitrogen (Paisley, Scotland). Prestained molecular weight 
protein markers were purchased from BioRad Laboratories (GmbH, Munich, 
Germany). Bicinoic acid (BCA) protein concentration reagents were purchased from 
Pierce Biotechnology (Rockford, Illinois) through Medical Supply Company (MSC) Ltd. 
(Dublin, Ireland). Nitrocellulose membrane and Western blotting filter paper were 
purchased from Schleicher and Schuell (GambH, Dassel, Germany). Complete 
protease inhibitor tablets were purchased from Roche (Boehringer-Mannheim, 
Indianapolis, USA). 
2.1.2 Molecular biology reagents 
All restriction enzymes were purchased from New England Biolabs through ISIS (Co. 
Wicklow, Ireland). Maxiprep kits was purchased from Qiagen Ltd. (West Sussex, UK).  
2.1.3 Plasmid sources 
HA-tagged ubiquitin, HA-tagged all-lysine-mutated ubiquitin (ubiquitin K0) and HA-
tagged K63R ubiquitin were provided by Dr Ruaidhri Carmody (University of Glasgow, 
UK). PDLIM2 and β-TRCP were gifts from Dr Rosemary O’Connor (University College 
Cork, Ireland). PS1 NTF, PS1 CTF and APP CT100 were gifts from Scios Incorporation. 
All TRAF constructs, TNFR1 and IL1-R1 were gifts from Genentech Inc. The rest of the 
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constructs listed below were generated previously in our lab. The following plasmids 
were used:  
Construct  Vector Source  Epitope Tag__ 
APP SW  pcDNA3 Scios Inc.  untagged 
APP CT100 pcDNA3 Scios Inc.  untagged 
Empty Vector  pcDNA3 Invitrogen  untagged 
IL-1R1 WT  pcDNA3 Genentech Inc.  untagged 
PS1 WT  pcDNA3 (Powell et al., 2009) untagged 
PS1 D257A/D385A  pcDNA3 (Elzinga et al., 2009b) untagged 
PS1 L271A  pcDNA3 created in lab  untagged 
PS1 F283A  pcDNA3 created in lab  untagged 
PS1 V309A  pcDNA3 created in lab  untagged 
PS1 S310A  pcDNA3 created in lab  untagged 
PS1ΔCUE  pcDNA3 created in lab  untagged 
PS2 WT  pcDNA3 (Elzinga et al., 2009b) untagged 
PS2ΔCUE  pcDNA3 created in lab  untagged 
PS1 WT  Nse Scios Inc.  untagged 
PS1 NTF  Nse Scios Inc.  untagged 
PS1 CTF  Nse Scios Inc.  untagged 
PDLIM2  Pcmv (Loughran et al., 2005) Myc 
TRAF2  pRK 5 Genentech Inc.  FLAG 
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TRAF3  pRK 5 Genentech Inc.  FLAG 
TRAF4  pRK 5 Genentech Inc.  FLAG 
TRAF5  pRK 5 Genentech Inc.  FLAG 
TRAF6  pRK 5 Genentech Inc.  FLAG 
TRAF6 DN  pRK 5 Genentech Inc.  FLAG 
TRAF2 DN  pRK 5  Genentech Inc.  FLAG 
TRAF6 C70A  pRK 5 (Twomey et al., 2009) FLAG 
TRAF6 K124A  pRK 5 (Twomey et al., 2009) FLAG 
β-TRCP  pAS1B Dr. Rosemary O’Connor HA 
TLR4  pcDNA3 Addgene  YFP 
TNFR1  pcDNA3 Genentech Inc.  untagged 
Ubiquitin WT Unknown (Carmody et al., 2007) HA 
Ubiquitin K63R Unknown (Carmody et al., 2007) HA 
Ubiquitin K0 Unknown (Carmody et al., 2007) HA 
The PS1, PS2 and IL-1R1 mutants which were created in our lab used human PSEN1 
(NCBI NM_000021.3), human PSEN2 (NCBI NM_000447.2) and human IL-1R1 (NCBI 
NM_000877.2) sequences as templates respectively. Names of the mutants and the 
corresponding primers are listed below. 
PS1ΔCUE: 
PS1 forward 5’ CGGGGTACCGCCATGACAGAGTTACCTGCACCGTTGTCC 3’ Kpn1 
PS1 CUE reverse   5’ TTCTGCATTATAAGCCACTAAATCATATACTGA 3’ 
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PS1 CUE forward 5’ GATTTAGTGGCTTATAATGCAGAAAGCACAGAA 3’ 
PS1 reverse 5’ CCGGAATTCCTAGATATAAAATTGATGGAATGCTAATTG 3’ EcoR1 
PS1ΔCUE: 
PS2 CUE reverse  5’  TTCCATCTCCGGAGCCACGAGATCATACACAGA 3’ 
PS2 CUE forward  5’ GATCTCGTGGCTCCGGAGATGGAAGAAGACTCC 3’ 
PS2 forward 5’ GCCGGGATCCGCCATGCTCACATTCATGGCCTCTG 3’ BamH1 
PS2 reverse 5’ GCCGGAATTCTCAGATGTAGAGCTGATGGGAG 3’ EcoR1 
 
PS1 L271A forward   5' GAGAGAAATGAAACCGCTTTTCCAGCTCTCATTTAC 3' 
PS1 L271A reverse    5' GTAAATGAGAGCTGGAAAAGCCGTTTCATTTCTCTC 3' 
PS1 F283A forward   5’ GAGAAATGAAACGCTTGCTCCAGCTCTCATTTACTCC 3’ 
PS1 F283A reverse    5’ GGAGTAAATGAGAGCTGGAGCAAGCGT TTCATTTCTC 3’ 
PS1 V309A forward   5’ GGGAAGCTCAAAGGAGAGCATCCAAAAATTCCAAG 3’ 
PS1 V309A reverse   5’ CTTGGAATTTTTGGATGCTCTCCTTTGAGCTTCCG 3’ 
PS1 S310A forward   5’ CGGAAGCTCAAAGGAGAGTAGCCAAAAATTCCAAG 3’  
PS1 S310A reverse   5’ CTTGGAATTTTTGGCTACTCTCCTTTGAGCTTCCG 3’ 
PS1 K76RK80R forward 5’ ACATTGAGATATGGCGCCAGGCATGTG 3’ 
PS1 K76RK80R reverse 5’ CACATGCCTGGCGCCATATCTCAATGT 3’ 
PS1K109R forward 5’ TACCCGGAGGGATGGGC 3’ 
PS1K109R reverse 5’ GCCCATCCCTCCGGGTA 3’ 
PS1 K155RK160R forward 5’ TTCTGTATAGATACAGGTGCTATAGGGTCATCCATG 3’ 
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PS1 K155RK160R reverse 5’ CATGGATGACCCTATAGCACCTGTATCTATACAGAA 3’ 
PS1 K187R forward 5’ GTGTTTAGAACCTATAACG 3’        
PS1 K187R reverse 5’ CGTTATAGGTTCTAAACAC 3’        
PS1 K216R forward 5’ TCACTGGAGAGGTCCACTTCG 3’ 
PS1 K216R reverse 5’CGAAGTGGACCTCTCCAGTGA 3’ 
PS1 K265R forward 5’ TGTCCGAGAGGTCCACTTCG 3’            
PS1 K265R reverse 5’ CGAAGTGGACCTCTCGGACA 3’            
PS1 K311RK314R forward 5’ GTATCCAGAAATTCCAGGTATAATGC 3’    
PS1 K311RK314R reverse 5 ’GCATTATACCTGGAATTTCTGGATAC 3’      
PS1 K380R forward 5’ GGGGAGTAAGACTTGGATTGG 3’ 
PS1 K380R reverse 5’ CCAATCCAAGTCTTACTCCCC 3’ 
PS1 K429RK430R forward 5’ CATTTTCAGGAGAGCATT 3’ 
PS1 K429RK430R reverse 5’ AATGCTCTCCTGAAAATG 3’ 
IL1-R1 1-540 forward CGGGGTACCGCCATGAAAGTGTTACTCAGACTTATTTG   Kpn1 
IL1-R1 1-540 reverse CCGGAATTCCTACCTGACATTCTTCCAGAACC    EcoR1 
IL1-R1 1-500 forward CGGGGTACCGCCATGAAAGTGTTACTCAGACTTATTTG   Kpn1 
IL1-R1 1-500 reverse CCGGAATTCCTATGGCATTTTCTCATAGTCTTGG     EcoR1 
IL1-R1 1-440 forward CGGGGTACCGCCATGAAAGTGTTACTCAGACTTATTTG   Kpn1 
IL1-R1 1-440 reverse CCGGAATTCCTAAATGACCTCAACAATGTCTTCCCC     EcoR1 
IL1-R1 1-390 forward CGGGGTACCGCCATGAAAGTGTTACTCAGACTTATTTG   Kpn1 
IL1-R1 1-390 reverse CCGGAATTCCTACAGTATATATGCGTCATAGGTCTTTCC     EcoR1 
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IL1-R1 1-356 forward CGGGGTACCGCCATGAAAGTGTTACTCAGACTTATTTG   Kpn1 
IL1-R1 1-356 reverse CCGGAATTCCTAATAGATGAAAACAGAACACAC EcoR1 
IL1R1 K445446R forward 5’ GAAAACGTAAGGAGAAGCAGAAGAC 3’ 
IL1R1 K445446R reverse 5’ GTCTTCTGCTTCTCCTTACGTTTTC 3’ 
IL1R1 K504507R forward 5’ GAATCGATTAGATTCATTAGGCAGAAACATG 3’ 
IL1R1 K504507R reverse 5’ CATGTTTCTGCCTAATGAATCTAATCGATTC 3’ 
IL1R1 K527532R forward 5’ CAGTCTGCAAGGACAAGGTTCTGGAGGAATGTCAGG 3’ 
IL1R1 K527532R reverse 5’ CCTGACATTCCTCCAGAACCTTGTCCTTGCAGACTG 3’ 
IL1R1 K548R forward 5’ CCTTCATCTAGACACCAGTTAC 3’ 
IL1R1 K548R reverse 5’ GTAACTGGTGTCTAGATGAAGG 3’ 
IL1R1 K378383R forward 5’ CCAATAAGAGCTTCAGATGGAAGGACCTATG 3’ 
IL1R1 K378383R reverse 5’ CATAGGTCCTTCCATCTGAAGCTCTTATTGG 3’ 
IL1R1 K393R forward 5’ GCATATATACTGTATCCAAGGACTGTTGGGGAAGG 3’ 
IL1R1 K393R reverse 5’ CCTTCCCCAACAGTCCTTGGATACAGTATATATGC 3’ 
IL1R1 K409R forward 5’ GTGATATTTTTGTGTTTAGAGTCTTGCCTGAGG 3’ 
IL1R1 K409R reverse 5’ CCTCAGGCAAGACTCTAAACACAAAAATATCAC 3’ 
IL1R1 K417422R forward 5’ CTTGGAAAGACAGTGTGGATATAGGCTGTTC 3’ 
IL1R1 K417422R reverse 5’ GAACAGCCTATATCCACACTGTCTTTCCAAG 3’ 
IL1R1 K357360R forward 5’ CTGTTTTCATCTATAGAATCTTCAGGATTGACATTGTG 3’ 
IL1R1 K357360R reverse 5’ CACAATGTCAATCCTGAAGATTCTATAGATGAAAACAG 3’ 
IL1R1 K360R forward 5’ CATCTATAAAATCTTCAGGATTGACATTGTG 3’ 
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IL1R1 K360R reverse 5’ CACAATGTCAATCCTGAAGATTTTATAGATG 3’ 
IL1R1 K378R forward 5’ CCAATAAGAGCTTCAGATGGAAAGACCTATG 3’ 
IL1R1 K378R reverse 5’ CATAGGTCTTTCCATCTGAAGCTCTTATTGG 3’ 
PS1 K76/80R, PS1 K109R, PS1 K155/160R, PS1 K187R, PS1 K216R, PS1 K265R, PS1 
K311/314R, PS1 K380R, PS1 K429/430R, IL-1R1 K357/360R, IL-1R1 K378/383R, IL-1R1 
K393R, IL-1R1 K409R, IL-1R1 K417/422R, IL-1R1 K445/446R, IL-1R1 K504/507R, IL-1R1 
K527/532R, IL-1R1 K548R, IL-1R1 K360/378R, IL-1R1 K356/360/378R, IL-1R1 
K360/378/383R, IL-1R1 K357/360/378/383R, IL-1R1 K360/378/383/527/532R are all 
made by site-directed mutagenesis as described below. PS1 CUE, PS2 CUE, IL-1R1 
1-535, IL-1R1 1-500, IL-1R1 1-440, IL-1R1 1-390, IL-1R1 1-356 are generated by PCR 
and DNA ligation in our lab. 
2.1.4 Antibodies 
All antibodies were obtained from commercial sources: Rat anti-human PS1-NTF and 
anti-human PS1-CTF were purchased from Chemicon (Hamphshire, UK); anti-HA 
were purchased from Covance (Berkely, California, USA); anti-Nicastrin antibody was 
purchased from BD Biosciences; anti-β-actin, anti-myc, anti-FLAG, anti-APP CTF and 
anti-β-Tubulin were purchased from Sigma-Aldrich (Dublin, Ireland); anti-Ubiquitin 
(P4D1), anti-p-JNK, anti-JNK1, anti-TRAF6, anti-Aph1, anti-PEN2, anti-IL-1R1 C20, 
anti-IL-1R1 N20 and TLR4 antibodies were purchased from Santa-Cruz Biotechnology 
(California, USA); polyclonal rabbit anti-human PS2 CTF and anti-TNFR1 antibodies 
were obtained from Cell Signaling Technology (Danvers, Massachusetts, USA). 
Infrared secondary antibodies IRDye®  680 Goat Anti-Rabbit IgG and IRDye®  800CW 
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Goat Anti-Mouse IgG were purchased from Licor Biosciences (Cambridge, UK). 
IRDye® 800CW Goat anti-Mouse lgG F(c) was purchased from Rockland through tebu-
bio (Dublin, Ireland).  
2.1.5 Cell lines 
Human Embryonic Kidney 293T (HEK293T) cells from lab stocks (originally purchased 
from ATCC) were cultured in cells were grown in Dulbecco’s modified Eagle’s 
medium DMEM-21 containing 10% (v/v) fetal bovine serum, 1% (v/v) L-glutamine, 
and antibiotics (50units/ml penicillin and 50μg/ml streptomycin). Fibroblasts derived 
from PS1/PS2-deficient mouse embryos were isolated as previously described (De 
Strooper et al., 1998). Fibroblast cell lines were generated by transformation of 
primary cultures with large T antigen (De Strooper et al., 1998). All murine 
embryonic fibroblast (MEF) cell lines were grown in DMEM-21, high glucose, 10% 
(v/v) FBS, 1% (v/v) glutamine, 1% (v/v) non-essential amino acids, 1% (v/v) sodium 
pyruvate, and penicillin/streptomycin with 5% (v/v) CO2. Cells were maintained in a 
humidified 37°C incubator with 5% CO2. All reagents were purchased from Sigma-
Aldrich (Dublin, Ireland). 
2.1.6 Bacterial strains and media used 
Lab stocks of the E. coli DH5α strain were grown in pre-made Luria-Bertani (LB) broth 
and LB agar which were purchased from Sigma-Aldrich (Dublin, Ireland).  
55 
 
2.2 Methods  
2.2.1 Molecular biology 
2.2.1.1 Computer software used in Bioinformatical analysis 
DNA sequence analysis and alignments were performed using Vector NTI.  
2.2.1.2 Competent cell preparation and transformation 
DH5α were streaked for single colonies and grown on an LB plate overnight at 37°C. 
A single colony was picked and grown in 5ml of LB medium overnight at 37°C. 3ml of 
overnight grown DH5α cells were inoculated into 100-200ml of LB solution and 
grown for 2-3 hours. Once cell density reached OD595 0.6-1.0, cells were harvested by 
centrifugation of cells at 3000x g for 15min at 4°C. The supernatant was discarded 
and the pellet resuspended in pre-cooled 0.1 M MgS04 at one third the volume of 
the bacterial culture volume. Cells were then harvested as above and the pellet 
resuspended in 0.1 M CaCl2 containing 15% (v/v) of glycerol with 1/25 of bacterial 
culture volume. Aliquots were put in pre-cooled tubes, frozen on dry ice and then 
stored at -80°C. 
2.2.1.3 Transformation of DH5α competent cells 
Competent cells were thawed on ice for 15-20 minutes. Approximately 1ng of a 
plasmid DNA or 2-18 μl of a ligation mixture was mixed with 100 μl of competent 
cells and incubated on ice for 15-45 minutes. Cells were heat-shocked at 42°C for 90 
seconds and immediately cooled on ice. 900 μl of LB broth was added and incubated 
at 37°C shaking for 50-90 minutes.  20-200 μl of the cell suspension was spread on a 
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pre-warmed LB agar plate containing an appropriate antibiotic (50μg/ml ampicillin or 
50 μg/ml kanamycin) and incubated at 37°C overnight.  
2.2.1.4 Site-directed mutagenesis 
Primers used for site-directed mutagenesis were designed using Vector NTI 11. KOD 
Hot Start Polymerase kit (#71086) from Millipore was used for the PCR reactions. The 
standard reaction setup is shown as below. 
 
The PCR programme setup is listed below. 
1. Polymerase activation  95°C for 2 min 
2. Denature   95°C for 20 s 
3. Annealing   Lowest Primer Tm°C for 10 s 
4. Extension   70°C for 25s/kb 
Repeat 2-4   20 cycles 
5. Final extension   70°C for 5 min 
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The PCR products were purified using Qiagen PCR purification kit (#28106). Purified 
PCR products were digested by DpnI restriction enzyme as described below. Then 
the PCR products were transformed in DH5α competent cells for further plasmid 
preparation and sequencing analysis. 
2.2.1.5 Plasmid DNA restriction digest and DNA gel electrophoresis 
Following NEB guildlines (http://www.neb.com/nebecomm/default.asp) add the 
following to an Eppendorf tube: 500ng plasmid DNA, 2μl 10x NEBuffer, 0.5μl 
100xBSA (if necessary), 0.5μl Restriction Enzyme (of one or more) and add dH2O to 
make the final volume 20μl. Mix and incubate at 37°C for 1-2 hours. Samples were 
then mixed with 5μl DNA running dye (10mM EDTA, 0.25% Bromophenol Blue, 50% 
Glycerol). Samples were loaded onto a 1% Agarose gel containing 0.5μg/ml of 
Ethidium Bromide so that DNA can be visualised and DNA was separated with an 
applied potential difference of 100V for about 1 hour. Gel was observed by 
illuminating on a 302 nm UV transilluminator. Commercially obtained DNA ladders 
were used as molecular weight markers. 
             
2.2.2 Cell Biology 
2.2.2.1 Calcium phosphate transfection of HEK293T cells 
Transfection was carried out on subconfluent human embryonic kidney (HEK293T) 
cell cultures using the calcium phosphate precipitation method. For a 10cm dish with 
10mls of culture media, 2.5 µg of each plasmid was added to 62μl 2M CaCl2 with up 
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to 438 µl of sterile water. This solution was added drop-wise over the course of two 
minutes to 500μl Hanks buffered salt solution (HBSS) and the resulting cloudy 
mixture was allowed to stand a further one minute. The 1ml precipitate solution was 
then added to the cell culture. Essentially the same procedure was performed for 
each well of a 6-well plate except 200 µl of the precipitate solution containing 1 µg of 
total DNA was added per well. In all instances the total amount of DNA in each 
culture was kept constant by addition of empty vector pcDNA3 (Invitrogen). Media 
was changed 8-16 hours post-transfection and cultures were harvested 24-48 hours 
post-transfection. 
2.2.2.2 Transfection of murine embryonic fibroblasts (MEF’s) 
Transfection was carried out on subconfluent MEF cell cultures using the TurboFect™ 
in vitro Transfection Reagent from BioRad Laboratories (GmbH, Munich, Germany). 
Prior to transfection, reagent was thawed and cell-culture media was replaced. Two 
hours later 2µg of plasmid DNA was diluted in 200µl serum free DMEM medium. 4µl 
of TurboFect™ was added to the DNA solution and mixed thoroughly. This solution 
was incubated for 20 minutes at room temperature. Then the combined solution 
was added drop-wise to 10 cm plates.  
2.2.2.3 Preparation of cellular protein extracts 
HEK293T cell cultures were washed with ice-cold phosphate-buffered saline (PBS) 
and lysed in 1 ml of lysis buffer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.1% (v/v) 
Nonidet P-40, 1 mM sodium orthovanadate and protease inhibitor mixture 
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(Complete™, Roche Molecular Biochemicals). Cells were lysed on ice for 30 minutes, 
spun at 21,920 x g at 4°C for 10 minutes and supernatants were collected. Lysates 
were normalised using the bicinchonic acid (BCA) method by Pierce.  
MEF cell cultures were transferred on ice to a 4°C cold-room (this is to prevent 
degradation of endogenous proteins by proteases) and cell cultures were washed 
with ice-cold phosphate-buffered saline (PBS). Removing any excess PBS, next a 
solution of RIPA buffer (50mM Tris-Cl, pH 7.4, 0.15m NaCl, 1% sodium deoxycholate, 
1% Triton X-100, 10mM EDTA, 0.1% SDS) containing 1x complete protease inhibitor 
was added (for 100 mm cell-culture dishes 1 ml was added). Cells were incubated 
with RIPA buffer for at least half an hour and then cells were removed by cell scraper. 
Cells were then transferred to eppendorf and were pushed through a syringe and 
needle 10 times to be broken up into viscous lysate. Lysate was finally spun down at 
21,920 x g at 4°C for 25 minutes and supernatants were collected. Lysate was 
normalised to ensure an equal amount of protein loaded to each sample using the 
bicinchonic acid (BCA) method by Pierce. 
2.2.2.4 Immunoprecipitation of proteins from cellular extracts 
Equivalent concentrations of lysates (for exogenously expressed proteins 200-500 μg 
of protein lysate and for endogenously expressed proteins 1000 μg of protein lysate) 
were pre-cleared for 1 hour at 4°C with 25 μl Protein-G sepharose beads. Pre-cleared 
lysates were immunoprecipitated for 2 hours at 4°C with 2-5 μg of the indicated 
antibody followed by incubation with 25 μl Protein-G sepharose beads overnight. 
Immunoprecipitates were then washed three times in 500 mM NaCl lysis buffer 
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followed by two washes in 150 mM NaCl lysis buffer. Samples were resolved by 10 % 
or 12 % SDS-PAGE, transferred to nitrocellulose membrane and visualised as outlined 
below. 
2.2.2.5 Immunoprecipitation of proteins from cellular extracts for ubiquitination 
analysis 
Cell cultures were washed twice in ice-cold PBS and detached from plates by gentle 
scraping in 1 ml PBS-EDTA (0.5 mM). The resulting suspensions were transferred into 
1.5 ml eppendorf and a sample removed for lysis and Western blot analysis as earlier 
described. Cells were harvested by spinning at 400 x g for 5 minutes at 4°C. Pellets 
were resuspended in 250 μl 1% (w/v) Sodium Dodecyl Sulphate (SDS) containing 
15mM N-ethylmaleimide (NEM) and protease inhibitors and boiled for 5 minutes on 
a heating block. Following cooling on ice, an equal volume of ice-cold covalent buffer 
(50mM Tris (pH 8.0), 150mM NaCl, 1 % Triton, 0.5 % sodium deoxycholate, 15 mM 
NEM and protease inhibitors) was added, lysate was mixed and spun at top speed at 
4°C for 20 minutes. The pellet was removed and lysates quantified using the BCA 
method as previously described. Samples were then subjected to 
immunoprecipitation with indicated antibodies as described previously, except that 
Protein-G sepharose beads were washed three times in covalent buffer.  
2.2.2.6 Western blotting 
Equivalent concentrations of lysates were denatured by addition of SDS loading 
buffer and boiling for 5 minutes on a heating block. However when blotting for PS1 
61 
 
or PS2, the boiling step was omitted as boiling PS1 or PS2 disrupts the epitope-
antibody recognition site (unpublished results J.V McCarthy). Similarly, washed 
Protein G beads were boiled in SDS loading buffer and boiled for 5 minutes on a 
heating block. Samples were resolved on 10 % (w/v) or 12 % (w/v) SDS-PAGE gels, 
transferred to nitrocellulose membrane (Schleicher and Schuell Bioscience). 
Following transfer, membranes were blocked for 1 hour at room temperature in 5 % 
(w/v) Marvel milk/PBS-Tween 0.1 % (v/v). Primary antibodies were diluted as 
outlined below in 5 % (w/v) Marvel milk/PBS-Tween 0.1 % (v/v) and incubated on the 
shaking membranes 4°C overnight. 
Antibody Name  Company Code  
 Working Dilution 
Anti-PS1-CTF  MAB5232 1:1000 
Anti-PS1-NTF MAB1563  1:1000 
Anti-PS2-CTF #2192 1:1000 
Anti-HA MMS-101R-200 1:3000 
Anti-β-actin A5316 1:3000 
Anti-FLAG F3165 1:3000 
Anti-Tubulin T4026 1:3000 
Anti-APPCTF A8717 1:4000 
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Anti-p75 G3231 1:1000 
Anti-IL-1R1 C20 SC-687 1:500 
Anti-Nicastrin N16420-150 1:4000 
Anti-Myc M5546 1:3000 
Anti-TNFR1 #3736S 1:1000 
Anti-p-JNK SC-6254 1:200 
Anti-JNK1 SC-571 1:200 
Anti-TRAF6 SC-8409 1:200 
Anti-Aph1 SC-30240 1:200 
Anti-PEN2 SC-32946 1:200 
Anti-ubiquitin SC-8017 1:200 
Anti-IL-1R1 N20 SC-688 1:200 
Anti-TLR4 SC-10741 1:200 
Membranes were washed three times in PBS-Tween or TBS-Tween for 10 minutes 
each and incubated in diluted secondary antibody for 1 hour at room temperature. 
1:10000 dilution in 1 % (w/v) Marvel/PBS-T/TBS-T was used for Licor antibodies. 
Following washing, proteins were detected with the Licor Odyssey Infrared Imaging 
System for Licor antibodies. 
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2.2.2.7 ELISA for Aβ40 and Aβ42 
HEK293T cells were transfected by calcium phosphate precipitation with indicated 
constructs. Thirty-six hours after transfection, cell culture medium was collected for 
ELISA analysis and cells were subjected to Western blotting. ELISA kits for Aβ40 and 
Aβ42 were purchased from Invitrogen (#KHB3481 and #KHB3441). ELISA analyses 
were carried out according to the manufacturer’s protocol. 
2.2.2.8 Reverse transcription PCR and Real-time PCR 
Thirty-six hours post transfection, HEK293T cells were subjected to total RNA 
extraction using High Pure RNA Isolation Kit from Roche (#11828665001). 5 μg total 
RNA was then applied in reverse transcription PCR using Super Script III reverse 
transcriptase from Invitrogen (#18080-044) following the manufacturer’s protocol. 
Then the Real-time PCR was set up using LightCycler 480 SYBR Green I Master kit 
from Roche (#04707516001) following the manufacturer’s protocol. Reactions were 
carried out and recorded using Roche LC480 96 well Real-time PCR machine. 
2.2.2.9 Fura-2 videomicroscopy and Ca2+ imaging 
MEF cells were cultured on 35mm glass-bottom dishes (MatTek #P35GC-0-10-C) and 
were allowed to grow to about 50% confluency. Prior to experimentation cells were 
washed twice with 1ml of modified Krebs-Henseleit Buffer (KHB) (120 mM NaCl, 4.8 
mM KCl, 2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 5 mM HEPES, 
1 mM probenecid). Cells were then loaded with 2 μM fura-2-acetoxymethyl ester 
(Bio-sciences #F-1201) and incubated for 30 min at 37°C. Cells were then washed 
twice with 1ml of Ca2+-free KHB (buffered with 0.5mM of EGTA to Ca2+) and 
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immersed in 1 ml of Ca2+-free KHB. The dishes were then placed on the stage of an 
Olympus 1X51 inverted fluorescence microscope within an encapsulating incubator 
(Solent Scientific, Segensworth, UK) maintained at 37 °C. To induce ER calcium 
discharge, 5 μl of 1mM Ionomycin (Sigma #I3909) was loaded to the culture and 
alterations in the cytosolic Ca2+ levels were detected by exciting the fura-2 loaded 
cells intermittently by 340 and 380 nm UV light (Cairn Monochromator and 75-W 
Xenon lamp, Cairn, Faversham, Kent, UK). Emitted light was collected via an Olympus 
UplanF1 1.3 NA 100x oil-immersion objective, filtered through a dichroic mirror (400 
nm cut-off) and recorded using a Hamamatsu ORCA-ER CCD videocamera 
(Hamamatsu Photonics Ltd., Hertfordshire, UK), set at exposure time of 500 ms per 
channel. Hardware was controlled and images were acquired using Andor IQ v1.9 
software (Andor, Belfast, Northern Ireland). Ratio images were generated and the 
perimeter of each cell was defined as a region of interest and the mean fura-2 ratio 
from within this region against time was exported to Microsoft Excel 2003 for further 
analyses. 
2.2.2.10 Flow cytometry for cell surface IL-1R1 
HEK293T cells or MEF cells were transfected with IL-1R1 constructs for 48 hours. 
Then cells were washed one time with ice-cold 1xPBS and detached from plates by 
PBSE buffer (1xPBS, 50mM EDTA). 1x106 cell aliquots were transferred to each assay 
tube and span at 1000rpm for 3 minutes. Then the supernatant was taken off and 
cells were suspended and incubated with mouse anti-IL-1R1 primary antibody 
diluted in PBSE buffer supplemented with 1%BSA for 45 minutes at room 
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temperature. After the incubation, cells were washed three times in PBSE buffer. 
Then the cells were incubated with secondary green-fluorescent anti-mouse 
antibody (Alexa Fluor 488) for 30 minutes at room temperature. Cells were then 
washed three more times and then analyzed on a FACScan flow cytometer (Becton 
Dickinson, Oxford, UK). Results were collected and analyzed by CellQuest and 
WinMDI softwares. 
2.2.2.11 Luciferase assays 
HEK293T cell cultures were transfected with wild-type IL-1R1 or IL-1R1 mutants and 
co-transfected with 100ng NF-κB reporter plasmid (plasmid containing three NF-κB 
binding elements and a luciferase reporter gene) (Promega) using the calcium 
phosphate transfection method. If IL-1β treatments are required, cells were serum-
starved overnight 24 hours after transfection and then treated with 10nM IL-1β for 6 
hours. Generally 48 hours after transfection, cells were harvested in 200 μl passive 
lysis buffer. Lysates were spun at 13,000 rpm for 10 minutes at 4°C and supernatants 
were transferred into a fresh eppendorf. Next 20 μl of each lysate was mixed with 
100 μl of luciferase substrate (Promega) and the light emission measured as relative 
light units (RFU) on a luminometer (Turner Designs). Protein concentrations were 
determined using the BCA method and the RFU/μg of each sample determined. 
Western Blot analysis for IL-1R1 confirmed expression of transfected IL-1R1 
constructs. 
2.2.2.12 In vitro ubiquitination assay 
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The peptide arrays which are synthesized by automatic SPOT synthesis on 
continuous Whatman cellulose membrane using Fmoc (9-
fluorenylmethyloxycarbonyl) chemistry with the AutoSpot-Rosbot ASS 222 (Intavis 
Bioanalytical Instruments) are produced and provided by Dr Patrick Kiely. Peptide 
arrays were spotted with peptides corresponding to the human IL-1R1 C-terminus 
sequence (301-569) (see Figure 4.1). In vitro ubiquitination assay was performed 
using Ubiquitination Kit (#UW9920) from Enzo Life Sciences. Standard reaction setup 
is listed below. The total reaction volume for immunoprecipitated protein is 50μl and 
for peptide array is 1ml. 
 
For immunoprecipitated protein, assay components were added to 0.5ml tubes. 
After gentle mix, the tubes were incubated at 37°C for 60 min under gentle shaking. 
After reaction, the substrate-conjugated beads were washed twice with covalent 
buffer. Then the beads were loaded with SDS sample loading buffer and were boiled 
for 5 min. After spinning for 2 min at 1000rpm, the supernatants were loaded on gel 
and analysed by Western Blotting. 
For in vitro ubiquitination assay of IL-1R1 arrays, the mixed reaction components 
were sealed with the peptide arrays in plastic bags and then were incubated at 37°C 
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for 60 min under gentle shaking. After reaction, IL-1R1 peptide arrays were washed 
in 0.2M NaOH stripping buffer to remove non-covalent binding. Ubiquitination status 
of the IL-1R1 peptide array was revealed by Western Blot analysis and probing the 
membranes with anti-ubiquitin antibody.  
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Chapter 3: 
RESULTS 
Presenilins are novel substrates of TRAF6-mediated 
ubiquitination 
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Introduction: 
An increasing number of type-I integral membrane proteins has been reported as 
proteolytic substrates of γ-secretase cleavage, including Notch receptor, APP and  IL-
1R1 which is reported as a γ-secretase substrate previously by our group (Elzinga et 
al., 2009b). Thus studying the regulation of γ-secretase activity is considered very 
important in understanding the pathogenesis of AD, the role of Notch signalling in 
cell differentiation and other γ-secretase substrates involved events. Presenilins, as 
the catalytic core of γ-secretase complex, are tightly regulated to maintain the 
homeostasis of the protein levels and functional γ-secretase complexes (Thinakaran 
et al., 1997). Presenilin holoproteins undergo endoproteolysis and the NTF and CTF 
associate as stable heterodimers (Thinakaran et al., 1996). In addition to 
endoproteolysis, presenilins are also regulated by diverse posttranslational 
modifications including phosphorylation (Kirschenbaum et al., 2001a, b; Twomey and 
McCarthy, 2006) and ubiquitination (Li et al., 2002; Massey et al., 2005). These 
modifications are not only essential for the stability and activation of presenilins, but 
are also important for the protease assembly and activity of γ-secretase complexes. 
For instance, SEL-10 was shown to interact with and enhance PS1 ubiquitination, and 
alter the cellular levels of PS1 holoprotein and its NTF/CTF heterodimers (Li et al., 
2002). Our group have also reported the association between PS1 and TRAF6 
previously (Powell et al., 2009). The interaction between PS1 and TRAF6 was shown 
to be ligand-dependent and disruption of this interaction antagonizes the γ-
secretase cleavage of a TRAF6-regulated receptor, p75NTR. 
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TRAF family proteins are critical regulators for the signal transduction of a wide 
variety of receptors (Chung et al., 2002a). For example, TRAF6 is an essential adaptor 
protein for IL-1R1/TLR4 signalling transduction to the activation of NF-κB and MAPK. 
TRAF6 possesses E3 ligase activity, as well as TRAF2 and TRAF5 among the TRAF 
family members. TRAF6 has been shown to facilitate a diversity of signalling 
pathways by catalysing different types of ubiquitination. TRAF6 facilitates K63-linked 
polyubiquitination at five different lysine residues within NEMO which leads to 
activation of IKK and NF-κB (Sebban-Benin et al., 2007b). Unlike Lys48-linked 
polyubiquitination, which targets proteins for proteasomal degradation, Lys63-linked 
polyubiquitination does not degrade targeted proteins, but activates signalling 
pathways. TRAF6 also promotes lysine-6, lysine-27 and lysine-29 linked 
ubiquitination of amino terminal fragments of huntingtin protein and involves in 
Huntington’s disease pathogenesis (Zucchelli et al., 2011). 
The autoubiquitination of TRAF6 is reported to be essential for TRAF6 activation in 
certain signalling pathway. TAB2 is reported to facilitate ubiquitination of TRAF6 
through its CUE domain which is also indispensable for TRAF6 interaction with IKK 
(Kishida et al., 2005). The CUE domain was firstly discovered as an ubiquitin-binding 
domain targeting ubiquitinated protein to degradation pathways (Ponting, 2000b). 
Later on, CUE domain was also revealed to promote the ubiquitination of the 
proteins that contain it (Shih et al., 2003a). 
TRAF6 is a critical regulator for RANK signalling. TRAF6-mediated RANK signalling is 
essential for the differentiation and activation of osteoclast (Armstrong et al., 2002). 
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Deficiency of TRAF6 results in severe osteopetrosis and disrupted osteoclast 
functions such as bone resorption and cytoskeletal organization (Lomaga et al., 
1999a; Armstrong et al., 2002). Interestingly, inhibition of ER Ca2+ signalling by 
blocking of the ER calcium ATPase, which interacts with PS1, results in reduction of 
osteoclastic survival and bone resorption (Mentaverri et al., 2003). Moreover, 
deficiency of PS1 in mice was reported to cause skeletal defects (Shen et al., 1997). 
In this study, we attempted to further characterise and determine the relevance of 
the interaction between presenilins and TRAF6. Firstly, we started with confirming 
the interaction between presenilins and TRAF6 and investigating the possible 
regulations mediated by TRAF6. Secondly, as TRAF6 is an E3 ligase, we sought to test 
if presenilins are novel substrates of TRAF6-mediated ubiquitination. Thirdly, as SEL-
10-mediated PS1 ubiquitination has been shown to regulate PS1 protein levels and 
APP processing (Li et al., 2002), we were planning to investigate the functional 
significance of TRAF6 mediated regulation of presenilins in terms of presenilin 
stability, γ-secretase activity and γ-secretase independent functions of presenilins. 
Finally, we attempted to study the CUE domain of presenilins as a novel presenilin 
ubiquitin-binding domain and reveal the function of this CUE domain. 
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3.1 TRAF6 increases transcriptional and cellular levels of 
presenilins 
3.1.1  PS1 and PS2 interact with TRAF6 
Our group has previously shown that PS1 contains a putative TRAF6-binding domain 
by sequence analysis of known TRAF6 interacting proteins. It was also demonstrated 
that PS1 interacts with TRAF6, in part via a conserved consensus motif within the 
hydrophilic loop of PS1, and that mutagenesis of two sites (Pro374 and Glu376) 
within this motif antagonizes the interaction between PS1 and TRAF6 (Powell et al., 
2009). In this study, we began by confirming the interaction of PS1 or PS2 with 
TRAF6. HEK293T cells were transfected with expression constructs encoding 
untagged PS1 or PS2 and co-transfected with FLAG-tagged TRAF6 or TRAF6 dominant 
negative mutant (TRAF6DN) lacking the catalytic N-terminus RING domain and zinc 
finger domains. Consistent with previous studies, immunoprecipitation of FLAG-
TRAF6 quantitatively co-precipitated PS1 (Figure 3.1A) and PS2 (Figure 3.1B) and 
reciprocal immunoprecipitation also revealed the same interactions. Interaction 
between TRAF6DN and presenilins suggests that the binding motif of TRAF6 for 
presenilins localises in the TRAF6 C-terminus domain. Western blot analysis of all cell 
lysates revealed equal protein expression levels. Interestingly, co-expression of 
TRAF6 with PS1 or PS2 enhanced the immunodetection of full length PS1 and PS2 
(Figure 3.1 A lane 3 and B lane 2). 
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Fig 3.1 PS1 and PS2 interact with TRAF6. HEK293T cells were transiently transfected 
with wild type Presenilins and co-transfected with FLAG tagged TRAF6 or TRAF6 DN. 
Thirty-six hours post-transfection extracts were prepared and immunoprecipitated 
(IP) for presenilins or FLAG-TRAF6 and then analysed for FLAG-TRAF6 or presenilins 
respectively by Western Blot. Co-precipitations of PS1 (A) or PS2 (B) with TRAF6 or 
TRAF6 DN were detected by immunoblotting with anti-presenilin or anti-FLAG 
antibodies, as indicated. Western blotting of whole cell lysates confirmed the 
expression of all transfected constructs. Data presented are representative of a 
typical experiment (n=3). 
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3.1.2 TRAF6 increases presenilin levels in a dose-dependent manner 
Having shown increased immunodetection of PS1 and PS2 full length with co-
transfection of TRAF6, we next investigated whether increased presenilin 
immunodetection was dose-dependent with increased expression of TRAF6. 
HEK293T cells were transfected with PS1 or PS2 and co-transfected with increasing 
amounts of TRAF6. Cell lysates were immunoblotted with anti-PS1 NTF (Figure 3.2A) 
or anti-PS2 CTF (Figure 3.2B) antibodies respectively. Consistent with data presented 
in Figure 3.1, co-expression of PS1 with increasing concentration of TRAF6 resulted in 
a dose-dependent increase in detectable levels of PS1 (Figure 3.2A) and PS2 (Figure 
3.2B) full length. Densitometry was used to measure the relative levels of PS1 and 
PS2 detected by Western blot. All levels of presenilins measured were normalised to 
the corresponding β-actin levels and expression levels of presenilin full length and 
fragments without TRAF6 were set as control (1 fold). Importantly, when co-
transfected with 1.6μg TRAF6, immunoreactivity of full length PS1 was increased by 
~3 fold and immunoreactivity of PS2 full length was increased by ~4 fold. PS1 and 
PS2 fragments were also increased by TRAF6 but only to the comparably lesser 
levels, suggesting a preferential increase in PS1 full length levels. Dosing amounts of 
TRAF6 were detected by immunoblotting with anti-FLAG antibody. 
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Figure 3.2 TRAF6 enhances immunodetection of PS1 and PS2. HEK293T cells were 
transfected with expression constructs for PS1 (0.8μg) or PS2 (0.8μg) and co-
transfected with increasing amounts of TRAF6 (0-1.6μg). Equal amount of plasmid 
was transfected in each culture by complement with empty vector. Cell lysates were 
analyzed by Western blot with anti-PS1 NTF, anti-PS2 CTF, anti-FLAG and anti-β-actin 
antibodies. PS1 and PS2 full length and fragment immunoreactivity was measured by 
densitometry and is shown as mean + SEM. n=4. 
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3.1.3 Effect of TRAF6 on presenilin immunodetection requires TRAF6 E3 ligase 
activity 
TRAF6 possesses E3 ligase activity and it requires its E3 ligase activity to maintain 
efficient signal transduction (Lamothe et al., 2007a). To investigate whether TRAF6 
E3 ligase activity is required for the effect on PS1 and PS2 immunodetection, we 
used a dominant negative TRAF6 mutant (TRAF6DN), which lacks the RING and zinc 
finger domains (TRAF6 300-524) and is defective in TRAF6 E3 ligase activity (Lamothe 
et al., 2008). HEK293T cells were transfected with wild type PS1 and co-transfected 
with increasing amounts of TRAF6 or TRAF6-DN. Cell lysates were analysis by 
Western blotting with anti-PS1 CTF antibody. Consistent with our previous data, co-
expression of TRAF6 with PS1 caused an increase in immunodetection of PS1. In 
contrast, co-expression of TRAF6-DN with PS1 did not increase PS1 immunodetection, 
but decreased immunodetection of PS1 in a dose-dependent manner (Figure 3.3A). 
Dosing expression of TRAF6 and TRAF6-DN were confirmed by Immunoblotting with 
anti-FLAG antibody. 
Having shown that the effect of TRAF6 on PS1 immunodetection may require its E3 
ligase activity, we next utilised a series of TRAF6 mutant constructs to confirm our 
hypothesis; the TRAF6 single RING finger cysteine mutant TRAF6C70A is defective in 
TRAF6 substrate ubiquitination, while the ubiquitin acceptor site mutant, 
TRAF6K124R is defective in TRAF6 autoubiquitination (Lamothe et al., 2007a). 
HEK293T cells were transfected with PS1 or PS2 and co-transfected with TRAF6, 
TRAF6-DN, TRAF6K124R and TRAF6C70A. Co-expression of either TRAF6-DN or 
TRAF6C70A, mutants that are defective in TRAF6 substrate ubiquitination activity,  
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Figure 3.3 Effect of TRAF6 on presenilin immunodetection requires TRAF6 E3 ligase activity. 
(A) HEK293 cells were transfected with expression constructs for PS1 and co-transfected 
with increasing amounts of TRAF6 or TRAF6-DN. Cell lysates were analyzed by Western Blot 
with anti-PS1 CTF, anti-FLAG and anti-β-actin antibodies. (B) HEK293 cells were transfected 
with PS1 and co-transfected with TRAF6, TRAF6-DN, TRAF6K124R and TRAF6C70A. Cell 
lysates were analyzed by Western Blot with anti-PS1 NTF, anti-FLAG and anti-β-actin 
antibodies. (C) HEK293 cells were transfected with PS2 and co-transfected with TRAF6, 
TRAF6-DN, TRAF6K124R and TRAF6C70A. Cell lysates were analyzed by Western Blot with 
anti-PS2 CTF, anti-FLAG and anti-β-actin antibodies. Experiment was repeated at least three 
times with the similar results. 
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failed to enhance levels of PS1 and PS2 (Figure 3.3B and C lane 3 and 5). In 
comparison TRAF6K124A, defective in TRAF6 autoubiquitination, retained its ability 
to increase PS1 and PS2 detectable levels (Figure 3.3B and C lane 4). Thus it suggests 
that levels of PS1 and PS2 are enhanced following over-expression of TRAF6 with 
catalytically active E3 ligase activity. 
3.1.4 TRAF2, TRAF5 and TRAF6 preferentially enhance presenilin levels 
As TRAF6 is not the only TRAF protein that contains a RING domain and functions as 
an E3 ligase (Lee and Lee, 2002), we selected other TRAFs to explore if enhanced 
immunoreactivity of presenilin is unique to TRAF6 or the effect is common among 
TRAF family members. HEK293T cells were transfected with PS1 or PS2 and co-
transfected with FLAG-tagged TRAF2, TRAF2-DN, TRAF3, TRAF4, TRAF5 and TRAF6. 
Though all TRAF family protein appeared to induce enhanced immunodetection of 
PS1 and PS2, co-expression with TRAF2, TRAF5 and TRAF6 consistently increased full 
length and fragment detections of PS1 and PS2 (Figure 3.4A and B). TRAF3 and 
TRAF4 only moderately enhanced presenilin detections. But to our surprise, TRAF2-
DN also induced increased presenilin levels which may be explained as TRAF2-DN 
could still be recruited with TRAF6 as an adaptor even without its catalytic RING 
domain. But this assumption needs to be further confirmed. Redundancies between 
TRAF family members have been reported before. For example, depletion of both 
TRAF2 and TRAF5 are required for abolishment of TNF-induced NF-κB activation 
(Tada et al., 2001). Similarly, deficiency of both TRAF2 and TRAF6 is necessary for 
abrogating CD40-mediated NF-κB activation and TRAF2 and TRAF6 associate at the 
CD40 complex (Davies et al., 2005; Ellison et al., 2006). For TLR signalling, mutations  
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Figure 3.4 TRAF2, TRAF5 and TRAF6 preferentially enhance immunoreactivity of 
the presenilins. HEK293 cells were transfected with PS1 (A) or PS2 (B) and co-
transfected with TRAF2, TRAF2DN, TRAF3, TRAF4, TRAF5 and TRAF6. Thirty-six hours 
post-transfection cell lysates were analyzed by Western Blotting with anti-PS1NTF or 
anti-PS2CTF antibodies. Blots were re-probed with anti-FLAG and anti-β-actin 
antibodies to show equivalent protein expression levels. 
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of both TRAF2 and TRAF6 binding sites in TRIF are required to abrogate type I IFN 
induction (Sasai et al., 2010). Collectively, redundancies between TRAF family 
proteins, especially between TRAF2, TRAF5 and TRAF6 have been observed by 
different groups and we investigated further at the level of presenilin regulations. 
3.1.5 TRAF6 increases PS1 mRNA level through JNK activation.  
Previous studies showed that expression of PS1 is regulated by c-jun-NH2-terminal 
kinase (JNK) activity (Lee and Das, 2008). Also auto-ubiquitination of TRAF6 could 
induce JNK activation and inhibition of TRAF6 polyubiquitination leads to suppressed 
JNK activation (Loniewski et al., 2007; Chen et al., 2012). To confirm this hypothesis 
and to determine if increased PS1 levels is caused partially from TRAF6 induced JNK 
activation, we applied an inhibitor for JNK activation, SP600125 and investigate its 
effects on both PS1 expression and transcription. HEK293T cells were transfected 
with PS1 and co-transfected with TRAF6 or TRAF6 C70A mutant. Twenty-four hours 
after transfection, cells were treated with SP600125 (40 μM) in serum-free medium 
for 12 hours. Cell extracts were then prepared and analysed for PS1 protein levels 
and JNK activity by Western blotting. As shown in Figure 3.5A, SP600125 decreased 
basal phosphorylation of JNK and overexpression of TRAF6 induced JNK activation in 
an E3 ligase activity dependent manner which could be attenuated by the JNK 
inhibitor. Inhibition of JNK activity also decreased full-length protein level of PS1 and 
attenuated TRAF6-induced increases in the expression of PS1. Furthermore, cells 
expressing PS1 or co-expressing PS1 and TRAF6 were treated with SP600125 and 
total RNA was extracted from these cells and subjected to reverse transcription PCR 
and Real-time PCR. We showed that PS1 mRNA level was decreased by inhibition of 
JNK (Figure 3.5B). TRAF6 increased the mRNA level of PS1 which is reversed  
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Figure 3.5 TRAF6 increases PS1 mRNA level through JNK activation. (A) HEK293T cells 
were transfected with PS1 alone or co-transfected with TRAF6 or TRAF6 C70A mutant. 24 
hours after transfection, cells were treated with 40 μM SP600125 in serum-free medium for 
12 hours. Cell extracts were then prepared and analysed for PS1 protein levels and JNK 
activity by Western blotting using PS1 NTF and phosphorylated JNK antibodies. Levels of PS1 
full-length and p-JNK were measured by densitometry and shown as mean + SEM. (B) 
HEK293T cells were transfected with PS1 alone or co-transfected with TRAF6 and treated 
with 40 μM SP600125 in serum-free medium for 12 hours. Then total RNA was extracted 
from these cells and subjected to reverse transcription PCR and Real-time PCR. Levels of PS1 
mRNA were shown as relevant 2^(-ddCt) values normalised to the levels of the house 
keeping gene GAPDH.  
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by SP600125, the JNK activation inhibitor, suggesting that TRAF6 regulates mRNA 
level of PS1 by inducing activation of JNK. 
3.1.6 Knock-out of TRAF6 decreases endogenous presenilin levels 
We also investigated effect of TRAF6 deficiency on presenilin levels by comparing the 
level of PS1 and PS2 in the MEF WT cells and the MEF TRAF6 knock-out (TRAF6-/-) 
cells. Control MEF cells and TRAF6-/- MEF cells were lysed and subjected to BCA assay 
to determine the protein concentration of the lysates. To achieve clear comparison, 
increasing amounts of cell lysates from each cell line were loaded and blots were 
subjected to PS1 NTF and PS2 CTF antibodies. Endogenous full-length presenilins are 
too faint to be detected, but we showed that levels of endogenous presenilin 
fragments are reduced in TRAF6 knockout MEF cells by about 30-40% (Figure 3.6A). 
Additionally, we attempted to restore TRAF6 level by exogenous expression of TRAF6 
in TRAF6-/- MEF cells (Figure 3.6B). Overexpression of TRAF6 partially rescued the 
levels of PS1NTF and PS2CTF. Expression of exogenous TRAF6 in TRAF6-/- cells and 
endogenous TRAF6 in control MEF cells were confirmed by blotting with anti-TRAF6 
antibody. Collectively, these data suggest that TRAF6 plays important role in the 
abundance of presenilins. However, knock-out of TRAF6 did not eliminate presenilins 
and previously we showed that other TRAF protein also increase presenilin levels, 
suggesting the potential functional redundancy among TRAF family proteins in 
regulating presenilin levels. 
3.1.7 TRAF6 alters turnover of PS1 
Having shown that TRAF6 enhances the immunodetection of presenilins and 
increase PS1 transcription through JNK activation, we next examined whether or not  
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Figure 3.6 Knock-out of TRAF6 decreases endogenous presenilin levels. (A) 
Increasing amount (5-40μg) of cell lysates from both wild type MEF cells and TRAF6 
knock-out MEF cells were subjected to Western blot analysis. Levels of PS1 NTF and 
PS2 CTF were revealed by blotting with PS1 NTF and PS2 CTF antibodies. Knock-out 
of TRAF6 was confirmed by probing with anti-TRAF6 antibody. (B) TRAF6-/- MEF cells 
were transfected with TRAF6 for 36 hours and then were harvested and subjected to 
Western blot together with untransfected cell lysates from wild-type MEF cells and 
TRAF6-/- MEF cells. Levels of PS1NTF and PS2CTF were revealed by blotting with PS1 
NTF and PS2 CTF antibodies. Expression of transfected TRAF6 in TRAF6-/- cells and 
endogenous TRAF6 in WT MEF cells were confirmed by blotting with anti-TRAF6 
antibody. 
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 the effects of TRAF6 on PS1 protein levels involved posttranslational modification of 
PS1. To test this we examined PS1 protein half-life using the protein synthesis 
inhibitor, cycloheximide. HEK293T cell cultures were either transfected with PS1 
alone, or co-transfected with TRAF6. Twenty-four hours post-transfection, cultures 
were supplemented with 20μg/ml cycloheximide. Cell cultures were then harvested 
0, 1, 2, 4, 8, 12 and 24 hours after cycloheximide treatment according to previous 
reports that the half-life of full length PS1 is ~50 minutes and the half-life of the 
NTF/CTF fragments is ~24 hours (Ratovitski et al., 1997; Zhang et al., 1998). Cell 
lysates were immunoblotted with anti-PS1 NTF antibody to reveal the levels of PS1 
full-length and NTF (Figure 3.7). The cellular level of full length PS1, when co-
expressed with TRAF6, declined relatively slowly especially after 12 hours of 
cycloheximide treatment. Densitometry was used to measure the immunodetection 
of PS1 full length. All PS1 full length levels were normalized to the corresponding 
tubulin levels and protein levels when cycloheximide was added were set as control 
(1 fold). Densitometry analysis showed that the half-life of PS1 full length is ~30 
minutes and TRAF6 increased the half-life of PS1 full length by ~1 hour (Figure 3.7 
lower panel). After 12 hours cycloheximide treatment, still ~20% of PS1 full length 
was detected with co-expression of TRAF6. Fragments of PS1 were more stable than 
full length and no significant difference in PS1 NTF was observed between samples 
with and without TRAF6. TRAF6 appeared to alter PS1 turnover, suggesting that 
TRAF6 also induces posttranslational modifications of PS1. 
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Figure 3.7 TRAF6 alters turnover of PS1. HEK293T cells were transiently transfected 
either with PS1 alone, or co-transfected with FLAG-TRAF6. Twenty-four hours after 
transfection, cell cultures were incubated with cycloheximide (20µg/ml) for 0, 1, 2, 4, 
8, 12 and 24 hours respectively. Cell lysates were analyzed for PS1 immunodetection 
by immunoblotting with anti-PS1 NTF and anti-FLAG antibodies. β-tubulin levels 
were also measured as loading control. Densitometry was used to measure levels of 
PS1 full length (FL) with blots probed with anti-PS1 NTF antibodies. Bars presented 
are the mean + SEM of four independent experiments. The differences between two 
groups are statistically significant (p<0.05). 
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3.2  Identification and characterisation of presenilin CUE domain  
3.2.1 Identification of CUE domain and its role in presenilin endoproteolysis 
The CUE domain was initially identified as a ubiquitin-binding motif in a yeast hybrid 
screen and named for the yeast Cue1p protein, which recruits the ubiquitin-
conjugating enzyme Ubc7p to the ER, where it is essential for the degradation of 
misfolded proteins (Biederer et al., 1997; Shih et al., 2003b). Since then, the CUE 
domain is reported to contribute to the stability and specificity of the CUE-ubiquitin 
complex, and moreover that CUE domain containing proteins play an important role 
in stabilizing its binding partner (Kang et al., 2003; Zhang et al., 2007). By sequence 
analysis of reported CUE domain-containing proteins with the amino acid sequences 
of PS1 and PS2, our group has identified a previously uncharacterised putative CUE 
domain in PS1 (271-310) and PS2 (277-316) (Figure 3.8A). The critical Phe/Pro and 
Val/Ser motifs in PS1 and PS2 are also conserved across other species (Figure 3.8B). 
As the putative CUE domain is localized in the cytosolic loop of PS1 and PS2 and it 
also contains the human PS1 and PS2 endoproteolytic cleavage sites (Met292/Val293 
and Met298/Val299) (Thinakaran et al., 1996; Jacobsen et al., 1999), we next 
examined the role of the putative CUE domain in presenilin endoproteolysis by 
mutagenesis of four single points in the CUE domain or deletion of the whole CUE 
domain (PS1 271-310/ PS2 277-316) from PS1 and PS2. PS1/PS2-deficient mouse 
embryonic fibroblast (PS1/PS2-/- MEF) cell lines were transfected with expression 
constructs directing the synthesis of wild type PS1, biologically inactive 
transmembrane aspartate mutant PS1D257A/D385A, CUE domain deletion mutant 
PS1ΔCUE, single CUE domain point mutants PS1S310A, PS1V309A, PS1F283A,  
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Figure 3.8 PS1 and PS2 contain a putative CUE domain. (A) alignment of amino acid 
sequences of the CUE domain from human TAB2, TAB3, Tollip, CUEDC2, PS1, PS2 and 
S.cervisiae Vps9. The important FP and di-Leu motifs are highlighted in red and 
yellow, while discrepancies in sequences are depicted in green. (B) PS1 CUE domain 
is conserved across species. Sequences of PS1 hydrophilic loop domain across 
different species were aligned. PS1 CUE domain consensus is conserved across all 
species examined. Alignments were carried out with AlignX software. 
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Figure 3.9 Endoproteolysis of PS1 is not altered by single point mutation of the 
critical CUE domain motifs. PS1/PS2-/- MEF cell cultures were transiently transfected 
with expression constructs encoding wild type PS1, PS1 D257A/D385A, PS1 CUE 
domain deletion mutant (PS1ΔCUE), PS1 S310A, PS1 V309A, PS1 F283A or PS1 L271A. 
Thirty-six hours post-transfection cell lysates were analyzed by SDS-PAGE gel and 
immunoblotted with anti-PS1 NTF (A), anti-PS1 CTF (B) and β-actin antibodies 
respectively. Asterisk indicates a series of non-specific bands. 
89 
 
 
 
 
 
Figure 3.10 Deletion of the CUE domain prevents the endoproteolysis of PS2. 
PS1/PS2-/- MEF cell cultures were transiently transfected with expression constructs 
encoding wild type PS2 and PS2 CUE domain deletion mutant (PS1ΔCUE). Thirty-six 
hours post-transfection cell lysates were analyzed by SDS-PAGE gel and 
immunoblotted with anti-PS2 CTF and β-actin antibodies. Experiments were 
repeated at least three times with similar results. 
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PS1L271A, wild type PS2 or PS2ΔCUE. Cell lysates were immunoblotted with anti-PS1 
NTF, anti-PS1 CTF or anti PS2 CTF antibodies, respectively. As anticipated, 
mutagenesis of PS1 catalytic sites (Asp257/Asp385) or deletion of PS1 or PS2 CUE 
domains inhibited the endoproteolysis of PS1 and PS2, and abolished the formation 
of PS1/PS2 endoproteolytic NTF/CTF fragments (Figure 3.9 and Figure 3.10). 
However, mutagenesis of the conserved single residues within PS1 CUE domain had 
no effect on PS1 endoproteolysis. 
3.2.2 TRAF6 enhances immunodetection of PS1/PS2 CUE domain deletion 
mutants 
We have already demonstrated that TRAF6 enhances PS1 immunodetection and that 
PS1/PS2 CUE domain deletion mutants are not able to undergo presenilin 
endoproteolysis into NTF/CTF fragments. We next sought to examine whether the 
PS1ΔCUE and PS2ΔCUE mutants, which lack the CUE domain and the ability to 
undergo endoproteolysis, are still stabilized by TRAF6. HEK293T cells were 
transfected with PS1ΔCUE or PS2ΔCUE, and co-transfected with increasing amounts 
of FLAG-TRAF6. Wild type PS1 and PS2 were also transfected with increasing 
amounts of TRAF6 as positive controls. Cell lysates were examined by Western 
blotting with antibodies to PS1 NTF and PS2 CTF. Consistent with previous data, co-
expression with increasing concentration of TRAF6 resulted in increased wild type 
PS1 and PS2 full length and fragment immunodetection. However, increased levels 
of full length PS1ΔCUE and PS2ΔCUE were also observed (Figure 3.11A and B), 
suggesting that the enhancing effects of TRAF6 on presenilin immunodetection are 
independent of the putative CUE domain in PS1 and PS2 or the endoproteolysis of  
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Figure 3.11 TRAF6 enhances immunodetection of PS1ΔCUE and PS2ΔCUE. HEK293T 
cells were transfected with expression constructs encoding wild type PS1 and 
PS1ΔCUE (A) or wild type PS2 and PS2ΔCUE (B) and co-transfected with increasing 
amounts of FLAG-TRAF6. Cell lysates were analyzed by Western blot with anti-PS1 
NTF or anti-PS2 CTF, anti-FLAG and anti-β-actin antibodies. Asterisk indicates a series 
of bands emerging with co-expression of PS1ΔCUE and TRAF6. Data are 
representative of one typical experiment repeated three times. 
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presenilins. PS1 and PS2 fragments observed with ΔCUE mutants are endogenous 
wild-type presenilin fragments in HEK293T cells and are not affected by 
overexpression of TRAF6, suggesting that TRAF6 does not regulate presenilin 
fragments. The observed increases in presenilin fragments arising from 
overexpression of TRAF6 arise as a consequence of the increased endoproteolytic 
full-length presenilins. Interestingly, a series of bands which could be caspase-
cleaved PS2CTF were detected in cells transfected with PS2ΔCUE and increasing 
amounts of TRAF6 (Figure 3.11B lane 5-8 asterisk).  
3.2.3 TRAF6 enhances PS1 immunodetection, independent of its CUE domain 
and γ-secretase complex catalytic sites 
Having shown that PS1ΔCUE and PS2ΔCUE immunodetection is enhanced by TRAF6, 
we hypothesised that single point mutants in the CUE domain and biologically 
inactive aspartate mutant might still be stabilized by TRAF6. To test this hypothesis, 
HEK293T cells were transfected with wild type PS1, PS1D257A/D385A, PS1ΔCUE, 
PS1S310A, PS1V309A, PS1F283A or PS1L271A, and co-transfected with or without 
TRAF6. Cell lysates were examined by Western blotting with an anti-PS1 NTF 
antibody. Again, detection of full length wild type PS1 and mutants was enhanced by 
co-expression of TRAF6 (Figure 3.12). Following densitometry analysis, levels of full 
length PS1 and its mutants are increased by TRAF6 by 2-6 folds. The especially high 
increased levels of full length PS1ΔCUE and PS1V309A are ascribed to their low 
expression levels when expressed on their own. In parallel to the study presented in 
this thesis, our group has also shown that PS1 and PS2 binds to K63-linked 
polyubiquitin chains through the conserved CUE domain and that deletion of the   
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Figure 3.12 TRAF6 enhances PS1 immunoreactivity independent of its CUE domain and γ-
secretase catalytic sites. (A) and (B), HEK293T cells were transfected with wild type PS1, 
PS1D257A/D385A, PS1ΔCUE, PS1S310A, PS1V309A, PS1F283A or PS1L271A and co-
transfected with TRAF6 as indicated. Cell lysates were analyzed by Western Blot with anti-
PS1 NTF, anti-FLAG and anti-β-actin antibodies. (C) PS1 full length (FL) and fragment levels 
were measured by densitometry. Data shown are mean + SEM of triplicate samples. 
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CUE domain or mutation of the valine residue within the CUE domain abolishes PS1 
binding to polyubiquitin, indicating a potential role of this newly identified CUE 
domain of PS1 and PS2 in presenilin functionality. As PS1D257A/D385A full length is 
still enhanced by TRAF6, we can conclude that neither the effect of TRAF6 on PS1 
depends on the integrity of the CUE domain, nor on PS1-dependent γ-secretase 
activity. 
3.2.4 Deletion of the putative CUE domain has no effect on the turnover of 
PS1 
As we have shown that the putative PS1 CUE domain deletion mutant is unable to 
undergo endoproteolysis (Figure 3.9), we were interested in whether full length 
PS1ΔCUE has distinct turnover comparing to wild type PS1. To test this we 
performed a comparative analysis of the half-life of PS1 and PS1ΔCUE proteins. 
HEK293T cells were transfected with PS1 or PS1ΔCUE. Twenty-four hours post-
transfection, cell cultures were treated with cycloheximide (20μg/ml) for increasing 
times (0, 1, 2, 4, 8, 12 and 24 hours). Cell lysates were then analysed by Western 
blotting with anti-PS1 CTF antibody (Figure 3.13). Similar declining trends of wild 
type PS1 and PS1ΔCUE were observed indicating that deletion of the CUE domain 
does not affect the turnover of PS1. Although deficient in endoproteolysis, PS1ΔCUE 
does not show any accumulation comparing to the WT PS1, revealing an effective 
mechanism regulating full-length presenilin levels in which TRAF6 is very possibly 
involved. 
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Figure 3.13 Deletion of the putative CUE domain has no effect on the turnover of 
PS1. HEK293T cells were transiently transfected with PS1 or PS1ΔCUE construct. 
Twenty-four hours after transfection, cell cultures were incubated with 
cycloheximide (20µg/ml) for 0, 1, 2, 4, 8, 12 and 24 hours respectively. Cell lysates 
were analyzed for PS1 immunodetection by immunoblotting with anti-PS1 CTF 
antibody. β-actin and β-tubulin levels were measured as loading control. 
Densitometry was used to measure levels of PS1 full length. Bars presented are the 
mean + SEM of triplicate samples. No statistical significance was observed between 
these two groups (p>0.1). 
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3.3 Presenilins are novel substrates of TRAF6-mediated 
ubiquitination 
3.3.1 TRAF6 ubiquitinates PS1 and PS1ΔCUE via Lys63-linked 
polyubiquitination  
Alteration in the ubiquitination status of PS1 has been shown to prevent PS1 
proteasomal degradation and increase PS1 stability (Aoyagi et al., 2010). Given that 
TRAF6 is an E3 ubiquitin ligase and that TRAF6 alters stability of PS1, we 
hypothesized that PS1 may be a novel ubiquitination substrate of TRAF6. To test 
whether PS1 is ubiquitinated by TRAF6 and what the ubiquitination type that TRAF6 
induces is, HEK293T cells were transiently transfected with wild type PS1 or PS1ΔCUE 
and co-transfected with TRAF6 or TRAF6-DN and co-transfected with HA-tagged 
ubiquitin (Ub) or the ubiquitin mutant, UbK63R, that is unable to form Lys63-linked 
polyubiquitination chain. Thirty-six hours post-transfection cells were harvested 
under stringent 1% SDS lysis condition and PS1 was immunoprecipitated with anti-
PS1 NTF antibody. Ubiquitination of PS1 was detected via Western blotting with anti-
HA antibody (Figure 3.14). A slight smear was detected where PS1 was co-expressed 
with ubiquitin which indicates the ubiquitination of PS1 (Figure 3.14 lane 3). 
Expression of PS1 and PS1ΔCUE with TRAF6 and ubiquitin showed much stronger 
smears suggesting that both PS1 and PS1ΔCUE are ubiquitinated by TRAF6 (Figure 
3.14 lane 4 and 6). Co-expression of PS1, TRAF6 and UbK63R showed no smear when 
probed with anti-HA antibody, but showed strong smear when the blot was re-
probed with anti-PS1 NTF antibody (Figure 3.14 lane 7 top and middle panel), 
indicating that polyubiquitination of PS1 is formed through ubiquitin Lys63 residue  
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Figure 3.14 TRAF6 induces Lys63-linked polyubiquitination of PS1. HEK293T cells 
were transfected with wild type PS1 or PS1ΔCUE and co-transfected with TRAF6 or 
TRAF6-DN and co-transfected with HA tagged ubiquitin (Ub) or UbK63R, as indicated. 
Under stringent SDS-denaturing immunoprecipitation condition, cell lysates were 
prepared and immunoprecipitated with anti-PS1 NTF antibody thirty-six hours after 
transfection. Precipitated PS1 and ubiquitination of PS1 were detected by 
immunoblotting with anti-PS1 NTF and anti-HA epitope antibodies. Western blot of 
whole cell lysates confirms equal expression of all constructs. Date shown is 
representative of a typical experiment which was repeated at least three times. 
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and TRAF6 could induce polyubiquitination via endogenous wild-type ubiquitin in the 
present of UbK63R mutant. Immunoglobulin G (IgG) of PS1 NTF antibody was also 
detected as marked in the figure. 
3.3.2 Knock-out of TRAF6 decreases ubiquitination and full-length level of PS1 
After showing that TRAF6 induces ubiquitination of PS1, we assumed that knock-out 
of TRAF6 should have the opposite effect on PS1. To verify the hypothesis, PS1 was 
transfected alone or co-transfected with HA-Ub in control MEF cells and TRAF6-/- 
MEF cells. Thirty-six hours post transfection cells were harvested under stringent SDS 
denaturing condition and then subjected to immunoprecipitation for PS1 and 
Western blot for HA-Ub. Ubiquitination of PS1 was observed when PS1 and HA-Ub 
were co-expressed in control MEF cells; however in TRAF6-/- MEF cells this 
ubiquitination was diminished (Figure 3.15) suggesting that TRAF6 is required for the 
ubiquitination of PS1. Moreover, when checking PS1 expressions by Western blot, 
we showed that in the absence of TRAF6, increasing overall cellular ubiquitination by 
over-expressing HA-Ub decreased full-length level of PS1 (Figure 3.15 lower panel 
lane 6), suggesting that TRAF6-mediated ubiquitination positively regulates the 
stability of full-length PS1 and some unknown E3 ligases may play the opposite role. 
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Figure 3.15 Knock-out of TRAF6 decreases ubiquitination and full-length level of 
PS1. Wild-type MEF cells and TRAF6 knock-out MEF cells were transfected with PS1 
or co-transfected with HA-Ub. Thirty-six hours post transfection cells were harvested 
under stringent SDS denaturing condition and then subjected to 
immunoprecipitation for PS1 and Western blot for HA-Ub. High molecular smears 
were detected with anti-HA epitope antibody revealing the ubiquitination status of 
PS1. Precipitated PS1 was detected by anti-PS1 NTF antibody. Western blot of whole 
cell lysates confirms expressions of all proteins.  
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3.3.3 Substrate specificity of PS1 ubiquitination comparing different E3 ligases. 
Having shown that PS1 is ubiquitinated by TRAF6, we next investigated the specificity 
of PS1 ubiquitination by testing other TRAF family members and E3 ligases. We 
introduced two known E3 ligases: PDLIM2 (PDZ and LIM domain 2) and βTRCP (beta-
transducin repeat-containing homologue protein) (Tanaka et al., 2007; Limon-Mortes 
et al., 2008). HEK293T cells were transiently transfected with wild type PS1 and co-
transfected with HA-Ub and co-transfected with TRAF6, TRAF6C70A, TRAF2, TRAF5, 
PDLIM2 or βTRCP. Thirty-six hours post transfection cells were harvested under 
stringent SDS denaturing condition and then subjected to immunoprecipitation and 
Western blot. High molecular smears were detected with anti-HA epitope antibody 
revealing the ubiquitination status of PS1. While TRAF2 did induce a detectable 
increase in PS1 ubiquitination, co-expression of PS1, HA-Ub and TRAF6 or TRAF5 
showed the strongest increase in PS1 ubiquitination (Figure 3.16 lane 3, 5 and 6). 
Importantly, co-expression of PS1, HA-Ub and the TRAF6 E3 ligase activity deficient 
mutant, TRAF6C70A, showed minimal increase in PS1 ubiquitination over 
background (co-expression of PS1 and HA-Ub) (Figure 3.16 lane 4), demonstrating 
that the observed increase in PS1 ubiquitination was TRAF-dependent. Furthermore, 
co-expression of βTRCP or PDLIM2 with PS1 and HA-Ub did not increase the 
ubiquitination of PS1 (Figure 3.16 lane 7 and 8), revealing that PS1 was not 
ubiquitinated by these two E3 ligases. Collectively, our results suggest that 
ubiquitination of PS1 is specific to TRAF family E3 ligases. 
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Figure 3.16 PS1 is preferentially ubiquitinated by TRAF family E3 ligases. HEK293T 
cells were transiently transfected with wild type PS1 and HA-Ub and co-transfected 
with TRAF6, TRAF6C70A, TRAF2, TRAF5, PDLIM2 or βTRCP. Thirty-six hours post 
transfection cells were harvested under stringent SDS denaturing condition and then 
subjected to immunoprecipitation and Western blot. High molecular smears were 
detected with anti-HA epitope antibody revealing the ubiquitination status of PS1. 
Precipitated PS1 was detected by anti-PS1 NTF antibody. Western blot of whole cell 
lysates confirms expressions of all proteins. Experiment was repeated more than 
three times showing the same result. 
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3.3.4 Only full-length PS1 is ubiquitinated by TRAF6, but not its fragments. 
Having shown PS1 as a substrate of TRAF6-mediated ubiquitination, we next 
investigated wheter full-length PS1 or either of its proteolytic fragments PS1-NTF or 
PS1-CTF are ubiquitinated by TRAF6. HEK293T cells were transiently transfected with 
full-length PS1 or PS1 NTF or PS1 CTF truncated mutants and co-transfected with HA-
Ub and TRAF6. Thirty-six hours post transfection cells were harvested under 
stringent SDS denaturing condition and then subjected to immunoprecipitation and 
Western blot. High molecular smears were detected with anti-HA epitope antibody 
revealing the ubiquitination status of full-length PS1 (Figure 3.17). No smear or 
obvious alteration was detected in the lower molecular panel when probing for HA-
ubiquitin suggesting that PS1-NTF and PS1-CTF truncated fragments are not 
ubiquitinated by TRAF6. Western blot analysis of the whole cell lysates showed that 
only the levels of full-length PS1 were dramatically increased by co-overexpression of 
ubiquitin and TRAF6, but not either of the NTF or CTF fragments. Collectively, our 
results suggest that TRAF6 regulates only the full-length PS1, but not the PS1 
fragments. As endoproteolysis of presenilin is considered to take place during its 
transport from ER to Golgi apparatus (Spasic et al., 2006b), regulation of the 
presenilins by TRAF6 should be revealed as an early cellular modulating event. In 
addition, whether regulation of TRAF6 has any effect on full-length presenilin 
functions should be examined.  
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Figure 3.17 Only full-length PS1 is ubiquitinated by TRAF6, but not its fragments. 
HEK293T cells were transiently transfected with wild type PS1, PS1 NTF or PS1 CTF 
and co-transfected with HA-Ub and TRAF6. Thirty-six hours post transfection cells 
were harvested under stringent SDS denaturing condition and then were subjected 
to immunoprecipitation for PS1 full-length, PS1 NTF or PS1 CTF. Ubiquitination status 
of immunoprecipitated PS1 full-length or fragments were revealed by Western blot 
analysis using anti-HA antibody. Western blot analysis of the whole cell lysates 
showed the levels of overexpressed PS1 full-length and its fragments. 
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3.3.5 TRAF6 increases the level of full-length APP as well as the levels of its 
intracellular and extracellular fragments 
Presenilins are the catalytic core of γ-secretase complex which facilitates the γ-
secretase dependent cleavage of APP (Citron et al., 1997). Abnormal production of 
the Aβ peptides is considered as the key pathogenesis of AD. As TRAF6 was shown to 
regulate the cellular levels of presenilin, we next investigated the effect of TRAF6 on 
APP and its cleavage. HEK293T cells are transfected with APP Swedish mutant (APP 
SW) alone or co-transfected with TRAF6. Twelve hours after transfection, selected 
cell cultures were treated with the γ-secretase inhibitor, Compound E (50nM), as 
indicated. Cells were harvested 24 hours after transfection. Lysates were subjected 
to Western blot analysis and probed with an anti-APP C-terminus antibody. 
Overexpression of TRAF6 increases the detectable level of full-length APP as well as 
the APP cleavage products, APP C99, APP C83 and APP AICD (Figure 3.18A). In 
parallel, culture medium was collected from cells expressing APP SW or co-
expressing APP SW and TRAF6 and was subjected to ELISA for the analysis of Amyloid 
peptides, Aβ40 and Aβ42. Consistent to the Western blot result where over-
expression of TRAF6 increases the detectable levels of APP and its proteolytic 
fragments, levels of soluble Aβ40 and Aβ42 were also increased (Figure 3.18B). As 
TRAF6 increases the overall levels of APP and its proteolytic fragments, using this 
experimental approach we are unable to conclude whether or not TRAF6 directly 
affects γ-secretase activity. 
3.3.6 Over-expression of TRAF6 does not affect γ-secretase activity 
Having shown the association between TRAF6 and the increased levels of presenilins 
and APP, we wanted to determine whether or not the observed effect of TRAF6 is  
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Figure 3.18 TRAF6 increases the level of full-length APP as well as the levels of its 
intracellular and extracellular fragments. (A) HEK293T cells were transfected with 
APP SW and co-transfected with FLAG-TRAF6. 12 hours after transfection, selected 
cell cultures were treated with Compound E (50nM) as indicated. Cells were 
harvested 24 hours after transfection. Lysates were subjected to Western Blots and 
probed with anti-APP C-terminal, anti-FLAG and anti-β-actin antibodies. (B) Culture 
medium (A lane 2 and 3) was collected before harvest and subjected to ELISA for 
Aβ40 and Aβ42. Data is presented by mean + SEM of three independent experiments. 
Difference observed between these two groups was significant (p<0.05). 
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specific for selected target proteins or a general feature on cellular proteins. Because 
TRAF6 associates with both PS1 and PS2 (Figure 3.1) and preferentially alters 
detectable levels of full-length PS1 and PS2 but not γ-secretase protease 
components, PS1-NTF and PS1-CTF (Figure 3.17), we decided to determine if TRAF6 
has any effect on the other γ-secretase protease components, Nicastrin, Aph-1 or 
Pen-2. Cells over-expressing empty vector or TRAF6 were lysed and TRAF6 was 
immunoprecipitated with an anti-FLAG antibody. The immunoprecipitates were then 
analysed for co-immunoprecipitation of Aph-1, Nicastrin, Pen-2 and/or PS1 by 
Western blotting.  Interestingly, only PS1 coprecipitated with TRAF6 (Figure 3.19A 
left panel). Whole cell lysates were also analysed by Western blotting for the levels 
of the γ-secretase components and then were quantitated by densitometry. Results 
suggest that TRAF6 only increased detectable levels of full-length PS1, but not any of 
the other γ-secretase components (Figure 3.19A middle and right panel). 
In previous reports, we have linked the over-expression of TRAF6 to the cellular 
levels of two γ-secretase substrates, IL1-R1 and p75NTR (Powell et al., 2009; Twomey 
et al., 2009). We also detected linkage between over-expression of TRAF6 and the 
levels of APP and its γ-secretase proteolytic products (Figure 3.18). Next, we decided 
to measure the effect of TRAF6 on γ-secretase activity by studying the cleavage of a 
truncated mutant of APP, APP CT100, which is the natural substrate for -secretase 
proteolysis and is directly processed by γ-secretase. In HEK293T cells, APP CT100 was 
transiently transfected alone or co-transfected with TRAF6, and cell lysates were 
subjected to Western blot analysis and probe with an anti-APP C-terminus antibody. 
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Figure 3.19 Over-expression of TRAF6 does not affect γ-secretase activity. (A) HEK293T 
cells were transfected with empty vector or FLAG-TRAF6 for 36 hours. Cell lysates were then 
subjected to immunoprecipitation for TRAF6 and Western blot for the γ-secretase 
components as indicated. Cell lysates were also analysed by Western Blot with anti-Aph-1, 
anti-Nicastrin, anti-Pen-2, anti-PS1 NTF, anti-FLAG and anti-β-actin antibodies. Protein levels 
were measured by densitometry. Results are presented by mean + SEM from three 
independent experiments. Only difference of PS1 full-length levels between these two 
groups are statistically significant (p<0.05). (B) HEK293T cells were transfected with APP 
CT100 and co-transfected with FLAG-TRAF6. 12 hours after transfection, selected cell 
cultures were treated with Compound E (50nM) as indicated. Cells were harvested 24 hours 
after transfection. Lysates were subjected to Western Blots and probed with anti-APP C-
terminal, anti-FLAG and anti-β-actin antibodies. Culture medium (B lane 2 and 3) was 
collected before harvest and subjected to ELISA for Aβ40 and Aβ42. Data is presented by 
mean + SEM of three independent experiments. No significant difference was observed 
between these two groups.  
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Our result showed similar levels of the APP CTD and ICD with or without over-
expression of TRAF6 which indicates that TRAF6 does not induce any major change 
on the cleavage of APP CT100, and therefore on γ-secretase activity (Figure 3.19 B 
lane 2 and 3). Treatment of parallel cultures with the γ-secretase inhibitor, 
compound E, confirmed that APP C100 derived proteolytic fragments observed are 
products of γ-secretase cleavage (Figure 3.19 B lane 4 and 5). To further confirm the 
result with a more sensitive and quantifiable assay, cell culture medium was 
collected and levels of Aβ40 and Aβ42 peptides were measured using an ELISA assay 
(Figure 3.19B right panel). Considering the effect of TRAF6 on endogenous APP, 
TRAF6 does not induce a significant change in -secretase activity or the cleavage of 
APP CT100, suggesting that γ-secretase activity is not altered by over-expression of 
TRAF6. 
3.3.7 Knock-out of presenilins or TRAF6 attenuates ER calcium signalling 
The observation that TRAF6 regulates full-length presenilins but not the γ-secretase 
activity lead us to focus on the known biological function of presenilin holoprotein, 
independent of presinilin function in γ-secretase protease complexes. Recent studies 
have revealed that presenilins function as the passive ER Ca2+ leak channels and FAD 
mutants cause deranged Ca2+ signalling and cannot rescue the deregulated ER Ca2+ 
leak activity in presenilin knock-out MEFs (Tu et al., 2006; Nelson et al., 2007; Nelson 
et al., 2010). To determine if TRAF6-mediated ubiquitination of presenilins, regulated 
presenilins function as an ER Ca2+ leak channel, firstly, we compared the ER Ca2+ leak 
activity in control MEF cells and presenilin double knock-out (DKO) MEF cells. MEF 
cells were cultured to grow to about 50% confluency. Prior to experimentation cells 
109 
 
were washed twice with 1ml of KHB and then were loaded with 2 μM fura-2-
acetoxymethyl ester and incubated for 30 min at 37°C, as described in materials & 
methods. Cells were then washed twice with 1ml of Ca2+-free KHB and loaded with 5 
μl of 1mM Ionomycin to induce complete depletion of the ER calcium store which 
could be measured to indicate the size of the ER Ca2+ pool. Alterations in the 
cytosolic Ca2+ levels were detected by exciting the fura-2 loaded cells intermittently 
by 340 and 380 nm UV light. After recording for 10 min, ratio images were generated 
and the perimeter of each cell was defined as a region of interest and the mean fura-
2 ratio from within this region against time was exported to Microsoft Excel 2003 for 
further analyses. Figure 3.20A shows an example of the ratio/time curves of both 
control MEFs and presenilin DKO MEFs reflecting the size of the ER Ca2+ store and 
the ability of presenilins as passive ER Ca2+ leak channels. Collectively, by showing 
that presenilin DKO MEF cells exhibited higher level of Ca2+ exposure, we reproduced 
the experiment showing attenuated passive ER Ca2+ leaking function in the presenilin 
DKO MEF cells compared to control MEF cells (Figure 3.20B) (Tu et al., 2006). 
Furthermore, to determine the role of TRAF6 in ER Ca2+ signalling function, we 
compared the ER Ca2+ pool size of both control MEF cells and TRAF6 knock-out MEF 
cells. Similar to the observation in presenilin DKO MEF cells, TRAF6 knock-out MEF 
cells also showed enlarged ER Ca2+ pool (Figure 3.20C), suggesting that knock-out of 
presenilins or knock-out of TRAF6 both result in deficiency in ER Ca2+ signalling. 
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Figure 3.20 Knock-out of presenilins or TRAF6 attenuates ER calcium signalling. wild type 
MEF (PS WT) cells and presenilin double knock-out (PS DKO) MEF cells or wild type MEF 
(TRAF6 WT) cells and TRAF6 knock-out MEF (TRAF6 -/-)cells were cultured to grow to about 
50% confluency. Prior to experimentation cells were washed twice with 1ml of KHB and then 
were loaded with 2 μM fura-2-acetoxymethyl ester and incubated for 30 min at 37°C. Cells 
were then washed twice with 1ml of Ca2+-free KHB and loaded with 5 μl of 1mM Ionomycin 
to induce ER calcium discharge. Alterations in the cytosolic Ca2+ levels were detected by 
exciting the fura-2 loaded cells intermittently by 340 and 380 nm UV light. After recording 
for 10 min, ratio images were generated and the perimeter of each cell was defined as a 
region of interest and the mean fura-2 ratio from within this region against time was 
exported to Microsoft Excel 2003 for further analyses. (A) Examples shown are the 
Ionomycin-induced Ca2+ signal curves in PS WT cells (dark line) and PS DKO cells (light line). 
(B) The average intensity of cytosolic Ca2+ exposure for both PS WT cells and PS DKO cells are 
shown as the mean + SEM from 21 cells measured from each cell line. (C) Ionomycin induced 
cytosolic Ca2+ concentration increase and restoration were recorded for both TRAF6 WT MEF 
cells and TRAF6 -/- MEF cells and shown as mean + SEM measured from 17 and 27 cells 
respectively. 
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3.3.8 TRAF6-mediated in vitro ubiquitination of PS1 
Different approaches have been carried out to optimize the in vitro ubiquitination 
assay for PS1. Because previous attempts to produce and purify recombinant PS1 
from E.coli cells have failed, we developed an in vitro ubiquitination assay utilizing; 
recombinant TRAF6 from BL21 E.coli cells, immunopurified PS1 from HEK293T cells, 
and an in vitro ubiquitination kit from Biomol (including human recombinant E1 and 
Ubc13/Mms2 E2 recombinant enzymes, recombinant ubiquitin and ATP). However, 
recombinant TRAF6 from bacteria cells did not possess measurable E3 ligase activity. 
Therefore, we resigned to using immunopurified TRAF6 from HEK293T cells over-
expressing FLAG-tagged TRAF6 extracted by recombinant 3XFLAG peptides which 
competes for the FLAG affinity agarose with FLAG-TRAF6. In vitro ubiquitination 
assays were performed by incubating immobilized PS1 conjugated to protein-G 
beads with recombinant E1 and E2 enzymes, recombinant ubiquitin, ATP and 
immunopurified TRAF6 at 37oC for 1 hour. Next, the PS1 conjugated beads were 
washed and then boiled in sample loading buffer and subjected to Western blot 
analysis with an anti-ubiquitin antibody. We successfully demonstrated that TRAF6 
ubiquitinated PS1 under these experimental conditions (Figure 3.21A). However, 
TRAF6 co-immunoprecipitated with immobilized PS1 during the incubation and was 
also observed on the Western blot (Figure 3.21A lowest panel).  
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Figure 3.21 TRAF6-mediated in vitro ubiquitination of PS1. HEK293T cells were 
transfected with PS1 or FLAG-TRAF6 (A) or FLAG-TRAF6 K124R (B) respectively. 36 
hours after transfection, cells were harvested and the lysates were subjected to 
immunoprecipitation for PS1 and FLAG-TRAF6 or FLAG-TRAF6 K124R respectively. 
TRAF6 conjugated FLAG affinity agarose was washed and incubated with 50 μl of 
100μg/ml 3xFLAG peptide solution for 30 mins. PS1 conjugated protein-G beads 
were also washed and incubated with 2μM E1, 0.5mg/ml E2, 50μM ubiquitin, 
100unit/ml inorganic pyrophophatase, 50mM DTT, 0.1M Mg-ATP and 20μl of TRAF6 
or TRAF6 K124R elution in 50μl reaction solution at 37 oC for 1 hour. After reaction, 
PS1 conjugated beads were washed again and boiled in sample loading buffer for 5 
mins. Sample loading buffer was then loaded on SDS-PAGE gel. Ubiquitination status 
was revealed by probing with anti-ubiquitin antibody. Immunoprecipitated PS1 and 
FLAG-TRAF6 were confirmed by probing with anti-PS1 and anti-TRAF6 antibodies.  
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In vitro ubiquitination assays without ATP also showed residual ubiquitin which could 
be attributed to auto-ubiquitination of TRAF6 (Figure 3.21A lane3).We tried to avoid 
this problem by using the TRAF6K124R mutant instead of the wild-type TRAF6. 
However, TRAF6K124R mutant did not appear to exert effective E3 ligase activity in 
the in vitro ubiquitination assay (Figure 3.21B). 
3.3.9 Identification of PS1 ubiquitination sites by site-directed mutagenesis 
To further study the function of TRAF6-mediated ubiquitination of PS1, we 
attempted to map the sites of PS1 ubiquitination by site-directed mutagenesis. There 
are 16 lysine residues in the human PS1 sequence, however 3 lysine residues localise 
in the transmembrane domain which precludes them as potential ubiquitination 
sites (Figure 3.22). Given this, we mutated the remaining 13 lysine residues and 
potential ubiquitin acceptor sites by site-directed mutagenesis and tested them in 
the in vivo ubiquitination assay. HEK293T cells were transfected with PS1 or the 
various PS1 lysine mutants and co-transfected with HA-Ub and TRAF6, as indicated 
(Figure 3.23). Thirty-six hour after transfection, cells were harvested under SDS-
denaturing condition. Cell lysates were then subjected to immunoprecipitation for 
PS1 and Western blotting for HA-Ub with an anti-HA antibody. Unfortunately, WT 
PS1 and all PS1 lysine mutants showed increased ubiquitination when they are co-
overexpressed with TRAF6 (Figure 3.23). Full-length levels of all PS1 lysine mutant 
were also increased by TRAF6. No obvious difference was observed in the 
ubiquitination profile of PS1 and any of the PS1 lysine mutants analysed, suggesting 
that TRAF6-mediated ubiquitination of PS1 possibly occurs at multiple lysine residues 
of PS1. Mutagenesis of multiple lysine residues or a different approach are required 
to map the ubiquitination sites of PS1. 
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Presenilin-1 Homo sapiens 
 
 
 
        10         20         30         40         50         60  
MTELPAPLSY FQNAQMSEDN HLSNTVRSQN DNRERQEHND RRSLGHPEPL SNGRPQGNSR  
 
        70         80         90        100        110        120  
QVVEQDEEED EELTLKYGAK HVIMLFVPVT LCMVVVVATI KSVSFYTRKD GQLIYTPFTE  
 
       130        140        150        160        170        180  
DTETVGQRAL HSILNAAIMI SVIVVMTILL VVLYKYRCYK VIHAWLIISS LLLLFFFSFI  
 
       190        200        210        220        230        240  
YLGEVFKTYN VAVDYITVAL LIWNFGVVGM ISIHWKGPLR LQQAYLIMIS ALMALVFIKY  
 
       250        260        270        280        290        300  
LPEWTAWLIL AVISVYDLVA VLCPKGPLRM LVETAQERNE TLFPALIYSS TMVWLVNMAE  
 
       310        320        330        340        350        360  
GDPEAQRRVS KNSKYNAEST ERESQDTVAE NDDGGFSEEW EAQRDSHLGP HRSTPESRAA  
 
       370        380        390        400        410        420  
VQELSSSILA GEDPEERGVK LGLGDFIFYS VLVGKASATA SGDWNTTIAC FVAILIGLCL  
 
       430        440        450        460  
TLLLLAIFKK ALPALPISIT FGLVFYFATD YLVQPFMDQL AFHQFYI  
 
 
 
Figure 3.22 Amino acid sequence of human PS1. 13 lysine residues are highlighted in 
yellow. Nine transmembrane domains are underlined respectively. The CUE domain 
is shown as blue letters. γ-secretase cleavage sites are lighted in red. The catalytic 
aspartate motifs and the important PAL motif are shown in red letters. 
  
115 
 
 
 
Figure 3.23 In vivo ubiquitination assays of PS1 lysine mutants. HEK293T cells were 
transiently transfected with wild type PS1 or PS1 lysine mutants and co-transfected 
with HA-Ub and TRAF6 as indicated. Thirty-six hours post transfection cells were 
harvested under stringent SDS denaturing condition and then subjected to 
immunoprecipitation and Western blot. High molecular smears were detected with 
anti-HA epitope antibody revealing the ubiquitination status of PS1. Precipitated PS1 
was detected by anti-PS1 NTF antibody. Western blot of whole cell lysates confirms 
expressions of all transfected proteins. Experiment was repeated more than three 
times showing the same result. 
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Discussion: 
The presenilin holoproteins have a relatively short half-life and the endogenous full-
length proteins are maintained at relatively low levels (Ratovitski et al., 1997; Zhang 
et al., 1998). Full-length presenilins undergo endoproteolytic cleavage and 
incorporate into γ-secretase complex as NTF/CTF heterodimers during its transport 
from ER to Golgi apparatus (Spasic et al., 2006b). Studies have mostly focused on the 
functions of the NTF/CTF heterodimer as the catalytic core of γ-secretase complex 
and on the regulation of γ-secretase activity. However, very little is known about 
how the full-length presenilins are regulated in the aspects of post-translational 
modification, trafficking and degradation and how their endoproteolysis are 
modulated. Emerging studies have revealed functions of full-length presenilins 
including their roles in calcium signalling, β-catenin signalling, protein trafficking and 
apoptosis (Hass et al., 2008; Coen and Annaert, 2010; Honarnejad and Herms, 2012). 
In this study, we characterised and determined the relevance of the interaction 
between presenilins and the E3 ubiquitin ligase, TRAF6 and subsequently focused on 
the regulation of -secretase independent function of the presenilins in calcium 
signalling. 
Our group has previously revealed an interaction between TRAF6 and presenilins 
which led us to the study of TRAF6-mediated regulation of presenilins (Powell et al., 
2009). There are numerous reports confirming the subcellular localisation of both 
presenilins and TRAF6 in the plasma membrane and endosome which supports the 
possibility of a physical and/or functional association between presenilins and TRAF6 
(Schultheiss et al., 2001; Okochi et al., 2002; Fukumori et al., 2006; Li et al., 2006a; 
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Zhang et al., 2006). Firstly, we confirmed the interaction between TRAF6 and both 
PS1 and PS2 and additionally we showed that the interaction is independent of the 
TRAF6 RING domain which possesses the E3 ligase activity of TRAF6 (Figure 3.1). We 
also noticed that over-expression of TRAF6 increased the detectable levels of 
presenilins in whole cell extracts. Then we further confirmed this effect by showing 
that presenilins levels are increased by TRAF6 in a dose-dependent manner, 
particularly the levels of full-length presenilins (Figure 3.2). The RING domain is 
reported to confer TRAF6 E3 ligase activity and is essential for TRAF6-mediate 
signalling pathways (Hsu et al., 1996a; Lamothe et al., 2008). In our study we 
investigated the relevance of TRAF6 E3 ligase activity and the effect of TRAF6 on 
presenilin immunodetection. Firstly we showed that TRAF6 dominant negative 
mutant (TRAF6DN) which lacks the critical RING domain could not increase the 
immunodetection of PS1 (Figure 3.3A). Secondly, given that autoubiquitination of 
TRAF6 is reported to be independent in IL-1 and RANKL induced activation of NFκB 
and MAPK pathways (Walsh et al., 2008), we found that TRAF6K124R, a TRAF domain 
single-point mutant that is defective in TRAF6 autoubiquitination, could still increase 
immunodetection of the presenilins. Finally we showed that TRAF6C70A, a RING 
domain single-point mutant that is defective in substrate ubiquitination, failed to 
enhance immunodetection of the presenilins (Figure 3.3B and C). Collectively, these 
results revealed that TRAF6 requires its E3 ubiquitin ligase activity to enhance 
presenilin detectable levels which means TRAF6-induced ubiquitination is involved in 
this regulation. Interestingly, other TRAF family members also appeared to increase 
the levels of PS1 and PS2 (Figure 3.4). To our surprise, TRAF2-DN also increases the 
level of presenilins indicating that TRAF2 may involve in this regulation as an adaptor 
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protein independent of its E3 ligase activity (Figure 3.4). Redundancies between 
TRAF family members have been reported before. For example, deficiency of both 
TRAF2 and TRAF6 is necessary for abrogating CD40-mediated NF-κB activation and 
TRAF2 and TRAF6 associate at the CD40 complex (Davies et al., 2005; Ellison et al., 
2006). For TLR signalling, mutations of both TRAF2 and TRAF6 binding sites in TRIF 
are required to abrogate type I IFN induction (Sasai et al., 2010). Similarly, depletion 
of both TRAF2 and TRAF5 are required for abolishment of TNF-induced NF-κB 
activation (Tada et al., 2001). In our study, we showed that TRAF family members 
could exert similar enhancing effects on presenilin levels even in the absence of the 
E3 ligase activity (Figure 3.4). 
TRAF6 has been shown to induce JNK activation and this function requires E3 ligase 
activity of TRAF6 (Lamothe et al., 2008). Additionally, transcription of PS1 is 
regulated by JNK activation (Lee and Das, 2008). To link TRAF6-increased presenilin 
levels to TRAF6 mediated JNK activation, we investigated PS1 protein level and 
mRNA level with the combination of TRAF6 over-expression and pharmacological 
inhibitor of JNK activity. We showed that over-expression of TRAF6 induces JNK 
activation, thus increasing presenilin mRNA and protein levels while inhibition of JNK 
activation reduces both (Figure 3.5). To find out if TRAF6 was involved in the 
regulation of PS1 post-translationally, we inhibited protein production to examine 
the half-life of PS1 full-length in the presence of over-expressed TRAF6.We showed 
that in addition to regulating PS1 transcription through JNK activation, TRAF6 also 
enhances the stability of PS1 and extend the half-life of PS1 full-length protein 
(Figure 3.7). Collectively, our data demonstrates that TRAF6-induced increases in the 
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cellular levels of presenilin should be considered as comprehensive consequences 
resulting from enhanced JNK activation and altered turnover of presenilin proteins. 
Our group also identified a putative CUE domain in the presenilins and other team 
member has shown that deletion of the CUE domain abolishes K63-linked 
polyubiquitin chains from binding to presenilins (data not published). The CUE 
domain on other proteins has been shown to mediate interactions between 
ubiquitin and CUE domain containing proteins, which facilitates their 
monoubiquitination (Davies et al., 2003; Shih et al., 2003b; Chen et al., 2006). Given 
that monoubiquitination is a signal regulatory modification that is important in 
altering protein activity, location or structure (Hicke, 2001), we were interested in 
examining the role of the CUE domain in presenilins functions. Firstly, we showed 
that deletion of the presenilin CUE domain prevents presenilin endoproteolysis as 
the cleaving sites are contained in the CUE domain (Figure 3.9 and 3.10). However, 
the four CUE domain single-point mutants were still able to undergo cleavage and no 
obvious difference was observed when compared to wild type PS1, suggesting that 
the single-point mutations of the critical CUE domain residues have no effect on PS1 
endoproteolysis. Secondly, we showed that CUE domain deletion mutants of PS1 and 
PS2 were still increased in a dose-dependent manner with co-expression of TRAF6 
(Figure 3.11). Finally, despite that the PS1 CUE domain deletion mutant is deficient in 
presenilin endoproteolysis, deletion of the CUE domain did not change the turnover 
of PS1ΔCUE comparing to wild-type PS1 (Figure 3.13), suggesting that separated 
from the endoproteolytic cleavage, level of full-length presenilin is tightly regulated 
by another system in which TRAF6 is probably involved. Collectively, regulation of 
TRAF6 on presenilin is independent of the CUE domain and turnover of the full-
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length presenilin is independent on its endoproteolysis. Although it has been shown 
that CUE domain of presenilin is essential for its polyubiquitin binding, function of 
the CUE domain needs to be further explored. 
The presenilin proteins undergo a variety of posttranslational modifications, which 
alter the functions of presenilins and their interaction with other proteins. For 
example, phosphorylation of the presenilins inhibits their cleavage by caspases and 
disrupts PS1 interaction with β-catenin (Walter et al., 1996a; Walter et al., 1999). 
Moreover, phosphorylation of PS1 is reported to affect turnover of PS1 and its 
NTF/CTF fragments as well as altering γ-secretase activity (Walter et al., 1996a; 
Walter et al., 1999). Modification such as polyubiquitination leads to the 
proteasomal degradation of presenilins (Kim et al., 1997b; Fraser et al., 1998; 
Marambaud et al., 1998). Ubiquilin involves in proteasome degradation pathway of 
presenilins by interacting with polyubiquitinated presenilin and preventing presenilin 
being targeted by proteasomal degradation (Mah et al., 2000; Massey et al., 2004). 
Moreover, it has been shown that mutation of two lysine residues in PS2 reduces its 
ubiquitination, results in the destabilization of PS2 and inhibits its binding to 
Ubiquilin, demonstrating the importance of ubiquitination modification for the 
stability and activity of PS2 (Ford and Monteiro, 2007). Only one of these two lysine 
residues is conserved in PS1 (K265). However, mutation of this single site did not 
cause any measurable change in ubiquitination or protein levels of PS1 (Figure 3.23).  
TRAF6 has been shown to regulate various signalling events through the formation of 
Lys-63 linked polyubiquitin chains on different target proteins such as MALT1 (Sun et 
al., 2004; Oeckinghaus et al., 2007), NEMO (Sebban-Benin et al., 2007a; Rahighi et al., 
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2009) or TRAF6 itself (Lamothe et al., 2007a). Similar to our observation that TRAF6 
increases the level of presenilin and alters its turnover, another E3 ligase SEL-10 was 
reported to alter PS1 turnover by ubiquitinating PS1 (Lamothe et al., 2007a) which 
leads us to investigate PS1 as a substrate of TRAF6-mediated ubiquitination. We 
showed that PS1 is modified by TRAF6 through K63-linked polyubiquitination (Figure 
3.14) and the ubiquitin-binding CUE domain of PS1 is not required for this 
modification. Furthermore we showed that PS1 is deficient in its ubiquitination in 
TRAF6 knock-out MEF cells and the full-length level of PS1 is decreased (Figure 3.15). 
Then we showed that PS1 ubiquitination is specifically regulated by TRAF family 
member that possess E3 ligase activity, but not by other irrelevant E3 ligases (Figure 
3.16). Presenilin holoproteins and NTF/CTF fragments have been reported to have 
distinct subcellular distributions. Full-length presenilins are localized within the ER 
whereas the NTF and CTF are predominantly localized to the Golgi apparatus (Zhang 
et al., 1998). Therefore to identify which forms of presenilin are regulated by TRAF6 
is important to understand the significance of this modification. We further showed 
that only full-length PS1 is the substrate of TRAF6-mediated ubiquitination, but not 
any of the fragments (Figure 3.17). Presenilin NTF/CTF heterodimer serves as the 
catalytic subunits of the γ-secretase complex. Consistent with the previous finding, 
TRAF6 was revealed not to interact with or affect any of the γ-secretase components, 
including Nicastrin, Pen-2 and Aph-1 (Figure 3.19). Additionally, we showed that 
over-expression of TRAF6 does not alter the γ-secretase cleavage of APP CT100, 
suggesting that γ-secretase activity is not regulated by TRAF6. 
Full-length presenilins were reported to function as passive ER Ca2+ leak channels 
and maintain the calcium homeostasis of the ER, disruption of which has been linked 
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to the pathogenesis of AD (Tu et al., 2006). Familial AD-linked mutations have been 
shown to disrupt presenilin function as ER Ca2+ leak channels (Nelson et al., 2007). 
Additionally, transmembrane 7 and 9 of mouse PS1 were reported to be essential for 
forming the conductance pore of the calcium leak channels (Nelson et al., 2011). PS1 
is reported to interact with sarco ER calcium-ATPase and expression of full-length 
PS1 is increased upon ER stress (Jin et al., 2010). However, little is known about how 
this full-length presenilin function is regulated in terms of the protein stability and 
the post-translational modification of full-length protein. As repression of PS1 
transcription by JNK inhibitor suppresses the ER Ca2+ leak and considering the full-
length levels of presenilins are regulated by TRAF6, we decided to examine if TRAF6 
is a regulator of presenilin ER Ca2+ channels. Similar to presenilin knock-out MEF cells, 
we found that TRAF6 knock-out MEF cells are deficient in maintaining the size of the 
ER Ca2+ pool (Figure 3.20), suggesting that knock-out of TRAF6 attenuates 
functioning of the ER Ca2+ leak channels. Ca2+ signalling is an important factor in the 
osteoclast differentiation and TRAF6 is also reported to be essential for RANKL-
mediated osteoclast differentiation (Lamothe et al., 2007b; Kajiya, 2012). 
Osteopetrosis observed in TRAF6 knock-out mice could potentially be linked to the 
deficiency in ER Ca2+ signalling (Lomaga et al., 1999b). We cannot yet prove that 
knock-out of TRAF6 disrupts ER homeostasis by affecting passive presenilin ER Ca2+ 
leak channels, however given that knock-out of TRAF6 decreases presenilin levels 
and TRAF6 stabilized full-length presenilin by inducing ubiquitination modification, 
we hypothesis that TRAF6 involves in the regulation of presenilin functioning as 
passive ER Ca2+ leak channels by stabilizing full-length presenilin through 
ubiquitination modification. 
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In conclusion, we report presenilins as novel substrates for TRAF6 induced lysine-63 
linked polyubiquitination. Moreover, we demonstrate that TRAF6-mediated 
ubiquitination of presenilin manipulates presenilin stability, but not γ-secretase 
activity. TRAF6 may regulate presenilin function as passive ER Ca2+ leak channels, 
however further work is required to map the precise TRAF6-targeted sites of 
presenilin ubiquitination and to determine the functions and effects of presenilin 
ubiquitination. 
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Chapter 4: 
RESULTS 
TRAF6-induced polyubiquitination of IL-1R1 C-terminus is 
essential for its membrane expression and signalling 
transduction 
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Introduction: 
Conventionally, TRAF6 is reported as an adaptor protein for the IL-1R1 signalling 
complex and is required for the association to IRAK1 and the recruitment of TAK1 
complex by facilitating K63-linked polyubiquitination on the substrates or itself (Qian 
et al., 2001; Jiang et al., 2002; Ye et al., 2002). Our group previously reported IL-1R1 
as a novel substrate of γ-secretase-dependent regulated intramembrane proteolysis 
and antagonism of γ-secretase activity was shown to impair responsiveness of IL-1R1 
to IL-1β stimulation, indicating that γ-secretase cleavage of IL-1R1 may be a control 
mechanism for IL-1R1-mediated signalling (Elzinga et al., 2009b). Additionally, TRAF6 
and IRAK2 have been shown to interact with PS1, revealing a potential role of TRAF6 
in modulating the regulated intramembrane proteolysis of IL-1R1. In addition to 
regulated intramembrane proteolysis, IL-1R1 undergoes various post-translational 
modifications including glycosylation (Dower et al., 1989), ubiquitination (Brissoni et 
al., 2006) and phosphorylation (Gallis et al., 1989). Additionally, our group showed 
that IL-1R1 is a substrate for TRAF6-mediated ubiquitination and TRAF6 enhances 
regulated intramembrane proteolysis of IL-1R1 (Twomey et al., 2009). Ubiquitination 
of different receptors have been reported as important regulating events for 
receptor trafficking and signalling transduction. For instance, monoubiquitination of 
Notch receptor is required for its ligand-induced activation and γ-secretase cleavage 
(Gupta-Rossi et al., 2004b). TRAF6-mediated K63-linked polyubiquitination of the 
nerve growth factor receptor TrkA triggers its internalization and signalling (Geetha 
et al., 2005). IL-1R1 itself is ubiquitinated upon IL-1β stimulation and is subsequently 
coupled by Tollip to its lysosomal degradation (Brissoni et al., 2006). The biological 
relevance of γ-secretase cleavage of IL-1R1 and the role of the subsequently 
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generated IL-1R1 ICD are still unknown. However IL-1R1 nucleus translocation has 
been reported (Aveleira et al., 2010) which suggests the possibility that the γ-
secretase generated IL-1R1 ICD may translocate to the nucleus. As mentioned above, 
TRAF6 is involved in the regulation of IL-1R1 regulated intramembrane proteolysis, 
studying and determining the regulatory mechanism controlling IL-1R1 cleavage may 
have significance in understanding the signal transduction potential of IL-1R1 ICD.  
In this study we attempted to map the sites of TRAF6-mediated ubiquitination of IL-
1R1 using different approaches including in vitro ubiquitination assay on IL-1R1 
peptide arrays and site-directed mutagenesis of IL-1R1 lysine residues. Upon 
identifying IL-1R1 ubiquitination sites, we sought to study the functional importance 
of TRAF6-mediated ubiquitination of IL-1R1 in terms of IL-1R1 signalling transduction, 
cellular localisation and regulated intramembrane proteolysis.  
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4.1 TRAF6-induced polyubiquitination of IL-1R1 C-terminus is 
essential for its membrane localization and signalling transduction 
4.1.1 Using Peptide array to map the sites of IL-1R1 ubiquitination 
To further study the role of TRAF6 induced IL-1R1 ubiquitination, we began with 
mapping the sites of TRAF6-mediated ubiquitination of IL-1R1. Firstly, we attempted 
to reveal the potential ubiquitination sites by applying the combination of in vitro 
ubiquitination assay and peptide arrays. Briefly, the IL-1R1 peptide arrays are 
synthesized as overlapping 18-mer peptides covering the entire C-terminus sequence 
of IL-1R1 which were produced by automatic SPOT synthesis and synthesized on 
continuous Whatman cellulose membrane using Fmoc (9-
fluorenylmethyloxycarbonyl) chemistry with the AutoSpot-Rosbot ASS 222 (Intavis 
Bioanalytical Instruments) (Figure 4.1). The in vitro ubiquitination reagents including 
ATP, recombinant E1, E2, ubiquitin and GST-TRAF6K124R (or GST as negative control) 
were placed on the cellulose membrane of the IL-1R1 peptide array and were 
incubated at 37oC for 1h. After the reaction, the peptide arrays were washed and 
subjected to anti-ubiquitin antibody to reveal the ubiquitination status of the IL-1R1 
peptides. We detected specific signals for certain IL-1R1 peptides which could be 
considered as ubiquitination of certain lysine residues (Figure 4.1). However, 
negative control reaction for which TRAF6 was replaced by GST also gave similar 
signals. To verify the E3 ligase specificity of our recombinant TRAF6 protein, we 
carried out a series of optimization of the in vitro ubiquitination assay with PS1 and 
recombinant TRAF6 or immunoprecipitated TRAF6 as shown above (Figure 3.20). 
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Figure 4.1 In vitro ubiquitination assay of IL-1R1 peptide arrays. Overlapping 18-
mer peptides covering the entire C-terminus sequence of IL-1R1 were produced and 
synthesized on continuous cellulose membrane. The sequence of each peptide has 
15 amino acids overlapped with the previous one and moves forward by 3 amino 
acids. IL-1R1 peptide arrays were incubated with 2μM E1, 0.5mg/ml E2, 50μM 
ubiquitin, 100unit/ml inorganic pyrophophatase, 50mM DTT, 0.1M Mg-ATP and 2μM 
GST-TRAF6 or GST in 50μl reaction solution at 37 oC for 1 hour. After reaction, IL-1R1 
peptide arrays were washed in 0.2M NaOH stripping buffer to remove non-covalent 
binding. Ubiquitination status of the IL-1R1 peptide array was revealed by probing 
the membranes with anti-ubiquitin antibody.  
  
A1: IESRFYKHPFTCFAKNTH 
A2:       RFYKHPFTCFAKNTHGID 
A3:               KHPFTCFAKNTHGIDAAY 
A4:                      FTCFAKNTHGIDAAYIQL 
A5:                            …………………………… 
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4.1.2 Juxtamembrane domain of IL-1R1 contains potential ubiquitination sites 
Have failed to map the IL-1R1 ubiquitination sites by in vitro approach, we decided to 
use mutagenesis approach and in vivo ubiquitination assay as an alternative plan. As 
there are 21 lysine residues in the intracellular domain of IL-1R1, we tried to narrow 
down the region containing potential ubiquitinated lysine residues by make IL-1R1 
truncated mutants. Intracellular domain of IL-1R1 was divided into five regions each 
of which contains 3 to 5 lysine residues (Figure 4.2). Then we made five IL-1R1 
truncated mutants by deleting one or multiple regions from the C-terminus (Figure 
4.2 lower graphic). To test the ubiquitination status of these truncated mutants, 
HEK293T cells were transfected with wild-type IL-1R1 or these five truncations and 
HA-Ub and co-transfected with or without TRAF6. Thirty-six hours post-transfection, 
cells were harvested and cell lysates were subjected to immunoprecipitation for IL-
1R1. Ubiquitination status of immunoprecipitated IL-1R1 was revealed by probing 
with anti-HA antibody. The shortest truncated mutant IL-1R1 (1-356) which lacks the 
entire intracellular domain showed dramatic reduction in the ubiquitination of IL-1R1 
(Figure 4.3). However, the second shortest mutant IL-1R1 (1-390) showed a similar 
ubiquitination profile when compared to the IL-1R1, suggesting that the 
juxtamembrane domain (356-390) contains potential lysine residues for TRAF6-
mediated ubiquitination. Analysis of the whole cell lysates by anti-IL-1R1 antibody 
revealed that all the full-length levels of the wild-type IL-1R1 and the truncations 
were increased by TRAF6 except for the shortest IL-1R1 (1-356), suggesting that the 
regulation of TRAF6 on IL-1R1 requires the juxtamembrane domain of IL1R1. 
Additionally, IL-1R1 (1-356) was detected as a single band in contrast to the multiple 
bands of wild-type or other truncations, indicating the importance of the  
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IL-1R1 Home Sapiens 
        10         20         30         40         50         60  
MKVLLRLICF IALLISSLEA DKCKEREEKI ILVSSANEID VRPCPLNPNE HKGTITWYKD  
        70         80         90        100        110        120  
DSKTPVSTEQ ASRIHQHKEK LWFVPAKVED SGHYYCVVRN SSYCLRIKIS AKFVENEPNL  
       130        140        150        160        170        180  
CYNAQAIFKQ KLPVAGDGGL VCPYMEFFKN ENNELPKLQW YKDCKPLLLD NIHFSGVKDR  
       190        200        210        220        230        240  
LIVMNVAEKH RGNYTCHASY TYLGKQYPIT RVIEFITLEE NKPTRPVIVS PANETMEVDL  
       250        260        270        280        290        300  
GSQIQLICNV TGQLSDIAYW KWNGSVIDED DPVLGEDYYS VENPANKRRS TLITVLNISE  
       310        320        330        340        350        360  
IESRFYKHPF TCFAKNTHGI DAAYIQLIYP VTNFQKHMIG ICVTLTVIIV CSVFIYKIFK  
       370        380        390        400        410        420  
IDIVLWYRDS CYDFLPIKAS DGKTYDAYIL YPKTVGEGST SDCDIFVFKV LPEVLEKQCG  
       430        440        450        460        470        480  
YKLFIYGRDD YVGEDIVEVI NENVKKSRRL IIILVRETSG FSWLGGSSEE QIAMYNALVQ  
       490        500        510        520        530        540  
DGIKVVLLEL EKIQDYEKMP ESIKFIKQKH GAIRWSGDFT QGPQSAKTRF WKNVRYHMPV  
       550        560  
QRRSPSSKHQ LLSPATKEKL QREAHVPLG  
 
 
Figure 4.2 Amino acid sequence of human IL-1R1 and five IL-1R1 truncations. 21 
lysine residues of the intracellular domain of IL-1R1 are labelled as blue letters. 
Transmembrane domain is marked with red letters. The intracellular domain of IL-
1R1 is divided into five regions and these regions are highlighted by different colours. 
Lower schematic shows the wild-type IL-1R1 and the five truncated mutants which 
have one or several regions deleted from the C-terminus. 
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Figure 4.3 Juxtamembrane domain of IL-1R1 contains potential ubiquitination sites. 
HEK293T cells were transiently transfected with wild-type IL-1R1 or the other five IL-
1R1 truncated mutants and HA-Ub and co-transfected with or without TRAF6 as 
indicated. Thirty-six hours post transfection cells were harvested under stringent SDS 
denaturing condition and then subjected to immunoprecipitation for IL-1R1 and 
Western blot for HA-Ub. High molecular smears were detected with anti-HA epitope 
antibody revealing the ubiquitination status of IL-1R1. Precipitated IL-1R1 was 
detected by anti-IL-1R1 N-terminus antibody. Western blot of whole cell lysates 
confirms expressions of all transfected proteins. Experiment was repeated at least 
three times showing the similar results. 
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juxtamembrane domain for its post-translational modification, including perhaps its 
ubiquitination. 
4.1.3 Identify IL-1R1 ubiquitination sites by mutagenesis of single or double 
lysine residues. 
To map the sites for IL-1R1 ubiquitination, we mutated 15 lysine residues of IL-1R1 C-
terminus domain respectively by making single or double lysine mutants, including 
the four lysine residues in the juxtamembrane domain and other potential lysine 
residues identified from the peptide array. Then we tested these mutants in the in 
vivo ubiquitination assay. HEK293T cells were transfected with wild-type IL-1R1 or IL-
1R1 lysine mutants and co-transfected with HA-Ubiquitin alone or in combination 
with TRAF6. Thirty-six hours after transfection, cells were harvested under SDS 
denaturing condition and cell lysates were subjected to immunoprecipitation for IL-
1R1. Ubiquitination status of immunoprecipitated IL-1R1 was revealed by probing 
with anti-HA antibody. Mutagenesis of any of the fifteen lysine residues alone did 
not cause any deficiency in TRAF6-induced ubiquitination of IL-1R1 (Figure 4.4), 
indicating the possibility that multiple lysine sites may be involved in IL-1R1 
ubiquitination. Moreover, by over-expressing the wild-type IL-1R1 along with all the 
lysine mutants, we detected deficiencies in the IL-1R1 CTD level for some lysine 
mutants including IL-1R1 K378/383R, K445/446R, K527/532R and K548R (Figure 4.5), 
which supports our speculation that ubiquitination of IL-1R1 may occur on multiple 
lysine residues and ubiquitination of these lysine residues is important for the 
production or stability of IL-1R1 CTD. 
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Figure 4.4 Single or double lysine mutation of IL-1R1 did not cause difference in IL-
1R1 ubiquitination. HEK293T cells were transiently transfected with wild-type IL-1R1 
or IL-1R1 lysine mutants and co-transfected with HA-Ubiquitin or HA-Ubiquitin and 
TRAF6 as indicated. Thirty-six hours post transfection cells were harvested under 
stringent SDS denaturing condition and then subjected to immunoprecipitation for 
IL-1R1 and Western blot for HA-Ub. High molecular smears were detected with anti-
HA epitope antibody revealing the ubiquitination status of IL-1R1. Precipitated IL-1R1 
was detected by anti-IL-1R1 antibody. Western blot of whole cell lysates confirms 
expressions of all transfected proteins. Experiment was repeated at least three times 
showing the similar results. 
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Figure 4.5 Mutagenesis of certain lysine residues caused deficiencies in the IL-1R1 
CTD levels. HEK293T cells were transiently transfected with wild-type IL-1R1 or IL-
1R1 lysine mutants. Thirty-six hours post transfection cells were harvested and the 
cell lysates were subjected to Western blot with anti-IL-1R1 C-terminus antibody. 
Full-length IL-1R1 and IL-1R1 CTD and ICD were detected and measured by 
densitometry. CTD levels of wild-type IL-1R1 and IL-1R1 lysine mutants were 
normalised to their full-length protein levels respectively and then were shown as 
relative level of the wild-type IL-1R1 CTD. Experiment was repeated at least three 
times showing the similar results. 
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4.1.4 Mutagenesis of all four lysine residues in the juxtamembrane domain 
caused severe alteration to the IL-1R1 protein. 
Having shown that the juxtamembrane domain of IL-1R1 may contain potential 
ubiquitination sites and ubiquitination of IL-1R1 may occur on multiple lysine 
residues, we mutated all four lysine residues in the juxtamembrane domain of IL-1R1. 
Then the IL-1R1 Quadra-lysine mutant was transfected in HEK293T cells as well as 
the wild-type IL-1R1 and the cell lysates were analysed by Western blot with anti-IL-
1R1 C-terminus and N-terminus antibodies. Mutagenesis of all four lysine residues in 
the juxtamembrane domain appeared to cause severe alteration to the IL-1R1 
protein and no protein was detected with an anti-IL-1R1 C-terminus antibody (Figure 
4.6). When probing with an anti-IL-1R1 N-terminus antibody, no IL-1R1 full-length 
but only an truncated N-terminus fragment was detected suggesting that 
mutagenesis of all four lysine residues in the juxtamembrane domain causes severe 
change to IL-1R1 protein and this mutant cannot be used for further experiment.  
4.1.5 Mutating IL-1R1 lysine 360/378/383 resulted in deficiency of CTD 
ubiquitination and reduction of the CTD level. 
Because mutagenesis of all four lysine residues in the juxtamembrane domain 
caused severe alteration and resulted in a non-functional mutant, we decided to 
take one step back and mutate only three lysine residues in the juxtamembrane 
domain. So we made three IL-1R1 lysine mutants with the first three (K356/360/378), 
last three (K360/378/383) or the middle two (K360/378) lysine residues of the 
juxtamembrane domain mutated. These IL-1R1 lysine mutants were then transfected  
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Figure 4.6 Mutagenesis of all four lysine residues in the juxtamembrane domain 
caused severe alteration to the IL-1R1 protein and resulted in a non-functional 
mutant.HEK293T cells were transiently transfected with wild-type IL-1R1 or IL-1R1 
K357/360/378/383R mutant. Twenty-four hours post transfection selected samples 
were treated with 50nM Compound E for 12 hours. Then all cells were harvested and 
the cell lysates were subjected to Western blot with anti-IL-1R1 N-terminus and anti-
IL-1R1 C-terminus antibodies. Experiment was repeated two times showing the 
similar results. 
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Figure 4.7 Mutating IL-1R1 lysine 360/378/383 resulted in deficiency of CTD 
ubiquitination and reduction of the CTD level. HEK293T cells were transiently 
transfected with wild-type IL-1R1 or IL-1R1 double/triple lysine mutants and co-
transfected with HA-Ubiquitin or HA-Ubiquitin and TRAF6. Thirty-six hours post 
transfection cells were harvested under stringent SDS denaturing condition and then 
subjected to immunoprecipitation for IL-1R1 and Western blot for HA-Ub. 
Ubiquitinated IL-1R1 full-length or CTD were detected with anti-HA antibody. 
Precipitated IL-1R1 was detected by anti-IL-1R1 antibody. Western blot of whole cell 
lysates confirms expressions of all transfected proteins. Experiment was repeated at 
least three times showing the similar results. 
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in HEK293T cells and co-transfected with HA-ubiquitin or HA-ubiquitin and TRAF6. 
Thirty-six hours post transfection cells were harvested under stringent SDS 
denaturing condition and then subjected to immunoprecipitation for IL-1R1 and 
Western blot for HA-Ub. TRAF6 induced poly-ubiquitination of the wild-type IL-1R1 
as well as the lysine mutants which were detected as similar high-molecular-weight 
smears (Figure 4.7). However, TRAF6-induced low-molecular-weight double bands 
(Figure 4.7 arrows) which is considered to be ubiquitinated IL-1R1 CTD, was not 
detected in cell lyasates expressing the IL-1R1 K360/378/383R mutant, suggesting 
these three lysine residues could be the ubiquitination sites for IL-1R1 CTD 
ubiquitination. Furthermore, when the whole cell lysates were analysed by Western 
blot for IL-1R1, IL-1R1 K360/378/383R mutant showed an obvious reduction in 
detectable levels of IL-1R1 CTD when compared to CTD levels of all other IL-1R1 
constructs (Figure 4.7 lower panel). However, full-length level of IL-1R1 
K360/378/383R mutant was similar to the full-length level of other IL-1R1 constructs, 
which is still increased by TRAF6. Notably, immunoprecipitated wild-type full-length 
IL-1R1 was detected as double bands both of which were enhanced by TRAF6, 
whereas the upper band of IL-1R1 K360/378/383R was not altered by TRAF6 (Figure 
4.7 asterisk), indicating the deficiency of the mutant in TRAF6-induced modification. 
Interestingly, similar deficiency has also been detected with IL-1R1 K527/532R 
mutant (Figure 4.4 second panel). 
4.1.6 Mutating IL-1R1 lysine 360/378/383/527/532 resulted in further 
reduction in the CTD level and deficiency of CTD ubiquitination. 
As mentioned above, the observed reduction in generation of the IL-1R1 CTD and 
reduced detection of the highest molecular form of the full-length IL-1R1 when  
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Figure 4.8 Mutating IL-1R1 lysine 360/378/383/527/532 resulted in further 
reduction in the CTD level and deficiency of CTD ubiquitination. HEK293T cells were 
transiently transfected with wild-type IL-1R1 or IL-1R1 double/triple/penta lysine 
mutants and co-transfected with HA-Ubiquitin or HA-Ubiquitin and TRAF6. Thirty-six 
hours post transfection cells were harvested under stringent SDS denaturing 
condition and then subjected to immunoprecipitation for IL-1R1 and Western blot 
for HA-Ub. Ubiquitinated IL-1R1 full-length or CTD were detected with anti-HA 
antibody. Precipitated IL-1R1 was detected by anti-IL-1R1 antibody. Western blot of 
whole cell lysates confirms expressions of all transfected proteins. Experiment was 
repeated at least two times showing the similar results. 
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lysine 360/378/383 residues were mutated have also been seen with another double 
lysine mutant, IL-1R1 K527/532R. Although these two groups of lysine residues are 
quite separated in the protein sequence, giving that the three-dimensional structure 
of IL-1R1 C-terminus is still unknown, these two domains could have close spatial 
localization and involve in the same TRAF6-mediated ubiquitination. So we further 
mutated lysine residues K527 and K532 and tested the IL-1R1 
K360/378/383/527/532R (IL-1R1 K5R) mutant in the in vivo ubiquitination assay. The 
IL-1R1 K5R mutant was transfected along with other IL-1R1 double/triple lysine 
mutants in HEK293T cells and co-transfected with HA-ubiquitin alone or HA-ubiquitin 
and TRAF6. Thirty-six hours post transfection cells were harvested under stringent 
SDS denaturing condition and then subjected to immunoprecipitation for IL-1R1 and 
Western blot for HA-Ub. High-molecular-weight ubiquitination was still similar for 
the wild-type IL-1R1 and the lysine mutants. However, in addition to the diminished 
low molecular weight ubiquitinated double bands observed with IL-1R1 
K360/378/383R mutant, another ubiquitinated IL-1R1 CTD band was abolished in 
cells expressing the IL-1R1 K5R mutant (Figure 4.8 arrows). Furthermore, the IL-1R1 
CTD and ICD of the IL-1R1 K5R mutant could hardly be observed even with over-
expression of TRAF6 (Figure 4.8 lower panel), suggesting TRAF6-targeted C-terminus 
lysine residues are further mutated. Notably, the highest molecular weight form of 
the full-length IL-1R1 was dramatically diminished in cells expressing the IL-1R1 K5R 
mutant (Figure 4.8 asterisk), suggesting its deficiency in TRAF6-induced regulation 
which could have significant effect on the functions of the receptor. 
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4.1.7 IL-1R1 CTD is poly-ubiquitinated by TRAF6. 
To verify that the IL-1R1 CTD is ubiquitinated by TRAF6, we performed an in vivo 
ubiquitination assay on an IL1-R1 extracellular domain truncated mutant (IL-1R1 CTF) 
which contains a small part of the extracellular domain, the transmembrane domain 
and intracellular domain. Also to find out the type of ubiquitination occuring, we 
replace wild-type ubiquitin with a ubiquitin lysine-all-mutated mutant (HA-UbK0) 
which has all seven lysine residues mutated to arginine and can only form 
monoubiquitination but not polyubiquitination of the substrates. HEK293T cells were 
transfected with IL-1R1 or the IL-1R1 K5R mutant and co-transfected with HA-
ubiquitin or HA-UbK0 and co-transfected with TRAF6. Thirty-six hours post 
transfection cells were harvested under stringent SDS denaturing condition and then 
subjected to immunoprecipitation for IL-1R1 and Western blot for HA-Ub. With the 
over-expression of HA-UbK0, TRAF6 did not induce ubiquitination of IL-1R1 (Figure 
4.9), suggesting that TRAF6 only mediates polyubiquitination of IL-1R1. Reprobing 
the blot with an anti-polyubiquitination antibody confirmed that TRAF6 induced 
polyubiquitination of IL-1R1 only in the presence of wild-type ubiquitin. 
Immunoprecipitated IL-1R1 CTF showed increased smear and ladders with over-
expression of TRAF6 (Figure 4.9 hash), suggesting that the C-terminus region of IL-
1R1 is ubiquitinated by TRAF6. Interestingly, co-expression of IL-1R1 and UbK0 
mutant increased the levels of IL-1R1 CTD and especially the ICD, indicating that 
polyubiquitination of these fragments may be required for their degradation.  
 
142 
 
 
Figure 4.9 IL-1R1 CTD is poly-ubiquitinated by TRAF6. HEK293T cells were 
transiently transfected with wild-type IL-1R1 or IL-1R1 K5R and co-transfected with 
HA-ubiquitin or HA-UbK0 and co-transfected with TRAF6. Thirty-six hours post 
transfection cells were harvested under stringent SDS denaturing condition and then 
subjected to immunoprecipitation for IL-1R1 and Western blot for HA-Ub. 
Ubiquitinated IL-1R1 full-length or CTD were detected with anti-HA antibody. 
Precipitated IL-1R1 was detected by anti-IL-1R1 antibody. Western blot of whole cell 
lysates confirms expressions of all transfected proteins. Experiment was repeated at 
least two times showing the similar results. 
143 
 
 
4.1.8 Mutagenesis of IL-1R1 C-terminus lysine residues leads to deficiency of 
IL-1R1 cell surface localization.  
Having shown that mutagenesis of IL-1R1 C-terminus residues results in a reduction 
in CTD level and deficiency in C-terminus ubiquitination, next we tried to investigate 
the effect of mutagenesis on the membrane localization of IL-1R1. HEK293T cells 
were transfected with empty vector, wild-type IL-1R1, IL-1R1 K5R or IL-1R1 
K360/378/383R (K3R) mutants. Forty-eight hours after transfection, cells were 
detached under non-permeabilization conditions and incubated with primary anti-IL-
1R1 antibody for 45 minutes and secondary green fluorescent antibody for 30 
minutes. After washings, levels of membrane IL-1R1 were measured by flow 
cytometry. HEK293T cells over-expressing IL-1R1 showed that more than 50% of the 
cells exhibited surface localization of IL-1R1, which was reduced by half when IL-1R1 
K5R was over-expressed (Figure 4.10). Over-expression of IL-1R1 K3R only caused 
subtle reduction in cell surface levels of IL-1R1 when compared to that of wild-type 
IL-1R1 expressing cells. Collectively, this data suggests that mutagenesis of TRAF6-
targeted IL-1R1 C-terminus lysine residues results in decreased IL-1R1 cell surface 
localization. 
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Figure 4.10 Mutagenesis of IL-1R1 C-terminus lysine residues leads to deficiency of IL-1R1 
cell surface localization. HEK293T cells were transfected with empty vector, wild-type IL-1R1, 
IL-1R1 K5R, IL-1R1 K360/378/383R (K3R) mutants. 48 hours after transfection, cells were 
detached under nonpermeabilized condition and incubated with primary anti-IL-1R1 
antibody for 45 minutes and secondary green fluorescent antibody for 30 minutes. After 
washings, levels of membrane IL-1R1 were measured by flow cytometry and shown as 
density plot and histogram graphs. Bars represent mean levels of surface IL-1R1 +SEM (n=3). 
Western blot of the cell lysates confirmed similar expression of all transfected constructs. 
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4.1.9 Mutagenesis of IL-1R1 C-terminus lysine residues causes attenuated NF-
κB activation.  
Having shown that IL-1R1 is ubiquitinated by TRAF6, we next examined the IL-1R1 
downstream signalling events, namely NF-κB activation and the effects that 
mutagenesis of potential ubiquitination sites may have on subsequent signalling 
events. Firstly we optimized the NF-κB luciferase gene reporter assays to avoid any 
artificial events due to overexpression of IL-1R1. HEK293T cells were transfected with 
a NF-κB-dependent luciferase reporter construct and co-transfected with empty 
vector or increasing amount of wild-type IL-1R1 or IL-1R1 K5R. Forty-eight hours 
after transfection, cells were harvested and luciferase activities of the cell lysates 
were measured. Over-expression of IL-1R1 induced a dose-dependent increase in NF-
κB activation. In contrast, lysates from cells expressing IL-1R1 K5R mutant had 
reduced NF-κB activation (Figure 4.11 A). Notably, the amount of over-expressed 
wild-type IL-1R1 was linearly corresponding to the activation level of NF-κB whereas 
over-expression of IL-1R1 K5R was saturated after more than 0.6μg DNA was 
transfected. Therefore, we decided to transfect 0.6μg DNA per well for the future 
experiments. 
To further examine IL-1R1 and IL-1R1 K5R mediated NF-κB activation, we tested IL-
1β-induced NF-κB activation in cells expressing wild-type IL-1R1 or IL-1R1 K5R 
expression constructs. HEK293T cells were transfected with a NF-κB-dependent 
luciferase reporter construct and co-transfected with empty vector, wild-type IL-1R1 
or IL-1R1 K5R expression vector. Twenty-four hours after transfection, cells were 
serum starved overnight in serum-free medium. Then one set of the cells were   
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Figure 4.11 Mutagenesis of IL-1R1 C-terminus lysine residues causes attenuated NF-κB 
activation. A. HEK293T cells were transfected with a NF-κB-dependent luciferase reporter 
construct and co-transfected with empty vector or increasing amount of wild-type IL-1R1 or 
IL-1R1 K5R. Forty-eight hours after transfection, cells were harvested and luciferase activity 
of the cell lysates were measured by luminometer. Cell lysates were also analysed by 
Western blot to confirm the expression of all transfected constructs. B. HEK293T cells were 
transfected with a NF-κB-dependent luciferase reporter construct and co-transfected with 
empty vector, wild-type IL-1R1 or IL-1R1 K5R as duplication. 24 hours after transfection, cells 
were serum starved overnight and then one set of the cells were treated with 10nM IL-1β 
for six hours. Cells were then harvested and luciferase activity was measured.  
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treated with IL-1β for six hours and the other set were left untreated. After 
treatment, cells were harvested and luciferase activities were measured. Consistent 
with Figure 4.11A, over-expression of IL-1R1 induced activation of NF-κB while 
expression of IL-1R1 K5R mutant induced lower NF-κB activation (Figure 4.11 B). IL-
1β stimulation lead to a robust activation of NF-κB in all cell cultures, however, cells 
expressing IL-1R1 K5R mutant showed a dramatic reduction in the NF-κB activation 
when compared to cells expressing wild-type IL-1R1. However, IL-1R1 K5R induced 
higher NF-κB activation than the empty vector, suggesting that this mutant is still 
functional but to a lesser extent. Collectively, mutagenesis of TRAF6-regulated IL-1R1 
lysine residues causes attenuated NF-κB activation. 
4.1.10 Mutagenesis of IL-1R1 C-terminus lysine residues results in deficiency in 
IL-1R1 CTD production rather than rapid CTD degradation.  
IL-1R1 full-length and CTD have been shown to undergo lysosomal degradation after 
its internalisation (Brissoni et al., 2006). IL-1R1 is targeted through its ubiquitination 
modification by a CUE domain containing protein Tollip for lysosomal degradation 
(Brissoni et al., 2006). So any change in IL-1R1 ubiquitination could cause alteration 
in its degradation.   To interpret the decreased CTD level caused by mutating of the 
IL-1R1 C-terminus lysine residues, we proposed two putative mechanisms for TRAF6 
mediated IL-1R1 regulation: 1) TRAF6-regulated lysine residues of IL-1R1 are critical 
for its membrane localization and its internalisation after which the extracellular 
domain shedding and γ-secretase cleavage occur (results shown by other group 
member). Thus deficiency in IL-1R1 membrane localization and internalization 
precludes IL-1R1 ectodomain shedding and production of IL-1R1 CTD. 2) TRAF6  
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Figure 4.12 Mutagenesis of IL-1R1 C-terminus lysine residues results in deficiency in IL-1R1 
CTD production rather than rapid CTD degradation. (A) HEK293T cells were transfected with 
IL-1R1 or IL-1R1 K5R mutant alone or co-transfected with TRAF6. Thirty-six hours after 
transfection, cell culture medium was collected and was subjected to Western blot with an 
anti-IL-1R1 N-terminus antibody. Cells were harvested under non-denaturing conditions and 
cell lysates were subjected to immunoprecipitation for IL-1R1 and then Western blot for 
TRAF6. Whole cell lysates were also analyzed by Western blot to confirm expression of all 
transfected plasmids (B) HEK293T cells were transfected with empty vector, wild-type IL-1R1 
or IL-1R1 K5R as duplication. Twenty-four hours after transfection, one set of cells were 
treated with 100uM concanamycin for twelve hours in serum-free medium. Then cells were 
harvested and analysed for IL-1R1 by Western blot. Β-actin levels were also measured to 
confirm equal loading. Experiment was repeated three time showing similar results. 
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stabilizes IL-1R1 CTD by inducing a different type of ubiquitination which is not 
targeted by lysosomal degradation. When the TRAF6 regulated sites within IL-1R1 
CTD are mutated, IL-1R1 CTD could only be modified and targeted by the 
degradative pathway which caused rapid degradation of IL-1R1 CTD. 
To test our hypothesis, firstly we investigated the TRAF6-induced ectodomain 
shedding of IL-1R1 and IL-1R1 K5R mutant. HEK293T cells were transfected with IL-
1R1 or IL-1R1 K5R mutant alone or co-transfected with TRAF6. Thirty-six hours after 
transfection, cell culture medium was collected and was subjected to Western blot 
probing by an anti-IL-1R1 N-terminus antibody. Over-expression of TRAF6 induced 
dramatic increase in the detection of soluble IL-1R1 ectodomain (Figure 4.12 A). In 
contrast, TRAF6 did not induce any detectable ectodomain shedding in cells 
expressing IL-1R1 K5R mutant, suggesting that mutagenesis of IL-1R1 C-terminus 
lysine residues results in deficiency in IL-1R1 ectodomain shedding, thus prevents the 
IL-1R1 CTD production. Cells were also harvested under non-denaturing conditions 
and cell lysates were subjected to immunoprecipitation for IL-1R1 and Western blot 
for TRAF6. Co-immunoprecipitation analysis revealed that interaction between IL-
1R1 and TRAF6 is not affected by mutagenesis of IL-1R1 C-terminus lysine residues. 
To test the second hypothesis, we applied a lysosomal inhibitor concanamycin to 
check if inhibition of lysosomal degradation could rescue the CTD level of IL-1R1 K5R 
mutant. HEK293T cells were transfected with empty vector, wild-type IL-1R1 or IL-
1R1 K5R as duplication. Twenty-four hours after transfection, one set of cells were 
treated with concanamycin (100uM) for twelve hours in serum-free medium. Cells 
were then harvested and analysed for IL-1R1 by Western blot. Full-length and CTD 
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levels of wild-type IL-1R1 were increased with concanamycin treatment, confirming 
that the full-length IL-1R1 and CTD are targeted by lysosomal degradation (Figure 
4.12). However, the full-length level of IL-1R1 K5R mutant was only slightly increased 
and the CTD level remained the same with concanamycin treatment, suggesting that 
mutagenesis of IL-1R1 lysine residues does not cause rapid CTD degradation. 
Collectively, mutagenesis of IL-1R1 C-terminus lysine residues results in deficiency of 
IL-1R1 ectodomain shedding and precludes the production of IL-1R1 CTD. 
4.1.11 TRAF6-mediated TLR4 ubiquitination and TRAF2-mediated TNFR1 
ubiquitination. 
TRAF6 is also essential for TLR4 signalling transduction and TLR4 signalling complex 
shares similar scheme as that of IL-1R1 (Verstak et al., 2009). However TNFR1 
signalling complex recruits another TRAF protein, TRAF2, that is reported to have an 
inhibitory effect on TNFR1 signals (Nguyen et al., 1999). To expand our 
understanding about TRAF family protein mediated regulation of other receptors, we 
investigated if TLR4 and TNFR1 are regulated by TRAF6 and TRAF2 respectively. 
Firstly, HEK293T cells were transfected with TLR4 and co-transfected with HA-Ub and 
TRAF6. Thirty-six hours post transfection cells were harvested under stringent SDS 
denaturing condition and then subjected to immunoprecipitation for TLR4 and 
Western blot for HA-Ub. Ubiquitination of TLR4 was clearly detected as a high-
molecular-weight smear (Figure 4.13). Additionally, over-expression of TRAF6 
appeared to increase the levels of TLR4 full-length and CTD. Our result suggests that 
TLR4 may undergo TRAF6-mediated regulation, similar to IL-1R1. 
Secondly, TRAF2 and TRAF6 mediated regulation of TNFR1 was also tested. HEK293T 
cells were transfected with TNFR1 and co-transfected with HA-Ub and TRAF2,   
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Figure 4.13 TRAF6-mediated ubiquitination of TLR4. HEK293T cells were transiently 
transfected with with TLR4 and co-transfected with HA-Ub and TRAF6. Thirty-six 
hours post transfection cells were harvested under stringent SDS denaturing 
condition and then subjected to immunoprecipitation for TLR4 and Western blot for 
HA-Ub. Ubiquitinated TLR4 was detected with anti-HA antibody. Precipitated TLR4 
was detected by anti-TLR4 antibody. Western blot of whole cell lysates confirms 
expressions of all transfected proteins.  
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Figure 4.14 TRAF2 and TRAF6 mediated ubiquitination of TNFR1. HEK293T cells 
were transiently transfected with TNFR1 and co-transfected with HA-Ub and TRAF2, 
TRAF2DN or TRAF6. Thirty-six hours post transfection cells were harvested under 
stringent SDS denaturing condition and then subjected to immunoprecipitation for 
TNFR1 and Western blot for HA-Ub.  Ubiquitination of TNFR1 was detected with anti-
HA antibody. Precipitated TNFR1 was detected by anti-TNFR1 antibody. Western blot 
of whole cell lysates confirms expressions of all transfected proteins.  
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TRAF2DN or TRAF6. Thirty-six hours post transfection cells were harvested under 
stringent SDS denaturing condition and then subjected to immunoprecipitation for 
TNFR1 and Western blot for HA-Ub. TRAF2 and TRAF6 did induce a certain level of 
TNFR1 ubiquitination observed as high-molecular-weight smears (Figure 4.14). 
However, the pattern of TNFR1 ubiquitination was quite different as two strong 
single bands which are ~10 kD above TNFR1 full-length and CTD respectively were 
observed and these two bands could be considered as the monoubiquitination form 
of the TNFR1 full-length and CTD. Monoubiquitination of TNFR1 was also proposed 
in other studies and was linked to the degradation after its endocytosis through 
lysosomal pathway (Chin and Horwitz, 2005, 2006). Moreover, over-expression of 
TRAF2 and TRAF6 appeared to decrease the levels of the TNFR1 full-length and CTD 
and this effect was dependent on TRAF2 E3 ligase activity. Collectively, TRAF2-
mediated ubiquitination may have a total diverse profile comparing to TRAF6-
mediated regulation of IL-1R1 and TLR4. 
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Discussion: 
Deficiency of TRAF6 causes severe osteopetrosis, which was observed with defective 
IL-1, CD40and LPS signalling (Lomaga et al., 1999b; Naito et al., 1999). TRAF6 was 
reported to be involved in osteoclast maturation and activation through its 
association with RANK signalling which requires its E3 ligase activity (Armstrong et al., 
2002; Lamothe et al., 2007b). However, signalling via IL-1R1 was shown to rescue the 
osteoclast activation defects caused by the disruption of TRAF6 and RANK interaction 
(Armstrong et al., 2002) suggesting that IL-1 signalling may also involve in this 
function. Additionally, TRAF6 is also required for TNF-related apoptosis-inducing 
ligand (TRAIL) induced osteoclast differentiation (Yen et al., 2012), underlining the 
importance of TRAF6 in regulating the signalling of TNF superfamily molecules. 
Deficiency of TRAF6 has also been shown to result in defects in immune and 
inflammatory responses which are linked to the defective IL-1 and CD40 signalling 
(Naito et al., 1999; Kobayashi et al., 2009).  
TRAF6 is intensively studied as the adaptor protein of IL-1R1/TLR4 signalling complex 
which facilitates K63-linked polyubiquitination of target protein to trigger 
recruitment and activation of downstream effector proteins. However, emerging 
evidences reveal TRAF6 as a regulator of a variety of receptors. For example, TRAF6 
mediates polyubiquitination of TrkA which is required for the internalization of TrkA 
(Geetha et al., 2005). TRAF6-induced K63-linked ubiquitination of Akt is essential for 
its membrane recruitment and phosphorylation upon ligand stimulation (Yang et al., 
2009). Our group previously reported IL-1R1 as a substrate of γ-secretase dependent 
regulated intramembrane proteolysis and TRAF6 was shown to positively regulate 
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the cleavage of IL-1R1 (Twomey et al., 2009). Additionally, TRAF6 was shown to 
induce ubiquitination of IL-1R1, but the function of this modification is to be 
elucidated. 
To investigate the function of TRAF6-mediated ubiquitination of IL-1R1, we 
attempted to map the sites of IL-1R1 ubiquitination. Ubiquitination of Notch1 
receptor was mapped to a single juxtamembrane lysine residue which regulates the 
γ-secretase cleavage of Notch1 (Gupta-Rossi et al., 2004b). Similarly, we narrowed 
the potential ubiquitination sites of IL-1R1 into the juxtamembrane domain which 
contains four lysine residues (Figure 4.3). Mutagenesis of single or double lysine 
residues did not show any dramatic difference in IL-1R1 ubiquitination comparing to 
the wild-type IL-1R1. However, mutation of lysine 360/378/383 residues resulted in 
deficient IL-1R1 CTD ubiquitination and reduced CTD level (Figure 4.7). The same 
deficiency was also observed with mutation of two other lysine residues, K527 and 
K532. These two lysine residues were further mutated and the IL-1R1 K5R mutant 
showed further reduction in CTD ubiquitination and CTD level (Figure 4.8). 
Additionally we showed that TRAF6 induces polyubiquitination of IL-1R1 and C-
terminus fragment is the substrate of TRAF6-mediated ubiquitination (Figure 4.9). 
Similarly, NEMO was also reported to be regulated by TRAF6 through K63-linked 
polyubiquitination at five different lysine residues, which leads to the activation of 
IKK and NF-κB (Sebban-Benin et al., 2007b), indicating the possibility of a common 
pattern in TRAF6-mediated regulation. Additionally, three mutated lysine residues 
(383,527,532) are localized in the IL-1R1 Toll/IL-1 receptor (TIR) homology domain 
which mediates receptor interaction with their signal-transduction components. 
However, these three lysine residues are not revealed in previous studies as 
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functional motifs of the IL-1R1 TIR domain (Slack et al., 2000). By alignment of the 
amino acid sequences of five IL-1R family proteins including IL-1R1, IL-1RAcP, IL-18R, 
ST2 and IL-1Rrp2, we found that K383 and K532 are highly conserved in the TIR 
domain of these receptors (Figure 4.15), suggesting that we may have identified 
novel functional motifs of IL-1R TIR domain. TRAF6-mediated ubiquitination sites of 
IL-1R1 intracellular domain could also be narrowed down to these two lysine 
residues. Studies have shown that IL-1R1 is modified by N-linked glycosylation, which 
is essential for the optimal IL-1 binding and activation (Mancilla et al., 1992). The 
diminished higher molecular weight form of full-length IL-1R1 observed in IL-1R1 K5R 
and K3R mutant (Figure 4.8) is probably the glycosylated form of IL-1R1. Therefore, 
mutagenesis of these lysine residues may not only alter IL-1R1 ubiquitination 
modification, but also prevent its glycosylation which is critical for the initiation of IL-
1 signal transduction. However, the nature of the higher molecular weight form of IL-
1R1 requires to be further confirmed. 
As mentioned above, TRAF6-mediated polyubiquitination of TrkA is required for its 
trafficking (Geetha et al., 2005). Similarly we showed that mutagenesis of TRAF6-
targeted sites of IL-1R1 caused defects in IL-1R1 membrane distribution (Figure 4.10). 
Furthermore, we showed that IL-1R1 K5R mutant is deficient in IL-1β-induced NF-κB 
activation (Figure 4.11). IL-1R1 was shown to undergo lysosomal degradation after 
its endocytosis (Brissoni et al., 2006). By inhibiting the lysosomal degradation, we 
concluded that mutagenesis of TRAF6-regulated sites of IL-1R1 causes deficiency in 
IL-1R1 ectodomain shedding and diminishes IL-1R1 CTD production, rather than 
causing rapid IL-1R1 CTD degradation (Figure 4.12). Unfortunately, mutagenesis of 
the five lysine residues in the IL-1R1 C-terminus region did not eliminate the 
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ubiquitination of full-length IL-1R1. Additional lysine residues in the intracellular 
domain or even in the extracellular domain may be targeted by TRAF6-mediated 
ubiquitination. Collectively, TRAF6-mediated polyubiquitination of IL-1R1 
intracellular domain is required for its membrane distribution and responsiveness to 
IL-1β stimulation. Mutating of TRAF6-targeted lysine residues results in defective IL-
1R1 ectodomain shedding and dramatic reduction in the IL-1R1 CTD production. 
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Figure 4.15 Human IL-1R family protein TIR domain alignments. Alignment of amino 
acid sequences of the TIR domain from human IL-1R1, IL-1RAcP, IL-18R, ST2 and IL-
1Rrp2. The highly conserved lysine residues are underlined. 
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Chapter 5: 
GENERAL DISCUSSION 
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5.1 Summary and Conclusions: 
Neurodegenerative disorders are characterized by an abnormal accumulation of 
neurotoxic macromolecules inside cells and in the extracellular space. In specific 
regions of the brain, proteins or their fragments undergo alteration in conformation 
and/or function and form aggregates, such as Aβ plaques and neurofibrillary tangles 
in AD, Lewy bodies in Parkinson’s disease and Inclusion bodies in Amyotrophic lateral 
sclerosis (ALS) and Huntington’s disease (Martin, 1999; Bates, 2003; Dupuis et al., 
2006; Wakabayashi et al., 2007). Posttranslational modifications of these neuronal 
proteins play a critical role in the development of neurodegenerative diseases. One 
hallmark of AD is the neurofibrillary tangles which consist of paired helical filaments 
and abnormal hyperphosphorylated microtubule associated protein tau (Iqbal et al., 
2009). While normal tau protein stabilizes microtubules and promotes their 
constitution, glycosylation of tau precedes its abnormal hyperphosphorylation which 
decreases its turnover and abets the self-assembly into tangles of paired helical or 
straight filaments, neutrophil threads and dystrophic plaque neuritis (Alonso Adel et 
al., 2004). The activity of one major phosphatase regulating tau phosphorylation, 
phosphatase-2A, is down-regulated whereas its inhibitors are over-expressed in the 
AD brains (Iqbal et al., 2009). Aβ was also shown to be phosphorylated by PKA which 
promotes Aβ aggregation (Kumar and Walter, 2011). Lipid peroxidation is an early 
event during the progression of AD and protein bound 4-hydroxy-2-nonenal (HNE) 
and acrolein have been found to be significantly elevated in AD brain (Lauderback et 
al., 2001; Lovell et al., 2001; McGrath et al., 2001). Protein-bound HNE alters 
conformation and function of proteins such as α-enolase, ATP synthase manganese 
superoxide dismutase, peroxiredoxin VI, dihydropyrimidine-related protein2 (DRP2), 
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α-tubulin and glutamine synthetase, thus involving in the course of AD including 
energy metabolism, mitochondrial dysfunction, cytoskeletal integrity, antioxidant 
defense, protein synthesis, stress response, neuronal communication and 
excitoxicity (Siems et al., 1996; Subramaniam et al., 1997; Perluigi et al., 2009; Reed 
et al., 2009; Hellberg et al., 2010). Parkinson’s disease pathology is characterized by 
the presence of Lewy bodies which include α-synuclein, ubiquitin, parkin and 
synphilin-1 (Wakabayashi et al., 2007). The major constituent of Lewy bodies is α-
synuclein. Several studies showed that the majority of α-synuclein within Lewy 
bodies is phosphorylated at multiple sites in the brains of Parkinson’s disease 
patients and phosphorylation modulates its aggregation and toxicity (Anderson et al., 
2006; Mbefo et al., 2010; Oueslati et al., 2010). α-synuclein also undergoes 
proteolysis and the N-terminus fragment has been shown to promote the 
fibrillization of the Lewy bodies (Murray et al., 2003; Li et al., 2005).  Ubiquitinated α-
synuclein has also been detected within the Lewy bodies and ubiquitination of α-
synuclein enhances its aggregation and inclusion formation (Lee et al., 2008; Rott et 
al., 2008; Szargel et al., 2009). Mutations in an important antioxidant, superoxide 
dismutase 1 (SOD1), contribute to the onset of ALS (Rosen, 1993). Activation of the 
SOD1 involves several posttranslational modification including copper and zinc 
binding and formation of intramolecular disulfide bonds (Furukawa and O'Halloran, 
2006). Mutant of SOD1 has been shown to exhibit increased affinity for copper and 
zinc-deficient SOD1 was shown to be superoxidative and therefore rapidly oxidize 
many intracellular components (Crow et al., 1997; Watanabe et al., 2007). 
Additionally, wild-type SOD1 was shown able to acquire toxic properties similar to 
familial ALS-linked mutant SOD1 by hyper-oxidation (Guareschi et al., 2012). 
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Huntington’s disease emerges as a consequence of a polyglutamine repeat 
expansion in the huntingtin gene (Ashley and Warren, 1995). The abnormal 
huntingtin protein undergoes proteolysis into fragments and these fragments are 
modified by ubiquitin. However, these fragments targeted by proteasome are not 
efficiently degraded, therefore leading to accumulation of aggregates forming 
neuronal inclusion bodies (Bates, 2003; Wang and Lashuel, 2012). 
A number of studies have reported that presenilins play an important role in synaptic 
function in the adult cerebral cortex (Ho and Shen, 2011). PS1 was found to associate 
with the postsynaptic N-methyl-D-aspartic acid receptor (NMDAR) and is thought to 
function at synapses by facilitating the proper synaptic delivery and localization of 
NMDARs (Saura et al., 2004). In vivo studies revealed essential roles of presenilins in 
synaptic plasticity, learning and memory and neuronal survival in the adult cerebral 
cortex. PS1 conditional knockout mice exhibited mild cognitive deficits in long-term 
spatial memory which appeared to be independent of the Notch signaling pathway 
(Yu et al., 2001). Conditional double knockout of PS1 and PS2 in the postnatal 
forebrain revealed severe deficits in hippocampal learning and memory as well as 
synaptic plasticity impairments (Saura et al., 2004). Inactivation of presenilins also 
resulted in delayed apoptosis and low percentage of apoptotic cell death (Wines-
Samuelson et al., 2010). An Ephrin receptor family member, EphA4, was identified as 
a substrate of γ-secretase and the EphA4 intracellular domain increases the number 
of dendritic spines (Inoue et al., 2009). Age-dependent in vivo accumulation of APP 
C-terminal fragments was observed at presynaptic terminals after inhibition of γ-
secretase activity by PS1 inactivation, indicating the existing role of APP signalling in 
neuronal functions (Saura et al., 2005). γ-secretase-mediated proteolysis of APP is 
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very similar to that of Notch. Elevated AICD levels have been reported in the AD 
brain (Ghosal et al., 2009). AICD was also reported to form complex with the nuclear 
adaptor protein Fe65 and the histone acetyltransferase Tip60 and translocate to the 
nucleus (Cao and Sudhof, 2001; Slomnicki and Lesniak, 2008). Transgenic mice 
overexpressing AICD and Fe65 showed abnormal activity of GSK3β which leads to 
hyperphosphorylation and aggregation of tau (Ryan and Pimplikar, 2005). 
Phosphorylation of the APP cytoplasmic domain by JNK3, the neuron-specific JNK 
protein, disrupts the interaction between AICD and Fe65 during neuron 
differentiation (Kimberly et al., 2005). Additionally, AICD expression was shown to 
induce neuron-specific apoptosis (Nakayama et al., 2008). AICD was also shown to 
regulate the expression of over 600 genes and some of them are related to cell 
death (Ohkawara et al., 2011). 
Intensive studies have focused on the role of presenilins as the catalytic core of γ-
secretase complex. Accordingly, efforts have been put on understanding the 
regulated intramembrane proteolysis of APP, the subsequent generation and 
deposits of Aβ and the selective inhibition of γ-secretase activity as potential 
treatment for AD patients (Jakob-Roetne and Jacobsen, 2009; Wolfe, 2009). 
However, γ-secretase-independent functions of presenilins have also been revealed, 
including their role in calcium signalling, cell adhesion, protein trafficking and 
apoptosis (Hass et al., 2008; Coen and Annaert, 2010). Non-proteolytic functions of 
presenilins are still expanding. Presenilins are recently reported to be necessary for 
the efficient lysosomal-autophagic degradation (Neely et al., 2011). More 
importantly, a number of familiar AD mutants of presenilin have been reported to 
alter the γ-secretase-independent functions of presenilins (Nelson et al., 2007; Lee et 
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al., 2010), which may provide a different insight into the pathogenesis of AD. 
Presenilin involves in the regulation of signal transduction via either cleavage of γ-
secretase substrates or interacting with signalling protein such as β-catenin (Xia et al., 
2001). Presenilin interacts with at least 60 different proteins, one among them is 
TRAF6 (McCarthy et al., 2009a). TRAF6 is an adaptor protein essential for the 
receptor complex of two γ-secretase substrates, IL-1R1 and p75NTR. However, by 
studying the interaction between TRAF6 and presenilin, we revealed that TRAF6 does 
not affect γ-secretase activity or apart from presenilin, does not appear to regulate 
any other component of γ-secretase complexes. We showed that TRAF6 stabilizes 
full-length presenilins by inducing K63-linked polyubiquitination. Furthermore we 
showed that regulation by TRAF6 may involve in the full-length function of presenilin 
as passive ER Ca2+ leak channels. 
IL-1 is a master cytokine of local and systemic inflammation and neutralization of IL-
1β results in a rapid and sustained reduction in disease severity. IL-1α precursor is 
constitutively present in the cells of healthy individuals whereas IL-1β is a product of 
a limited number of cells including blood monocytes, tissue macrophages and 
dendritic cells and activation of IL-1β precursor requires intracellular cleavage by 
caspase 1 (Agostini et al., 2004; Martinon et al., 2009). Caspase-1 existing in tissue 
macrophages and dendritic cells is inactive and requires a specialized group of 
intracellular proteins termed the “inflammasome” for its activation (Agostini et al., 
2004). However, caspase-1 is present in an active state in circulating human blood 
monocytes and highly metastatic human melanoma cells (Netea et al., 2009; 
Okamoto et al., 2010). Higher level of IL-1β was detected in blood monocytes from 
patients with autoinflammatory disease than the cells from healthy individuals 
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(Gattorno et al., 2008; Colina et al., 2010). An increase in the secretion of active IL-1β 
is observed in monocytes from patients with a gain-of-function mutation in a gene 
originally called cold-induced autoinflammatory syndrome-1 (Hoffman et al., 2001). 
This mutation results in a single amino acid change in an intracellular protein named 
nucleotide-binding domain and leucine-rich repeat-containing protein 3 (NLRP3), 
which associates with procaspase-1 and other intracellular proteins to form the 
“inflammasome” (Agostini et al., 2004). However, approximately one-half of the 
patients with classic symptoms and biochemical markers of Cryopyrin-associated 
periodic syndromes (CAPSs), familial Mediterranean fever and other 
autoinflammatory diseases do not have mutations. Caspase-1-independent 
activation of IL-1β has also been reported, for example, irritant-induced 
inflammation in muscle tissue, sartilage destruction in joints and urate crystal-
induced inflammation are IL-1β dependent but caspase-1 independent (Fantuzzi et 
al., 1997; Guma et al., 2009; Joosten et al., 2009). Moreover, one of the neutrophil 
proteases, proteinase-3, cleaves the inactive IL-1β close to caspase-1 cleavage site 
and releases active IL-1β (Fantuzzi et al., 1997; Joosten et al., 2009). In autoimmune 
responses, IL-1β has been shown to increase the expansion of naive and memory 
CD4 T cells and is required for red blood cell antibody productions (Ben-Sasson et al., 
2009). IL-1β also plays a pivotal role in the differentiation of T cells in to Th17 cells 
and mice deficient for IL-1R1 or IRAK1 do not develop Th17 cells (Matsuki et al., 2006; 
Chung et al., 2009; Gulen et al., 2010; Joosten, 2010). Neuroinflammation has been 
recognized as a fundamental response to not only acute injury, but also to chronic 
neurodegenerative disease as severity of neuroinflammatory response has been 
observed alongside the course of AD (Sheng et al., 1997a, b). Elevations of IL-1β have 
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been detected in the brains of aged AD mouse models and plaque associated 
microglia (Benzing et al., 1999; Lim et al., 2000). Additionally, IL-1 has been shown to 
increase APP mRNA expression, translation and its γ-secretase cleavage (Goldgaber 
et al., 1989; Gray and Patel, 1993; Brugg et al., 1995; Rogers et al., 1999; Liao et al., 
2004). Therapeutic strategies for autoinflammatory and autoimmune diseases have 
been focused on the blockade of IL-1 signalling. Competing for IL-1R ligand-binding 
sites was achieved by applying naturally occurring or chimeric IL-1R antagonist (IL-
1Ra) and IL-1R-blocking antibody. IL-1 could also be neutralized by soluble IL-1 decoy 
receptors and anti-IL-1 antibodies (Dinarello, 2011; Dinarello et al., 2012). 
In addition to IL-1R1, over one hundred type I integral membrane proteins have been 
identified as substrates for γ-secretase-dependent proteolysis (McCarthy et al., 
2009a). Regulated intramembrane proteolysis by γ-secretase therefore involves in 
the regulation of multiple cellular events including differentiation (Shih Ie and Wang, 
2007), gene transcription (May et al., 2002; Murakami et al., 2003; Kinoshita et al., 
2006), cell adhesion (Ferber et al., 2008; Waschbusch et al., 2009), protein turnover 
(Kopan and Ilagan, 2004) and immune response (Carey et al., 2007; McCarthy et al., 
2009b). A common feature of all the γ-secretase substrates is that all substrates 
release their ectodomain after proteolysis in their extracellular domain and 
ectodomain shedding is required for the subsequent γ-secretase cleavage. However, 
relatively little is known about how γ-secretase cleavage is regulated, where the 
cleavage occurs and what modification of the substrate is involved in this proteolysis. 
Palmitoylation, ubiquitination and phosphorylation of the γ-secretase substrates 
have been shown to regulation the γ-secretase cleavage of its substrates (Gupta-
Rossi et al., 2004a; Takahashi et al., 2008; Underwood and Coulson, 2008). IL-1R1 
167 
 
was previously reported to be ubiquitinated by TRAF6 and this regulation involves in 
the proteolysis and signalling transduction of this receptor (Twomey et al., 2009). In 
this study, by further characterizing TRAF6-mediated ubiquitination of IL-1R1, we 
found that five lysine residues in IL-1R1 C-terminus are targeted by TRAF6-mediated 
polyubiquitination. Moreover, mutagenesis of these five lysine residues reduces the 
cell surface localization of IL-1R1, attenuates the responsiveness to IL-1β stimulation 
and diminishes the production of IL-1R1 CTD, suggesting that TRAF6-mediated 
ubiquitination is essential for the distribution and signalling transduction of IL-1R1. 
 
5.2 Future Perspectives: 
5.2.1 Map ubiquitination sites of presenilins and investigate the functions of 
TRAF6-mediated ubiquitination of presenilins 
We have performed site-directed mutagenesis and in vitro ubiquitination assay of 
peptide arrays to map the sites of PS1 ubiquitination sites. Single or double lysine 
mutations of PS1 did not reveal any potential sites for PS1 ubiquitination suggesting 
that multiple lysine residues may be involved in this modification. In vitro 
ubiquitination assay could still be optimized by figuring out if TRAF6K124R mutation 
has E3 ligase activity in vitro or by distinguishing ubiquitination of substrates from 
TRAF6 autoubiquitination. Then the presenilin peptide arrays could still be used to 
determine the ubiquitination sites. Additionally, our group is generating new 
constructs to be used in mass spectrometry analysis to identify the ubiquitination 
sites of certain candidate proteins. 
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Upon identifying the ubiquitination sites of presenilin, we could mutate these 
residues and test the property of these mutations in terms of protein turnover, 
TRAF6-mediated ubiquitination and γ-secretase activity. Knock-out of TRAF6 has 
been shown to attenuate the ER calcium signalling and we assume that destabilized 
full-length presenilins cause this deficiency. By obtaining presenilins mutants that are 
deficient in TRAF6-mediated ubiquitination, we could verify that if TRAF6-mediated 
ubiquitination of presenilin involves in the regulation of the ER Ca2+ leak function. 
Furthermore, by immunohistochemistry approaches we could determine in which 
subcellular compartment this regulation occurs and the correlation between 
presenilin ubiquitination and proteasomal degradation. These experiments would 
provide novel insights into how full-length presenilins are regulated and help 
understanding the functions of full-length presenilins. As disrupted function of full-
length presenilin has been linked to familial AD mutants (Nelson et al., 2007), our 
study will provide understanding of the relevance between γ-secretase independent 
presenilin functions and AD pathogenesis. 
In addition to TRAF6, other TRAF family members have also been shown to stabilize 
presenilins and induce ubiquitination. However TRAF2DN mutant has also been 
shown to enhance presenilin levels. By further characterizing presenilin 
ubiquitination mediated by other TRAFs, we would find out if other TRAF proteins 
induce presenilin ubiquitination through their E3 ligase activity or only enhance this 
modification as adaptor proteins. These experiments would reveal the redundancy 
among TRAF family members and help to understand regulation of full-length 
presenilins by TRAF family proteins. 
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5.2.2 Further characterize the role of TRAF6-mediated ubiquitination in IL-1R1 
protein turnover, trafficking and regulated intramembrane proteolysis. 
One study reported that lysine residues are preferentially ubiquitinated when they 
are localized next to certain residues which could be phosphorylated or are polar 
uncharged or negatively charged (Catic et al., 2004). Thirteen out of twenty-one 
lysine residues in the intracellular domain of IL-1R1 fit into these profiles and 3 of 
them (K383, 527, 532) are identified in this study as TRAF6-mediated ubiquitination 
sites of IL-1R1. K383 and K532 are also identified as highly conserved motifs in the 
TIR domain of IL-1R family members. Mutagenesis of these five lysine residues 
reduces the membrane localization of IL-1R1, attenuates the responsiveness to IL-1β 
stimulation and diminishes the production of IL-1R1 CTD. Further characterization 
should be able to show if TRAF6-mediated ubiquitination is required for 
internalization or the ectodomain shedding and proteolysis of the IL-1R1 receptor 
and thus find out the cause for deficient IL-1R1 CTD production. By subcellular 
fractionation and immunohistochemistry, it is also possible to determine that when 
the IL-1R1 K5R mutant is deficient in plasma membrane localization, in what other 
subcellular compartment does it accumulate and does the mutant have alternative 
trafficking or degradative pathway. Moreover, requirement of TRAF6-mediated 
ubiquitination for IL-1R1 signalling transduction could be investigated in terms of 
ligand binding, signalling complex assembly and downstream signalling protein 
recruitment. Further studies would generate intriguing insight into the regulation of 
IL-1R1 signalling and distinguish between γ-secretase cleavage dependent and 
independent IL-1R1 signalling. 
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Although IL-1R1 K5R mutant is deficient in membrane localization, ubiquitination of 
full-length receptor mediated by TRAF6 was not affected comparing to wild-type IL-
1R1 and full-length mutant was still stabilized by TRAF6. This observation led us to 
the speculation that TRAF6 may associate with IL-1R1 not only in the membrane 
signalling complex, but also in other compartments. As mentioned above, mass 
spectrometry analysis is going to be applied for mapping other ubiquitination sites of 
IL-1R1. Identifying additional ubiquitination sites in IL-1R1 intracellular domain or 
even in the ectodomain may lead us to understand the mechanism how the full-
length IL-1R1 is modified and transported and why TRAF6 enhances the level of IL-
1R1 full-length protein. As blockade of IL-1 signalling is considered as therapeutic 
strategy for some autoinflammatory and autoimmune diseases, our discovery of 
important residues for IL-1R1 signalling transduction may provide alternative 
approach for the treatment of IL-1 related diseases. 
TLR4 and TNFR1 were also shown to be regulated by TRAF6 and TRAF2 respectively 
through ubiquitination. TLR4 seemed to adhere to similar pattern of regulation by 
TRAF6-mediated ubiquitination as IL-1R1 where TRAF6 induces ubiquitination and 
enhances cellular level of the receptor. Upon mapping the sites of TLR4 
ubiquitination, mechanism of this regulation should be revealed by experiments that 
have been performed with IL-1R1. However, TRAF2-mediated ubiquitination of 
TNFR1 seemed to play a total diverse role where TNFR1 showed a different 
ubiquitination pattern and was destabilized by TRAF2 and TRAF6. TRAF2 and TRAF6 
have both been report to negatively regulate TNFR1 activity (Nguyen et al., 1999; 
Funakoshi-Tago et al., 2009). Therefore, further characterization of TRAF-mediated 
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ubiquitination of TNFR1 may provide novel understanding of TNF signalling and the 
diversity of TRAF family mediated regulation. Additionally, study of the γ-secretase 
dependent cleavage of its substrate will generate novel knowledge about the 
regulated intramembrane proteolysis of these type I integral membrane proteins 
and the functional significance of their intracellular domain generated by γ-secretase 
cleavage. 
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